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RESUME (Version French) 
La fibrillation auriculaire (FA) représente un enjeu mondial de santé publique. Les estimations 
suggèrent que son incidence devrait doubler d'ici 20 ans. Bien que les progrès accomplis dans le 
diagnostic et le traitement de la FA soient considérables, la pathologie reste associée à une 
morbidité et une mortalité importantes notamment en raison de son rôle dans la survenue des 
accidents vasculaires cérébraux d’origine ischmiques. Il est généralement reconnu que la fibrose 
est un processus central qui contribue au remodelage pathologique du massif auriculaire, 
conduisant au développement et au maintien de la FA. Cependant, les mécanismes sous-jacents de 
la fibrose et du rtemodelage tissulaire dans la FA restent mal connus. La prévalence de la FA est 
liée à l'âge. Le raccourcissement télomérique, caractéristique du vieillissement, est corrélé 
positivement à l'incidence de la FA indiquant qu'il s'agit d'un facteur de risque majeur de 
développer la pathologie. 
La sénescence est une réponse cellulaire caractérisée par un arrêt de croissance associé à 
l’acquisition d’un phénotype pro inflammatoire. Elle joue un rôle dans le développement normal, 
le maintient de l'homéostasie tissulaire et limite la progression tumorale. Cependant, la sénescence 
est également considérée comme une cause majeure de maladie liée à l’âge. La sénescence peut 
être induite par différents stimuli, notamment un dysfonctionnement télomérique, suite à une 
exposition à des rayonnements ionisants, les espèces réactives de l’oxygène (ROS), de fortes 
concentrations en glucose ou l’exposition des cellules à des cytokines pro inflammatoires. Il est 
bien établi que l’arrêt du cycle cellulaire est médié par p21 et p16, deux inhibiteurs de la kinase 
dépendante des cyclines (CDK). De plus, les dommages persistants de l’ADN sont rapportés pour 
être à la base du phénotype caractéristique inflammatoire et tumorigène des cellules sénescentes. 
On parle du phénotype sécrétoire associé à la sénescence (SASP). Ce SASP, largement dépendant 
de la signalisation NF-κB, est caractérisé par l’exposition de molécules d’adhérence, l’activation 
de métalloprotéinases (MMP) ainsi que la sécrétion de nombreuses cytokines. Il a également été 
montré que la sénescence des cellules endothéliales (CE) pouvait se produire dans différents 
contextes pathologiques in vivo. En effet, des niveaux élevés de sénescence vasculaire ont été 
observés dans l'arc aortique de rats spontanément hypertendus et dans l'aorte de rats diabétiques. 
Des études sur des cellules en culture ont montré que la sénescence des CE était associée à une 
diminution de l’expression de la monoxyde d'azote synthase endothéliale (eNOS), à l'induction 
d'un état pro inflammatoire et à des dommages de l'ADN. En outre, la surexpression du suppresseur 
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de tumeur p53 est responsable d’un dysfonctionnement endothélial et d’une biodisponibilité 
réduite du monoxyde d’azote (NO) dans des aortes de rat ex vivo et des CE en culture. 
Le stress oxydatif a été suggéré comme un contributeur majeur au développement de la 
dysfonction endothéliale et à l’hyper contractilité artérielle liée au vieillissement. Ceci en réduisant 
la biodisponibilité de facteurs vasodilatateurs comme le NO et le facteur hyperpolarisant 
dépendant de l'endothélium, mais également par l'induction de réponses contractiles dépendantes 
de l'endothélium. Le stress oxydatif implique plusieurs sources de ROS, notamment la 
nicotinamide adénine dinucléotide phosphate (NADPH) oxydase, les mitochondries, les eNOS non 
couplés et les cyclooxygénases. En outre, des études antérieures ont montré que l'apocynine, un 
inhibiteur de la NADPH oxydase, restaurait les relaxations dépendantes de l'endothélium altérées 
au cours du vieillissement et ce, aussi bien dans les micro-vaisseaux humains, que dans les modèles 
animaux. La vitamine C également, par son action antioxydante, permet de restaurer 
l’augmentation de flux sanguin induite par l'acétylcholine, réduite chez les sujets âgés. 
De nombreux travaux suggèrent que le système rénine angiotensine (RAS) est acteur majeur du 
dysfonctionnement endothélial lié au vieillissement. En effet, l'enzyme de conversion de 
l'angiotensine (ACE) et les récepteurs AT1R de l’angiotensine II (Ang II) sont augmentés dans 
paroi artérielle d’individus âgés. De plus, les traitements par les inhibiteurs de l’ACE ou les 
antagonistes des récepteurs de l’Ang II préviennent le dysfonctionnement endothélial lié au 
vieillissement. En outre, des études antérieures ont démontré un rôle clé de l'Ang II dans la 
pathogenèse de la FA. Le récepteur AT1R est connu pour activer les protéines kinases activées par 
les mitogènes (MAPK), qui favorisent le remodelage auriculaire en induisant la prolifération des 
fibroblastes, l'hypertrophie cellulaire et l'apoptose. 
On sait depuis longtemps que la FA a été associée à l'activation de facteurs de coagulation locaux 
et circulants. Cette hypercoagulabilité augmente considérablement le risque de formation de 
caillots et d'accident vasculaire cérébral chez les patients atteints de FA. Cependant, le rôle 
potentiel de cette hypercoagulabilité dans le remodelage du tissu auriculaire et plus spécifiquement 
le rôle de la thrombine ou du facteur Xa (FXa) sont inconnus. Outre ses effets hémostatiques, il a 
également été démontré que la thrombine induisait des effets cellulaires par l’activation des 
récepteurs activés par les protéases (PAR). 
Les récepteurs PAR constituent une famille de récepteurs couplés aux protéines G qui s'activent 
par clivage protéolytique du domaine N-terminal, révélant un nouveau ligand captif qui se lie de 
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manière intramoléculaire pour induire une transduction de signal intracellulaire. Quatre membres 
de la famille PAR sont identifiés, PAR-1 à 4. PAR-1 étant principalement activé par la thrombine, 
alors que PAR-2 est principalement activé par la trypsine et les protéases analogues. De nombreux 
types de cellules sont activés par l’action de la thrombine sur les PAR, notamment les plaquettes, 
les cellules musculaires lisses (CML) vasculaires, les lymphocytes et les CE, liant ainsi la 
coagulation à l'inflammation. Les récepteurs PAR-1 et PAR-2 sont exprimés dans le cœur. PAR- 
1 est exprimé par les myocytes, les fibroblastes, les CE et les CML. Bien que PAR-2 soit également 
exprimé par les myocytes, les CE et les CML, son expression par les fibroblastes n'a pas été 
confirmée. 
La thrombine entraine l'expression de P-sélectine à la surface des plaquettes et des CE, de 
molécules d’adhésion telles que ICAM-1, VCAM-1 et la E-sélectine à la surface des fibroblastes, 
des CML et des CE ainsi que l'expression de diverses cytokines telles que l'interleukine-6 et la 
chimiokine MCP-1. Ces mécanismes conduisent au recrutement de leucocytes dans la paroi 
vasculaire, à leur diapédèse, et contribue aux processus inflammatoires et fibrotiques. De plus, la 
thrombine induit l'apoptose des CE par l'activation de NF-κB et des caspases, et augmente la 
perméabilité vasculaire en modifiant la structure et les adhérences endothéliales. Finalement, lla 
démonstration récente que certains anticoagulants oraux directs, comme le dabigatran, puissent 
limiter la progression du remodelage auriculaire suggère un rôle direct de la thrombine dans ce 
processus. 
Des effets directs du FXa ont également été rapportés. Le FXa augmente l'expression des 
récepteurs PAR et de médiateurs inflammatoires dans des sections d’oreillette humaines. D’autres 
travaux ont établi que la tachyarythmie par elle même, était capable d’augmenter l'expression du 
récepteur PAR-1. D’une façon générale, il est probable que l’activation des récepteurs PAR 
contribuent au remodelage structural des oreillettes, caractérisées notamment par une fibrose et 
une dilatation. Ces modifications de substrat jouent un rôle majeur dans la perpétuation de la 
fibrillation auriculaire. Par ailleurs, la réaction inflammatoire, la fibrose tissulaire et l'hypertrophie 
cellulaire contribuent de manière significative à la perte de conductivité électrique entre les 
myocytes et par conséquent majorent les perturbations de conduction dans les oreillettes 
pathologiques. Par conséquent, au vu de l’efficacité des inhibiteurs spécifiques de la coagulation 
dans la prévention des modifications cellulaires arythmogènes, le rôle des récepteurs PAR et/ou 
de l’hypercoagulabilité dans le développement de la FA pourrait être déterminants. 
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Cette étude vise à caractériser les changements phénotypiques associés à la sénescence des CE 
auriculaires et à déchiffrer le lien entre vieillissement et thrombogénicité. En outre, nous avons 
évalué la contribution de facteurs de la cascade de coagulation, tels que la thrombine, dans 
l'induction de la sénescence prématurée des CE auriculaires et l’acquisition d'un profil pro- 
thrombotique et pro-fibrotique. 
Pour mener à bien cette étude, un modèle original de culture primaire de CE auriculaires a été mis 
au point. Les cultures ont été obtenues après digestion à la collagénase d’oreillettes de porcs. La 
sénescence endothéliale a été évaluée par la mesure de l’activité bêta-galactosidase (SA-β-gal) par 
cytométrie en flux, par l’expression de protéine par Western blot, par la mesure de l’agrégation 
plaquettaire, par la mesure d’acteurs du remodelage de la matrice extracellulaire par zymographie 
(MMP matricielles) et par mesure du stress oxydatif (sonde dihydroéthidium). Une sénescence 
réplicative a été induite par le passage des CE auriculaires de P1 à P4 et une sénescence prématurée 
par l'exposition à un inhibiteur de la eNOS (L-NAME), le peroxyde d'hydrogène, la thrombine ou 
l’Ang II. 
La sénescence des CE auriculaires est caractérisée par une augmentation de l'activité de la SA-β- 
gal, une augmentation d’un régulateur de la sénescence cellulaire, la protéine p53, et d’inhibiteurs 
clés de la CDK, p21 et p16. L'exposition des CE auriculaires à la thrombine entraîne une 
augmentation concentration-dépendante de l'activité de la SA-β-gal, à un niveau similaire à celui 
induit par l’Ang II et le peroxyde d'hydrogène. La réponse pro-sénescence à la thrombine a 
également été associée à une expression accrue de p16, p53 et p21. De plus, le phénotype des CE 
auriculaires sénescentes était caractérisé par: (i) une thrombogénicité cellulaire accrue via une 
augmentation de l'expression du facteur tissulaire, une diminution de la eNOS et un potentiel 
antiagrégant plaquettaire réduit, (ii) une augmentation des protéines d’adhésion cellulaire comme 
ICAM-1, (iii) une protéolyse matricielle et un remodelage pro fibrosant attestée par l’expression 
accrue des MMP-2 et 9 et du TGF-β1, et (iv) l’activation du SRA local par l’expression accrue des 
récepteurs AT1R et de l’ACE. Le losartan, un antagoniste des récepteurs AT1R comme le 
Perindoprilat, un inhibiteur de l'ACE, empêchent la sénescence des CE auriculaires. Tout comme 
l'Ang II, la thrombine provoque un stress oxydatif et cet effet est bloqué par la N-acétylcystéine, 
un antioxydant, par l'inhibiteur de la NADPH oxydase le VAS-2870, par l'inhibiteur de la 
cyclooxygénase, l’indométacine et par les inhibiteurs de la chaîne respiratoire mitochondriale 
(roténone, myxothiazol et KCN), ainsi que par le losartan et le périndoprilat. De plus, nous avons 
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également des données préliminaires suggérant un effet similaire du facteur Xa sur l'induction de 
la sénescence et l'augmentation du stress oxydatif dans les CE auriculaires. 
Ainsi, à partir de cette étude, nous pouvons conclure que la sénescence de l'endothélium auriculaire 
favorise la thrombogénicité, l'inflammation, le remodelage matriciel et la régulation positive du 
SRA local. Les présents résultats indiquent en outre que la thrombine est un puissant inducteur de 
sénescence prématurée des CE auriculaires caractérisée par une altération de la voie protectrice du 
NO et par l'induction de réponses pro-inflammatoires et pro-fibrotiques. Ils mettent en évidence 
l'implication du SRA local et suggèrent qu’un ciblage de la voie Ang II / AT1R pourrait constituer 
une stratégie thérapeutique prometteuse pour limiter les effets délétères du vieillissement 
endothélial auriculaire. 
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RESUME (English version) 
 
Atrial fibrillation (AF) has become a serious epidemic health problem across the world, and the 
incidence is expected to double within the next 20 years. Although there is considerable 
progression in the diagnosis and treatment of AF, it is associated with increased morbidity and 
mortality. It is generally known that atrial fibrosis contributes to atrial structural remodeling, 
leading to the development and maintenance of AF. However, the underlying mechanisms of 
fibrosis in AF remain unclear. Whilst numerous epidemiological studies have demonstrated the 
close link between AF and ageing, the description of precise mechanisms is still lacking. Among 
Pioneering study has demonstrated that short telomere length, a hallmark of aging and senescence, 
was associated with the incidence of AF suggesting that senescence per se could pave the way to 
AF onset. Senescence is a cellular response characterized by a stable growth arrest and other 
phenotypic alterations that include the acquisition of a proinflammatory secretome. Senescence 
plays a role in normal development, maintains tissue homeostasis, and limits tumor progression. 
However, senescence has also been implicated as a major cause of age-related disease. Senescence 
can be induced by a plethora of stimuli, including ionizing radiation telomere dysfunction, 
ROS, high glucose concentrations or inflammatory cytokines. It has been established that the 
underlying cell cycle arrest is mediated by p21 and p16, two cyclin-dependent kinase inhibitors, 
and that persistent DNA damage signaling drives the hallmark - inflammatory and tumorigenic 
- phenotype of senescent cells, termed the senescence-associated secretory phenotype (SASP). 
This SASP, which prominently involves NF-κB signaling, comprises adhesion molecules, 
metalloproteinases, and many cytokines. Endothelial cell senescence has also been shown to 
occur in vivo in several types of pathological arteries. Indeed, high levels of vascular senescence 
have been observed in the aortic arch of spontaneously hypertensive rats and in the aorta of diabetic 
rats. Studies with cultured cells have indicated that endothelial cell senescence is associated with 
the down-regulation of endothelial nitric oxide synthase (eNOS), the induction of a 
proinflammatory state, and DNA damages. In addition, it was previously established that the 
overexpression of endothelial p53, a mediator of endothelial senescence, induced endothelial 
dysfunction and decreased nitric oxide (NO) bioavailability in rat aortic sections and the down- 
regulation of eNOS in cultured endothelial cells. 
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Oxidative stress has been suggested to be a major contributor to the development of aging-related 
endothelial dysfunction by reducing the bioavailability of both the endothelial NO and the 
endothelium-dependent hyperpolarization response, and possibly also by induction of 
endothelium-dependent contractile responses. Indeed, a high level of oxidative stress is observed 
throughout the aged arterial wall, which has been suggested to involve several sources of ROS 
including nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, mitochondria, 
uncoupled eNOS, and cyclooxygenases. The major relevance of this pathway was emphasized by 
previous studies demonstrating (i) that the NADPH oxidase inhibitor apocynin improved aging- 
related blunted endothelium-dependent relaxations in human microvessels, mice aortas, and in the 
rat mesenteric artery, a(ii) that the antioxidant vitamin C enhanced the blunted acetylcholine- 
induced forearm blood flow in old subjects. 
 
Several lines of evidence have suggested that the angiotensin system is a major contributor to the 
aging-related endothelial dysfunction. Indeed, both angiotensin-converting enzyme (ACE) and 
AT1 receptors are upregulated within the old arterial wall, and treatments with either an ACE 
inhibitor or an AT1 receptor antagonist prevented aging-related endothelial dysfunction. Also, 
previous studies have demonstrated a key role of Ang II in the pathogenesis of AF. Ang II type 1 
receptor (AT1) activation is known to induce the activation of mitogen-activated protein kinases, 
(MAPK) which, in turn, favors atrial remodeling through fibroblast proliferation, cellular 
hypertrophy and apoptosis. 
 
It is known for many decades that AF has been associated with the activation of local and 
circulating coagulation factors (hypercoagulability). This AF-related hypercoagulability 
significantly enhances the risk of clot formation and stroke in patients with AF. However, little 
has been described about the potential role of this AF-related hypercoagulability in atrial tissue 
remodeling and predominantly the role of thrombin or factor Xa. Apart from its haemostatic 
effects, thrombin has also been shown to induce cellular effects that have been mediated by 
protease-activated receptors (PARs). 
 
PARs constitute a family of G protein-coupled receptors that become activated by proteolytic 
cleavage of the N-terminal domain, revealing a new tethered ligand that binds intramolecularly to 
activate the receptor and to induce intracellular signal transduction. Four members of the PAR 
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family are identified, PAR-1 to 4. PAR-1 being mainly activated by thrombin, whereas PAR-2 
being primarily activated by trypsin and trypsin-like proteases. Numerous cell types are activated 
by thrombin, including platelets, vascular smooth muscle cells (VSMCs), lymphocytes and 
endothelial cells (ECs) through the PARs activation, thus linking coagulation with inflammation. 
Both PAR-1 and PAR-2 are found in the heart. PAR-1 is chiefly expressed by myocytes, 
fibroblasts, endothelial cells, and SMCs. Although PAR-2 is also expressed by myocytes, 
endothelial cells, and SMCs, its expression by fibroblasts has not been confirmed. 
 
Thrombin activates proinflammatory signaling pathways, which lead to the expression of adhesion 
molecules and P-selectin on the membrane of platelets and ECs, as well as expression of various 
cytokines such as interleukin -6 and chemokines MCP-1 and adhesion molecules such as ICAM- 
1, VCAM-1 and E-selectin from fibroblasts, VSMCs and ECs, leading to leukocyte recruitment to 
the vessel wall and contributing to inflammatory and fibrotic processes. Moreover, thrombin 
induces ECs apoptosis through the activation of nuclear factor κB (NF-κΒ) and caspases, regulates 
prosctacyclin and NO production leading to ECs shape change and to the enhancement of barrier 
permeability. Thrombin contributes in formation of left atrial remodeling and it has been known 
that direct oral anticoagulants, such as the direct thrombin inhibitor dabigatran, can prevent its 
progression. 
 
Moreover, direct signaling effects of factor Xa (FXa) have also been noted. FXa increased the 
expression of PARs and inflammatory molecules in human atrial tissue slices. The cellular effects 
of this stimulation have been likely to contribute to structural remodeling in fibrillating and dilated 
atria. Inflammatory changes, tissue fibrosis, and cellular hypertrophy significantly contribute to 
loss of electrical conductivity between myocytes leading to conduction disturbances in fibrillating 
and dilated atria. Overall, the role of PAR activation and hypercoagulability in the development of 
AF might be important for the notion that specific coagulation inhibitors may prevent not only 
structural tissue remodeling but also arrhythmogenic cellular changes favouring AF maintenance. 
 
Thus, this study aims to characterize phenotypical changes associated with atrial endothelial cells 
(AEC) senescence and to depict the link between ageing and thrombogenicity. In addition, we also 
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evaluate the possibility that coagulation cascade-derived factors such as thrombin could induce 
premature AEC senescence leading to the acquisition of a pro-thrombotic and pro-fibrotic profile. 
 
To conduct the study, an original model of primary cell culture of atrial endothelial cells was 
established in the laboratory. In this model, atrial endothelial cells were obtained after collagenase 
digestion of porcine atria freshly sacrificed and cultured (primary cultures). Endothelial 
senescence was assessed by senescence-associated beta-galactosidase activity (SA-β-gal), using 
flow cytometry, protein expression by Western blot analysis, platelet aggregation using an 
aggregometer, extracellular matrix remodeling by gel zymography and oxidative stress using the 
redox-sensitive probe dihydroethidium. Replicative senescence was induced by passaging AECs 
from passage P1 to P4, and premature endothelial cell senescence by exposing AECs at passage 
P1 to L-NAME, an endothelial NO synthase (eNOS) inhibitor, H2O2, thrombin and angiotensin II. 
 
AEC senescence was characterized by an increase in SA-β-gal activity and an up-regulation of 
p53, a key regulator of cellular senescence, and of p21 and p16, key cyclin-dependent kinase 
inhibitors. Exposure of AECs to thrombin caused concentration-dependent increased in SA-β-gal 
activity to a similar level as that induced by the pro-senescence inducers Ang II and hydrogen 
peroxide. The pro-senescence response to thrombin was also associated with an increased 
expression of p16, p53 and p21. Moreover, senescent AECs phenotype was characterized by (i) 
cell thrombogenicity through an up-regulation of tissue factor expression, eNOS down-regulation 
and reduced NO-mediated inhibition of platelet aggregation, (ii) cell adhesion through up- 
regulation of ICAM-1, (iii) proteolysis and fibrosis remodeling through MMP-2, 9 and TGF-ß1 
expression, and (iv) up-regulation of the local Ang II system through enhanced AT1 receptors 
(AT1R) and angiotensin-converting enzyme (ACE) expression. Losartan, an AT1 receptor 
antagonist, and Perindoprilat, an ACE inhibitor, prevented atrial endothelial cell senescence. 
Thrombin induced oxidative stress in the same extent to Ang II and this effect was prevented by 
the antioxidant N-acetylcysteine, the NADPH oxidase inhibitor VAS-2870, the cyclooxygenase 
inhibitor indomethacin and by inhibitors of the mitochondrial respiratory chain (rotenone, 
myxothiazol and KCN), and also by the AT1R antagonist losartan and perindoprilat. Moreover, 
preliminary findings may suggested that factor Xa, another marker of hypercoagulability may 
contribute to the induction of senescence and increased oxidative in atrial endothelial cells (data 
now shown). 
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Altogether, the present data demonstrates the existence of a new paradigm linking atrial 
endothelial senescence to thrombogenicity, inflammation, matrix remodeling and the up- 
regulation of the local Ang II system. The present findings further indicate that thrombin is a potent 
inducer of premature senescence in atrial endothelial cells leading to an endothelial dysfunction 
with the down-regulation of the protective NO pathway and the induction of pro-infiltrative and 
pro-fibrotic responses. They further suggest the involvement of the local angiotensin system and 
that targeting the Ang II/AT1R pathway may be a promising therapeutic strategy to delay atrial 
endothelial ageing and subsequent atrial tissue remodeling. 
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1 ATRIAL FIBRILLATION 
1.1 Introduction and definition 
 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia observed by the clinician 
and constitutes the most important cause of embolic stroke. AF is characterized by a rapid and 
high rate (400–600 beats/minute) of asynchronous atrial cell depolarization of the atria without 
discrete P waves on the surface electrocardiogram (ECG) causing a loss of atrial contractile 
function and irregular ventricular rates (Calvo et al., 2018; Wijffels et al., 1995). It affects more 
than 33 million people worldwide (Chugh et al., 2014) and is also the number one cause of 
hospitalization for arrhythmias (Heijman et al., 2014; Miyasaka et al., 2006). Prevalence increases 
with advancing age and so are its associated comorbidities, like heart failure (Sardar et al., 2016). 
The pathophysiology of AF is complex, involving dynamic interactions among several factors, 
including substrate, triggers, and perpetuators, and the therapeutic approaches/strategies aims at 
targeting each steps of the disease progression from atrial tissue remodeling, initiation of the 
abnormal electrical rhythm, perpetuation of arrhythmia, thrombus formation and stroke. 
 
1.2 Classification of atrial fibrillation 
AF is classified as first detected or diagnosed AF which is independent of its duration, and presence 
or absence of any symptoms; paroxysmal AF constituting episodes lasting less than 24–48 h that 
terminate spontaneously but may also last up to7 days; persistent AF that is sustained beyond 7 
days requiring termination by either direct electrical cardioversion or pharmacological 
intervention; long-lasting persistent AF consisting of episodes lasting longer than one year mainly 
present the cases where a rhythm control strategy is recommended mostly to consider catheter 
ablation of AF; permanent AF in which the presence of the AF is accepted by the patient and 
physician, and no further attempts will be made either to restore or maintain sinus rhythm; lone 
AF consisting of patients below age 60 with clinically detectable structural cardiovascular disease, 
which could be paroxysmal, persistent, permanent; AF burden which can be defined as the 
proportion of time patients are in AF (Calkins et al., 2017; Calvo et al., 2018; Kirchhof et al., 
2016a; Shenasa et al., 2014). 
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Figure 1: Rhythm of healthy heart and fibrillating heart (Shenasa et al., 2014) 
 
 
1.3 Epidemiology and impact for patients 
 
 
1.3.1 Incidence and prevalence of atrial fibrillation 
The ratio of men and women with AF worldwide, in 2010, is about 1.5:1 (Chugh et al., 2014). This 
represents, at the global level in 2010, an estimated number of 20.9 million men and 12.6 million 
women with AF. Developed countries show greater number of frequency and presence of AF 
(Colilla et al., 2013). It is estimated that about 25% i.e. 1 in every 4 middle-aged adults in Europe 
and US will suffer from AF (Go et al., 2001a; Heeringa et al., 2006; Lloyd-Jones et al., 2004). The 
risk of AF becomes twofold every 10 years of life. The growing frequency of AF is highlighted 
by the anticipated numbers of AF patients – by 2030, the number of AF patients will be between 
14-17 million with 120,000 – 215,000 new AF patients every year (Colilla et al., 2013; Krijthe et 
al., 2013; Zoni-Berisso et al., 2014). The higher occurrence of AF is observed especially in older 
individuals and in patients with certain health conditions such as hypertension, heart failure, 
coronary artery disease (CAD), valvular heart disease, obesity, diabetes mellitus, or chronic kidney 
disease (CKD) (Ball et al., 2013a; Chiang et al., 2012; Kannel et al., 1998; McManus et al., 2012; 
Nguyen et al., 2013; Oldgren et al., 2014; Zoni-Berisso et al., 2014). Generally, the estimated 
numbers approximately show that 3% of adults aged 20 years or older suffer from AF (Bjorck et 
al., 2013; Haim et al., 2015). Better diagnosis of AF has contributed towards AF prevalence. Better 
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detection of silent AF (Kishore et al., 2014; Sanna et al., 2014; Wang et al., 2003) coupled with 
increasing age and health conditions susceptible for AF (Schnabel et al., 2015) have all contributed 
towards the higher incidence and prevalence of atrial fibrillation. 
 
1.3.2 Morbidity, mortality, and health care burden of atrial fibrillation 
AF is independently responsible for higher risk of death in women as opposed to men. Studies 
suggest that AF, as an existing condition, doubles the mortality risk for women and results in a 
1.5-fold increase in mortality risk for men (Andersson et al., 2013; Benjamin et al., 1998; Stewart 
et al., 2002) (Table 1). Certain conditions can be treated to mitigate the risk of death, for instance, 
anticoagulation can reduce the likelihood of death by stroke but the current evidence suggests that 
cardiovascular deaths due to heart failure and sudden death are still frequent even in AF patients 
under anticoagulant therapy (Kotecha et al., 2014). AF is linked to higher occurrence of heart 
failure and stroke i.e. it results in increased morbidity (Krahn et al., 1995; Stewart et al., 2002; 
Wolf et al., 1991). Recent studies indicate the diagnoses of AF in 20-30% of patients of ischaemic 
stroke either prior to, during or after the first occurrence (Grond et al., 2013; Henriksson et al., 
2012; Kishore et al., 2014). 10-40% of AF patients are hospitalized every year (Kirchhof et al., 
2014; Kotecha et al., 2014; Steinberg et al., 2014). Poor lifestyle resulting in decreased quality of 
life (Marzona et al., 2012; Thrall et al., 2006) and depression (von Eisenhart Rothe et al., 2015) 
are common in AF patients. The cognitive impairment and white matter lesions in the brain (Ball 
et al., 2013b; Knecht et al., 2008; Ott et al., 1997) are also very frequently observed in such 
patients. AF has and will continue to significantly result in increased healthcare costs unless it is 
prevented and treated effectively. The direct costs associated with AF-related treatments and 
complications are approximately 1% of total healthcare expenditure in the UK and between 6-26 
billion US dollars in United States for year 2008 (Kim et al., 2011; Stewart et al., 2004). 
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Table 1: Morbidity and mortality linked with AF (Kirchhof et al., 2016a) 
1.4. Atrial fibrillation risk factors 
1.4.1 Ageing 
AF is strongly age dependent, and it affects approximately 1%, 4% and 15% at 50, 65 and 80 years, 
respectively (Andrade et al., 2014). Aging plays a critical role in the genesis of AF and also 
increases the risks of cardiac dysfunction and stroke in AF patients. Clinical and laboratory 
evidence indicates that aging is significant in the creation of atrial electrical and structural 
remodeling that leads to increased susceptibility to AF occurrence. Aging is commonly associated 
with cardiovascular comorbidities, oxidative stress, calcium dysregulation, atrial myopathy with 
apoptosis, and fibrosis, which all contribute to the genesis of AF (Lin et al., 2018). Mounting 
evidence suggests that extracellular matrix (ECM) and perivascular fibrosis were increased 
progressively with age, leading to cardiac remodeling and dysfunction in elderly individuals (Horn 
and Trafford, 2016; Sahin et al., 2011). Besides, telomere attrition affects mitochondrial function, 
thus promoting aging (Sahin et al., 2011), and short telomere length is considered to be a hallmark 
of aging (Lopez-Otin et al., 2013). Recently, Carlquist et al found that AF subjects had shorter 
20  
telomeres compared without a history of AF subjects (Carlquist et al., 2016). Such finding suggests 
that aging, and/or replicative senescence, may contribute to the development and maintenance of 
AF (Xie et al., 2017). Koura and colleagues (Koura et al., 2002) demonstrated that with aging, the 
amount of interstitial fibrosis and fatty infiltrates increases, predisposing the atrial muscle to 
electrical impulse conduction disturbances. These disturbances, such as the so-called zigzag 
electrical impulse propagation aberrancy, are considered to be “trigger” events that lead to AF 
initiation and maintenance. At the cellular level, several anomalies may also contribute to age 
related AF initiation. For example, atrial myocytes in an aged atrium exhibit a prolonged action 
potential duration (APD). Moreover, evidences were provided that a larger APD heterogeneity 
exist across the atrium (Xu et al., 2013). 
 
 
Figure 2: Histological analysis of a rabbit’s adult and aged (age >2 years) left atrium (LA) after 
Masson trichome staining. (A) showing marked fibrosis associated with cell loss and 
cardiomyocytes hypertrophy accompanied with increased fiber diameter and large-volume nuclei 
in the aged rabbit LA when compared with adult rabbit LA (B) with normal cardiomyocytes (Lin 
et al., 2018; Tsai et al., 2014). 
 
1.4.2 Hypertension 
Hypertension has been shown an independent risk factor for incident AF. The Framingham cohort 
displayed an independent increased risk of AF by factors of 1.5 in men and 1.4 in women related 
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to hypertension (Benjamin et al., 1994; Rogers et al., 2018). Hypertension increases sympathetic 
output which may lead to increased left atrial pressure and volume, as well as renin–angiotensin– 
aldosterone system (RAAS) activation, thereby leading to atrial fibrosis, structural  and  
electrical atrial remodeling, and promotion of AF (Brandes et al., 2018; Lau et al., 2012). Long-
term longitudinal studies from Framingham Heart Study1 and Women’s Health Study revealed 
both high systolic and diastolic BP increase the risk of developing AF (Tedrow et al., 2010).  
Moreover,  in  spontaneously  hypertensive  rats,   the   inducibility   of   atrial tachycardia was 
increased, accompanied by a rise in atrial fibrosis (Choisy et al., 2007). In a sheep model of long-
standing elevated blood pressure induced by prenatal corticosteroid exposure multiple 
proarrhythmic abnormalities were seen: increased AF stability, reduced conduction velocities, 
(Hong and Glover, 2018; Shenasa et al., 2014) and increased fibrosis with myocyte hypertrophy 
and myolysis (Kistler et al., 2006). 
The first evidence that optimal treatment of hypertension may prevent AF and improve outcomes 
came from intervention trials in hypertensive patients. In the Losartan Intervention for Endpoint 
Reduction in Hypertension (LIFE) study, which compared the use of ARB losartan with the beta- 
blocker atenolol, losartan prevented more cardiovascular morbidity and death than atenolol for a 
similar reduction in BP (Dahlof et al., 2002). A post-hoc analysis from this trial showed that the 
greatest reduction (40 %) in risk of incident AF occurred in patients who achieved optimal systolic 
BP levels of <130 mmHg, compared to those with systolic BP ≥142 mmHg. Moreover, incident 
AF occurred less frequently in patients treated with losartan than in those treated with atenolol, 
although there was no significant difference in BP reduction (Wachtell et al., 2005). A Danish 
nationwide nested case-control study also found less new-onset AF in patients with hypertension 
treated with ARBs or ACE inhibitors compared to beta-blockers or diuretics (Marott et al., 
2014). These findings suggest that inhibition of the renin–angiotensin system itself might have a 
beneficial effect on the reduction of incident AF besides BP control (Brandes et al., 2018) 
 
1.4.3 Heart failure and coronary artery disease 
AF may be caused by any cardiac condition with, however, a predominance of heart failure (HF) 
and coronary artery disease (CAD) (Benjamin et al., 1994; Benjamin et al., 1998; Kannel et al., 
1983; Kannel and Benjamin, 2008; Krahn et al., 1995; Roy et al., 2009). HF represents major AF 
risk factor as HF patients are associated with approximately 5-fold increased risk of AF onset 
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(Kannel et al., 1998). The risk of AF increases with the severity of HF clinical symptoms (Jais et 
al., 2000; Maisel and Stevenson, 2003; Tsang et al., 2002). Atrial fibrosis is markedly increased in 
the setting of HF, similar to that observed with aging and hypertension-related AF. Moreover, in 
HF too, the formation of atrial interstitial fibrosis plays a strong determinant of the occurrence of 
AF (Cha et al., 2004; Shinagawa et al., 2002; Tanaka et al., 2007). Specifically, the spatial 
distribution of atrial fibrosis could be an indicator of AF electrophysiologic mechanisms—reentry 
or spontaneous focal discharges—and of the exact locations of AF electrical sources. Therefore, 
understanding of fibrosis or scar distribution could be an asset in the performance of tailored AF 
ablation procedures (Trayanova, 2014). Thus, HF-related fibrosis formation has been one of the 
main targets of so-called upstream therapies, such as inhibitors of the renin-angiotensin- 
aldosterone system (Savelieva et al., 2011). 
Acute and chronic CAD has emerged as a substantial risk factor of AF onset (Miyasaka et al., 
2006) and perpetuation (Goldberg et al., 2002; Kannel et al., 1983; Wong et al., 2000). Although 
AF after ventricular myocardial infarction might be also triggered by an increase in intra-atrial 
pressure in the context of acute ventricular dysfunction, (Moller et al., 2003; Tsang et al., 2001) 
various works have shown that isolated atrial infarction is common. It was documented that the 
pathophysiologic role of atrial ischemia/infarction in AF onset has been greatly underestimated. 
Understanding of the pathophysiology linking CAD and AF has benefited from experimental 
studies. These works have highlighted several atrial ischemia/infarction related electrophysiologic 
changes. Spontaneous discharges have been significantly more numerous in cells bordering the 
infarcted region. Atrial ischemia/infarction had also been shown to reduce atrial refractory periods, 
to increase AF inducibility and adversely modulate regional electrical impulse propagation, and 
finally lead to an acceleration of atrial drivers (Anumonwo and Kalifa, 2016). 
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Figure 3: Panel (A) depicts the association between AF and HF cycle whereas, panel (B) HF-AF 
cycle. (ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; EDP, end diastolic pressure; 
LAP, left atrial pressure; LVD, left ventricular dilation) (Shenasa et al., 2014). 
 
1.4.4 Diabetes 
The Veterans Health Administration Hospitals study showed that the prevalence of AF in patients 
with diabetes mellitus was 14.9%, this being pointedly higher than that of hypertension. Thus, 
diabetes mellitus represents a strong and independent risk factor for the occurrence of AF, with an 
odds ratio of 2.13 (Pb.0001) (Lin et al., 2013; Movahed et al., 2005). The proposed mechanisms 
linking diabetes mellitus and AF include autonomic remodeling, structural remodeling, electrical 
remodeling, and insulin resistance. With respect to structural remodeling, in a diabetes mellitus rat 
model Kato et al. has demonstrated fibrosis in the atria with formation of anchoring points for 
reentry circuits and changes in the forward propagation of fibrillatory wavelets, thus resulting in 
atrial fractionated potentials and conduction delay (Kato et al., 2006). The atrial tissue collected 
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from diabetes mellitus patients which were then biopsied during coronary artery bypass graft 
surgery, displayed mitochondrial dysfunction causing oxidative stress which could also be 
involved in the formation of hyperglycemia-associated AF substrates, which ultimate lead to atrial 
interstitial fibrosis (Anderson et al., 2009). It is documented that the advanced glycation end 
products (AGEs) and AGE receptors (RAGEs) (both constituting the AGERAGE system) enable 
the interstitial collagen deposition in atrial myocardium of diabetes mellitus rats by encouraging 
up-regulation of the expression of connective tissue growth factors, and, as a consequence, result 
in myocardial structural remodeling (Koektuerk et al., 2016). Interestingly, in the atrial 
myocardium of rats with induced diabetes mellitus, the expression of Cx43 was found to be 
increased whereas its phosphorylation was decreased, thus leading to disorders of intercellular 
electrical coupling and consequent atrial arrhythmia (Mitasikova et al., 2009). 
 
1.4.5 Thyroid Dysfunction 
In the setting of hyperthyroidism, AF has been considered as one of the most frequent rhythm 
disturbance with its occurrence ranging from 2% to 20% (Klein and Danzi, 2007). When compared 
with a population with normal thyroid function and a 2.3% prevalence of AF, the incidence of AF 
in overt hyperthyroidism has been 13.8%. Shimizu et al. demonstrated that in a cohort of patients 
with hyperthyroidism studied for age distribution, AF incidence increased stepwise in each decade, 
climaxing at about 15% in patients N70 years, thus showing that hyperthyroidism-related AF has 
been more common with advancing age (Auer et al., 2001; Shimizu et al., 2002). Various potential 
mechanisms of AF in hyperthyroidism are proposed constituting elevation of left atrial pressure as 
a result of increased left ventricular mass and impaired ventricular relaxation, enhanced atrial 
ectopic activity, and ischemia secondary to raised resting heart rate (Bielecka-Dabrowa et al., 
2009; Fazio et al., 2004; Sgarbi et al., 2003). Interestingly, it is recently documented that both 
hypothyroidism and hyperthyroidism cause increased AF vulnerability in a rat thyroidectomy 
model (Zhang et al., 2013). In fact, hypothyroidism and hyperthyroidism, while inducing opposite 
electrophysiological changes in heart rates and atrial effective refractory period, both pointedly 
increase AF susceptibility (Weltman et al., 2015) . 
 
1.4.6 Alcohol 
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The connection of episodic heavy alcohol (ethanol) use with the onset of AF is termed as “holiday 
heart syndrome”. However, more recently, it is proposed that even habitual heavy alcohol 
consumption could be linked with a risk of AF (Balbao et al., 2009). Related to alcohol 
consumption and AF, Kodama et al. showed a meta-analysis of studies to summarize the estimated 
risk of AF associated to alcohol. It was found that the pooled estimate for AF for highest vs. lowest 
alcohol intake in individual investigations was 1.51 and a positive relationship between AF risk 
and heavy alcohol intake had been consistently found in all stratified analyses (Kodama et al., 
2011). Over the last few years, a number of mechanisms by which alcohol consumption could be 
linked to the development of AF have been suggested: a direct toxic effect on cardiac myocytes, a 
hyperadrenergic state which has been reached during both drinking and withdrawal of alcohol, an 
impaired vagal tone, an increase in intra-atrial conduction time (which is also testified by a P-wave 
prolongation) (Corradi, 2014b). 
 
1.4.7 Pericardial fat and obesity 
A considerable portion of the epicardial surface in large mammals is normally covered by adipose 
tissue, and fat cells (adipocytes) may be participating in myocyte-adipocyte cross talk significant 
in the normal function of the myocardium. Obesity considerably increases plasma levels of free 
fatty acids as well as overall visceral and epicardial adiposity in the studies comprising humans 
and animal models. With obesity, extensive fatty infiltration leads to elevated levels of biofactors. 
These biofactors have been potentiated by paracrine and vasocrine signaling pathways and 
overload the myocardium resulting in deterioration of the myocardial function and also lead to 
abnormal impulse initiation mechanisms and myocyte atrophy. In obese patients, it is also 
documented that steatosis of the myocardium well correlates with epicardial fat behaves as an 
independent contributing factor to myocardial dysfunction. Additionally, experimental studies in 
isolated myocytes reveal that excess epicardial adiposity, or its biofactors, lead to abnormality in 
myocardial electrical excitation (Anumonwo and Kalifa, 2014; Shenasa et al., 2014). 
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Figure 4: Management of AF-related risk factors by life style modification (Hong and Glover, 
2018). 
 
 
 
Figure 5: Risk factors and proposed mechanisms associated with AF (Fabritz et al., 2015). 
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1.4.8 Post-operative atrial fibrillation 
The most common arrhythmia after cardiac surgery is AF occurring in approximately 20–50% of 
patients depending on the type of surgery performed. AF occurs in 30–40% of patients post 
coronary artery bypass graft (CABG) and up to 60–70% of patients with combined CABG and 
valve surgery. Majorly, post-op AF converts to sinus rhythm spontaneously in the first 24–48 h, 
but if it takes longer than 48 h it increases the risk of stroke and prolongs hospitalization and 
associated expenses. Post-operative AF affects both early and late mortality after isolated CABG. 
Most of the complications being related to stroke thus, post-operative surveillance and long-term 
management with antiarrhythmic agents and antithrombotic management have been warranted. 
Preoperative treatments with beta-blockers have been shown to effectively decrease the risk of AF. 
Colchicine as well as statins has been effective in prevention of this arrhythmia (Deftereos et al., 
2013; Omae and Kanmura, 2012; Shenasa et al., 2014). 
 
1.4.9 Genetic risk factors 
Genetic predisposition also cannot be ignored (Kirchhof et al., 2016b) A considerable portion of 
AF occurring in younger ages has been known to be associated with a genetic predisposition than 
the accompanying disease. Some studies conducted report that more than 30% of AF have a 
common genetic variation. Among the various known genetic factors, the most important variants 
have been located close to the paired-like homeodomain transcription factor 2 gene on 
chromosome 4q25 (Gudbjartsson et al., 2007). This genetic variation has been known to be 
associated with up to a 7-fold increase the incidence of AF. In addition to the genetic variants that 
are likely to cause AF itself, gene mutations that contribute to the atrial remodeling process and 
electrophysiological changes described above may also mediate the occurrence of AF (Cha, 2018). 
 
1.4.10 Other risk factors 
Chronic kidney disease and smoking are accepted as independent AF risk factors but their 
respective importance is still debated. An example of a controversial risk factor is exercise. 
Although moderate physical activity may decrease AF incidence, a cumulative life practice of 
more than 1500 h is associated with 3-fold AF risk. Pathophysiologic mechanisms are still unclear, 
but the role of an increased vagal tone seems to be accepted (Anumonwo and Kalifa, 2014). 
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2. ATRIAL FIRILLATION MECHANISM AND PATHOPHYSIOLOGY 
The lack of reliable experimental models resembling this complex arrhythmia presents one of the 
major problems in understanding the mechanism leading to AF. However, an increased awareness 
of the role of “atrial remodeling” over the past 10 to 15 years has significantly increased our 
understanding of AF pathophysiology. Atrial remodeling constitutes any persistent change in atrial 
structure or function. Many forms of atrial remodeling promote the occurrence or maintenance of 
AF by acting on the fundamental arrhythmia mechanisms (Nattel et al., 2008) as illustrated in 
Figure below. AF requires both a trigger and a susceptible substrate (Dobrev and Nattel, 2010; 
Iwasaki et al., 2011b; Schotten et al., 2011). The trigger for initiation and maintenance of AF is 
mostly related to an enhanced electrical activity of the pulmonary vein cardiomyocyte sleeves, 
while non-pulmonary vein sources also become more important as AF continues to persistent form. 
Thereafter, AF is often sustained by a primary “driver” mechanism, which may be either focal 
ectopic sources or rapid local re-entry in a vulnerable substrate. Re-entry also involves both a 
substrate (a modified atrium or a portion of it) and a trigger (often an ectopic beat) (Nattel et al., 
2008). The excitation seems to propagate through the susceptible substrate with a circular or spiral 
wavefront, mentioned as a rotor, thereby sustaining the AF and the alteration of the structure of 
the atrium (substrate). 
Atrial remodeling has the ability to enhance the probability of ectopic or reentrant activity through 
a multitude of potential mechanisms (Khaji and Kowey, 2017; Nattel et al., 2008) 
 
 
Figure 6: Schematic illustration of atrial fibrillation (Nattel et al., 2008). 
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Figure 7: AF mechanisms and relationship to clinical forms (A) represents local ectopic firing, 
(B) represents single circuit reentry, (C) represents multiple-circuit reentry. (D) represents various 
AF clinical forms in relation to mechanisms. Paroxysmal forms involve local triggers/drivers 
mainly from pulmonary veins (PVs). Reentry substrates (initially functional and then structural) 
become prominent as AF continues towards permanent. Where, RA: right atrium; SVC: superior 
vena cava; LA: left atrium; IVC: inferior vena cava (Nattel et al., 2008). 
 
2.1 Electrophysiological remodeling 
Sustained AF with atrial rhythms as high as 350 to 600 bpm, in turn, results in electrophysiological 
remodeling, which consists of mainly the outward K+ current (Ito), the ultra-rapid delayed rectifier 
K+ current (IKur), and L-type Ca2+ current (ICa,L), and, in parallel, upsurges in the inward rectifier 
K+ current (IK1), the agonist-independent form of the acetylcholine-dependent K+ current (IK,ACh), 
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and the slow component of the delayed rectifier K+ current (IKs). The consequence of these various 
alterations in currents leads to shortening of the action potential and effective refractory period 
(ERP), and thus maintenance of AF (Nattel et al., 2008). Significantly, this electrophysiological 
remodeling may also be accompanied with abnormal Ca2+ handling and enhanced propensity of 
potentially proarrhythmic Ca2+ release events from sarcoplasmic reticulum during diastole, which 
has the potential to compromise atrial contractility and show an exasperating role in the initiation 
and maintenance of ectopic (triggered) activity (Beavers et al., 2013; Chelu et al., 2009; Dobrev 
et al., 2011; Hove-Madsen et al., 2004; Neef et al., 2010; Voigt et al., 2014; Voigt et al., 2012). 
Electrophysiological remodeling is vague when the heart is in sinus rhythm, and is less recurrent 
in paroxysmal AF, mainly due to reversibility during AF-free intervals (Dobrev and Nattel, 2010; 
Voigt et al., 2014; Voigt et al., 2013). Remodeling can occur within h, days, or weeks of the onset 
of arrhythmia. It is linked with a higher incidence of delayed after depolarizations (DADs) and 
triggered activity (Voigt et al., 2014). 
 
Figure 8: AF mechanism (Ferrari et al., 2016). 
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2.2 Atrial stretch and mechanical remodeling 
Several studies have documented that the size of the atrium is an important determinant of AF 
occurrence. The Framingham study, which prospectively followed up adults with routine M-mode 
echocardiograms, revealed that left atrial size is an independent risk factor for the subsequent 
development of AF with a hazard ratio of 1.39 for every 5-mm incremental increase in left atrial 
size. Likewise, in the Cardiovascular Health Study, a left atrial diameter > 5 cm had been 
associated with a relative risk of 4.05 (1.95–8.35) for the development of AF (Corradi, 2014a). 
From a pathophysiologic point of view, atrial stretch is shown to result in a wide range of 
electrophysiologic changes, constituting prolongation of late repolarization while early 
repolarization has been shortened, increased excitability, and changes in the nature of AF electrical 
sources. Using optical mapping techniques, it was previously established that atrial stretch 
increases the frequency or reentries (rotors) and the spatiotemporal stability of AF waves. In 
patients with HF or mitral valve disease, it is not uncommon to have restoration of sinus rhythm 
when the size of the atria diminishes after surgical repair of the valve. Moreover, once AF has been 
initiated, the hemodynamic status of the patient worsens because of the loss of atrial contraction, 
creating a vicious circle that greatly favors AF maintenance (Anumonwo and Kalifa, 2014). The 
mechanical (contractile) remodeling is started as fast as the electronic one, usually within 48 h 
after AF onset. The decreased release of calcium ions, secondary to down regulation of the 
channels responsible, and the loss of sarcomeres (myolysis) leads to contractile remodeling. The 
loss of mechanical atrial activity results in atrial dilatation and formation of thrombi and, also leads 
to AF progression through the formation of a larger space for fibrillatory wave perpetuation. Due 
to loss of sarcomeres, the recovery of contractile activity after the conversion to sinus rhythm 
becomes more difficult than reverse electrical remodeling (Vizzardi et al., 2014). 
 
2.3 Structural remodeling and fibrosis 
By contrast to electrophysiological remodeling, structural remodeling happens on a larger 
timescale over months or even years, and seems to be connected with age, hypertension, and 
numerous comorbid cardiac diseases. This is the basis for early and aggressive management of 
allied situations, such as hypertension, heart failure, and coronary artery disease, which may 
precede AF (Nattel et al., 2014; Van Gelder et al., 2011). The intimate molecular mechanisms are 
not fully comprehended, though interstitial fibrosis, mainly through the cardiomyocyte– 
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myofibroblast interaction, has been frequently suggested. Indeed, AF favours the differentiation 
of fibroblasts into myofibroblasts, which secrete more collagen than fibroblasts, express some 
cardiac channels, including IKur, and exert a paracrine activity on cardiomyocytes. This interaction 
has been critical to both electrophysiological and structural remodeling, including maintenance of 
the re-entrant substrate (Heijman et al., 2014). 
Reactive interstitial fibrosis separates muscle bundles, whereas reparative fibrosis replaces dead 
cardiomyocytes, interfering with electric continuity and slowing conduction. Fibroblasts can 
couple electrically to cardiomyocytes and, when increased in number, promote reentry and/or 
ectopic activity (Akoum et al., 2011; Yue et al., 2011). AF itself may enhance structural 
remodeling generating a long term positive feedback loop that leads to the development of 
permanent forms (Iwasaki et al., 2011b). 
Marrouche et al., showed that the magnitude of atrial fibrosis correlates with increased risk of 
AF as well as progression from paroxysmal to persistent and permanent. Thus, categorized the 
magnitude of atrial fibrosis to Utah 1–4. Utah 1 has 0–5% fibrosis, Utah II >5–20%, Utah III 
>20–35% and Utah IV >35% (Mittal et al., 2011; Shenasa et al., 2014) 
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Figure 9: The link between types of AF and magnitude of atrial fibrosis which is observed by 
delayed-enhanced magnetic resonance imaging (MRI) (Shenasa et al., 2014). 
 
Atrial interstitial fibrosis may be the consequence of non-specific scar-like reparative methods 
subsequent to cardiomyocyte necrosis or, more interestingly, be secondary to reactive fibro- 
proliferative signaling pathways. Numerous secreted factors are found to be profibrotic and 
potential mediators of structural remodeling. In addition to their individual effects, they often act 
synergistically. Angiotensin II and transforming growth factor-1 (TGF-1) are well-established 
profibrotic molecules, and recent evidence points to significant roles for platelet-derived growth 
factor (PDGF), connective tissue growth factor (CTGF), the ANP and the highly promising 
galectin-3 (Corradi et al., 2008; Nattel et al., 2008). 
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Figure 10: Profibrotic and proremodeling responses of angiotensin II. Where, Ang II, 
angiotensin II; DAG, diacylglycerol; ERK 1/2, extracellular signal-related kinase 1/2; JAK, 
Janus kinase; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MEK 
1/2, mitogen-activated/ERK kinase 1/2; MMP, matrix metalloproteinase; NF-κB, nuclear factor-
κB; PKC, protein kinase C; PIP2, phosphatidylinositol bisphosphate; PLC, phospholipase C; 
SMAD, SMA- and MAD-related proteins; STAT, signal transducers and activators of 
transcription; TAK1, TGF-β1–activated kinase 1; TF, transcription factor; TGF-βR, TGF-β 
receptor and IP3, inositol 1,4,5-trisphosphate (Nattel et al., 2008). 
 
2.3.1 Angiotensin II 
Angiotensin II (Ang II), through its Ang II type 1 receptors (AT1R) has the capacity of 
encouraging, each time, cardiomyocyte hypertrophy (Sadoshima and Izumo, 1996), endothelial 
changes (Usui et al., 2000), vasoconstriction, apoptotic cardiomyocyte death, and myocardial 
fibrosis (Corradi, 2014a). Ang II facilitates cardiac fibrosis in a variety of cardiac pathologies, 
including hypertensive heart disease, CHF, myocardial infarction, and cardiomyopathy. Marked 
atrial dilation with focal fibrosis and AF was seen in transgenic mice with cardiac-restricted ACE 
overexpression (Xiao et al., 2004). Angiotensin II (Ang II), has been also known to promote 
aging and cellular senescence (Shan, Bai et al. 2008). Ang II mainly acts by binding to 2 discrete 
receptor subtypes, angiotensin type I (AT1R) and type II (AT2R) receptors both of which have 
opposing actions. AT1R signaling through the Shc/Grb2/SOS adapter-protein complex triggers 
the small GTPase protein Ras, which instigates mitogen-activated protein kinase phosphorylation 
cascades that are centrally involved in remodeling (Hunyady and Catt, 2006) The mitogen-
activated protein kinases ERK (extracellular signal related kinase)-1 and -2, p38, and JNK (c-Jun 
N-terminal kinase) activate transcription factors (Elk-1, c-jun, and c-fos) that regulate gene 
expression. Moreover, AT1R activation also activates phospholipase C. Phospholipase C, in turn, 
breaks down membrane phosphoinositol bisphosphate (PIP2) into diacylglycerol and inositol 
1,4,5-trisphosphate (IP3). Diacylglycerol stimulates protein kinase C, and IP3 causes intracellular 
Ca2+ release, both of which endorse remodeling. Signal transduction also happens through the 
JAK/STAT pathway, 
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galvanizing transcription factors such as activator protein-1 and nuclear factor-κB. AT2R 
instigation inhibits mitogen-activated protein kinases (Hunyady and Catt, 2006) via 
dephosphorylating actions of phosphotyrosine phosphatase and protein phosphatase 2A and results 
in antiproliferative and survival-promoting effects that are opposite to AT1R-mediated changes. 
 
Figure 11: Cardiomyocyte-fibroblast crosstalk. Humoral and mechanical stimuli are amplified by 
various autocrine and paracrine mechanisms which lead to tissue fibrosis. Where, Ang II: 
angiotensin II; AT-R: angiotensin receptor; ECM : extracellular matrix; TGF transforming growth 
factor; TGF-βR: trasforming growth factor beta receptor (Burstein and Nattel, 2008). 
 
2.3.2 Transforming growth factor-β1 (TGF-β1) 
TGF-β1 is secreted by both cardiomyocytes and fibroblasts and acts as a primary downstream 
mediator of Ang II effects in both autocrine (influencing the cell that produces Ang II/ TGF-β1) 
and paracrine (influencing adjacent cells) manners. Ang II induces TGF-β1synthesis, which 
potently stimulates fibroblast activity. In turn, TGF-β1 reciprocally enhances the production of 
Ang II and additional profibrotic factors to create positive feedback (Rosenkranz, 2004) TGF-β1 
acts primarily through the SMAD protein (homolog of the Drosophila protein “mothers against 
decapentaplegic,” or MAD, and the Caenorhabditis. elegans protein, SMA) pathway to stimulate 
fibroblast activation and collagen deposition (Attisano and Wrana, 2002). Cardiac overexpression 
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of constitutively active TGF-β1 causes selective atrial fibrosis, atrial conduction heterogeneity, 
and AF promotion (Zhang et al., 2014). Mechanical stretch can itself induce in fibroblast Ang II 
and TGF-β1 expression, therefore greatly influencing the atrial structural remodeling and its 
propensity to arrhythmic disorders (Schotten et al., 2003). 
 
2.3.3 Platelet-derived growth factor (PDGF) 
PDGF rouses fibroblast proliferation and differentiation. Occupation of PDGF receptors causes 
them to dimerize, which stimulates a tyrosine kinase that forms part of the PDGF receptor 
molecule. This tyrosine kinase phosphorylates intracellular domains of the PDGF receptor 
(autophosphorylation). Autophosphorylation activates PDGF receptors, resulting in signaling via 
mitogen-activated protein kinase, JAK/ STAT, and phospholipase C pathways shared with TGF- 
1 and Ang II. PDGF seems to underlie atrium-selective fibroblast hyperresponsiveness, which may 
explain why atria are much more susceptible to fibrotic remodeling than ventricles (Burstein et 
al., 2008). 
 
2.3.4 Connective tissue growth factor (CTGF) 
CTGF is a member of the CCN (Cyr61, CTGF, NOV) (Wu et al., 2016) protein family and a major 
downstream effector of TGF-β1 fibrosis promotion. Areas with active myocardial remodeling 
show coordinate CTGF expression with TGF-1 (Chuva de Sousa Lopes et al., 2004) CTGF is 
upregulated by both Ang II and TGF-β1, (Chen et al., 2000) and it directly activates fibroblasts 
(Ahmed et al., 2004). 
 
2.4 Coagulation cascade components and AF 
It is known for many decades that AF has been associated with the activation of local and 
circulating coagulation factors (hypercoagulability). This AF-related hypercoagulability 
significantly enhances the risk of clot formation and stroke in patients with AF (Watson et al., 
2009). However, little has been known about the potential role of this AF-related 
hypercoagulability in atrial tissue remodeling and predominantly the role of thrombin or factor Xa. 
Apart from its haemostatic effects, thrombin also shows cellular effects that have been mediated 
by protease-activated receptors (PARs) (Papadaki et al., 2017). 
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PARs constitute family of G protein-coupled receptors that become activated by proteolytic 
cleavage of the N-terminal domain, revealing a new tethered ligand that binds intramolecularly to 
activate the receptor and to induce intracellular signal transduction. Four members of the PAR 
family are identified, PAR-1 to -4. PAR-1 being mainly activated by thrombin, whereas PAR-2 
being primarily activated by trypsin and trypsin-like proteases. Numerous cell types are activated 
by thrombin, including platelets, vascular smooth muscle cells (VSMCs), lymphocytes and 
endothelial cells (ECs) through the PARs activation, thus linking coagulation with inflammation 
(Papadaki et al., 2017). Both PAR1and PAR2 are found in the heart. PAR1 is chiefly expressed 
by myocytes, fibroblasts, endothelial cells, and SMCs (Antoniak et al., 2011). Although PAR2 is 
also expressed by myocytes, endothelial cells, and SMCs, its expression by fibroblasts has not 
been confirmed. 
Thrombin activates proinflammatory signaling, which lead to the expression of adhesion mole- 
cules and P-selectin on the membrane of platelets and ECs, as well as expression of various 
cytokines such as interleukin -6 and chemokines MCP-1 and adhesion molecules such as ICAM- 
1, VCAM-1 and E-selectin from fibroblasts, VSMCs and ECs, leading to leukocyte recruitment to 
the vessel wall and contributing to inflammatory and fibrotic processes. Moreover, thrombin 
induces ECs apoptosis through the activation of nuclear factor κB (NF-κΒ) and caspases, regulates 
prosctacyclin and nitric oxide production leading to ECs shape change and to the enhancement of 
barrier permeability (Papadaki et al., 2017). Thrombin contributes in formation of left atrial 
remodeling and it has been known that direct oral anticoagulants, such as direct thrombin inhibitors 
(DTIs), can prevent its progression (Jumeau et al., 2016a). 
An arrhythmogenic potential has been suggested for thrombin in ventricular myocytes in addition 
to effects related to tissue remodeling (Spronk et al., 2014). The action potential duration is 
prolonged by thrombin. Also, thrombin increased ventricular arrhythmias in reperfusion 
experiments performed in adult rat hearts (Spronk et al., 2014). In addition, thrombin enhanced 
arrhythmogenesis in rabbit pulmonary vein preparations, by reducing the spontaneous beating rate 
and inducing delayed after depolarizations and burst firing (Chang et al., 2012). Besides an 
arrhythmogenic potential, thrombin also caused an increased release of atrial natriuretic peptide 
from adult rat atrial cardiomyocytes (Klapper et al., 1996) as well as from rat ventricular myocytes 
(Spronk et al., 2014). Thrombin and PAR1 being detected in human autopsied hearts, and their 
expression levels were higher in left atrial tissue compared with left ventricular tissue (Ito et al., 
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2013). Thrombin-activated PAR1 also induced arrhythmogenic effects in atrial preparations and 
increased sodium influx by increasing the persistent sodium current in human atrial 
cardiomyocytes (Pinet et al., 2008). 
Moreover, direct signaling effects of factor Xa (FXa) have also been noted. FXa persuaded the 
expression of PARs and inflammatory molecules in human atrial tissue slices (Bukowska et al., 
2013) and tachyarrhythmia alone also increased the expression of PAR1. The cellular effects of 
this stimulation have been likely to contribute to structural remodeling in fibrillating and dilated 
atria (Sabri et al., 2000). Inflammatory changes, tissue fibrosis, and cellular hypertrophy 
significantly contribute to loss of electrical conductivity between myocytes and thus conduction 
disturbances in fibrillating and dilated atria. Overall, the pivotal role of PAR activation and 
hypercoagulability in the development of AF was underlined by the recent demonstration that 
specific coagulation inhibitors targeting thrombin or Xa may prevent arrhythmogenic cellular 
changes or tissue remodeling (Jumeau et al., 2016b). 
Figure 12: Cellular locations of PAR1 and PAR2 and the effetcs observed by thrombin- or factor 
Xa-mediated PAR acivation on the heart and vasculature, which leads to atherosclerosis and AF 
(Spronk et al., 2014). 
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2.5 Neural/Autonomic Remodeling 
Autonomic nervous system factors play an important role in AF. Vagal discharge increases 
acetylcholine-dependent K current (IKACh), decreasing APD and stabilizing reentrant rotors. 
Adrenoceptor activation enhances diastolic Ca2+ leak and encourages DAD-related ectopic firing 
by hyperphosphorylating RyR2s. Atrial sympathetic hyperinnervation ensues in persistent AF 
patients and tachycardia-remodeled dogs. Autonomic neural remodeling adds to positive feedback 
loops that enhance AF persistence and recurrence. Suppression of autonomic signaling may 
contribute to the efficacy of PV-directed ablation procedures for AF, particularly in certain patient 
subsets; in experimental AF models, model-specific autonomic ganglion ablation effects depend 
on autonomic innervation changes (Chou and Chen, 2009; Dobrev et al., 2011; Iwasaki et al., 
2011a; Nishida et al., 2011). 
 
2.5 Anatomic Factors 
 
 
2.6.1 Roles of specific structures 
Haïssaguerre et al. observed that PVs are a major source of ectopic beats with 94% of the triggers 
initiating AF originate within one or more PVs and may interact with the surrounding left atrial 
substrate through discrete or wide fascicles and, can frequently initiate paroxysms of AF (triggered 
AF episodes). In fact, irregular atrial sleeves of cardiomyocytes with potential spontaneous 
electrical activity extend over the veno-atrial junction into the PV wall and have electrical activity 
(Corradi, 2014b). The sleeves (whose size is up to 25 mm in length) mainly consist of circularly 
or spirally oriented bundles of cardiomyocytes that interconnect with each other in a continuous 
pattern with some gaps throughout. Several mechanisms have been associated with PV 
arrythmogenicity. Experimentally, triggered activity and irregular high-frequency rhythms have 
been observed following ryanodine infusion, atrial stretching, rapid atrial pacing and congestive 
heart failure, but, seemingly, not in normal PV cardiomyocytes. In this situation, the anatomical 
and electrical isolation of PVs has become a foundation of ablation techniques (Allessie et al., 
2010; Haissaguerre et al., 1998; Verma, 2011). However, the success of this PV isolation is limited 
in some patients with paroxysmal AF and, especially, in the great majority of those subjects with 
persistent/permanent AF, very likely because of more extensive atrial remodeling additionally 
involving extra-PV locations (Chen et al., 1999; Oral et al., 2002). The most frequent sites of non- 
41  
PV atrial triggers include the posterior wall of the left atrium, the superior vena cava, the coronary 
sinus, the ligament of Marshall, and the region adjacent to the atrioventricular valve annuli. 
Furthermore, the atrial ganglionated plexi may play a significant role in the pathogenesis of AF 
(Corradi et al., 2013). 
 
2.6.2 Regional Ion Current Differences 
The LA has most important role in AF initiation and maintenance, mainly for paroxysmal AF. 
Reentrant rotors are usually faster in the LA than in the right atrium, causing them more likely to 
be drivers, mainly because of larger K currents that reduce APD. PV cardiomyocytes have shorter 
APDs due to larger delayed rectifier K currents and smaller ICaL, along with reduced resting 
potentials because of smaller IK1 (Iwasaki et al., 2011a) 
 
Figure 13: AF trigger points. Red abbreviations showing the most and black abbreviations 
showing the less AF common trigger points. Where, CS: coronary sinus; CVs: canal veins; LAPW: 
left atrial posterior wall; LM: ligament of Marshall; PVs: pulmonary veins (Corradi, 2014a). 
 
2.7 Atrial fibrillation and inflammation 
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Wondering whether inflammation is the cause or consequence of AF is probably the “chicken and 
egg” conundrum. Based on the available literature, very likely, both hypotheses are true. 
Inflammation constitutes a noteworthy trigger for the arrhythmia and, at the same time, AF 
produces an inflammatory environment. In addition, many studies provide convincing evidence 
that inflammation plays an important role in the pro-thrombotic state associated with AF. The 
mechanism linking these two phenomena involve activated inflammatory cells (i.e., monocytes, 
macrophages, and lymphocytes) which trigger endothelial dysfunction, platelet activation, and 
increase fibrinogen production (Guo et al., 2012). 
Several inflammatory markers—such as C-reactive protein (CRP), tumor necrosis factor alpha 
(TNFα), interleukin 2, interleukin 6 (IL-6), interleukin 8 (IL-8), and monocyte chemoattractant 
protein 1 (MCP1) are linked with AF (e.g. in post-operative AF) and its outcome (Ozaydin, 2010). 
Marcus et al. found increased CRP levels in the left atrium than in the corresponding coronary 
sinus and concluded that trans-cardiac cytokine gradients in AF ascend by sequestration of 
inflammatory cytokines in the heart (Guo et al., 2012). Also, the presence of inflammation in the 
heart or systemic circulation not only predicts the onset of AF and recurrence in the general 
population, but also in patients after cardiac surgery, cardioversion, and catheter ablation. 
Mediators of the inflammatory response can change atrial electrophysiology and structural 
substrates, thereby resulting in enhanced vulnerability to AF. Inflammation also modulates 
calcium homeostasis and connexins, which are linked with triggers of AF and heterogeneous atrial 
conduction. Myolysis, cardiomyocyte apoptosis, and the activation of fibrotic pathways via 
fibroblasts, transforming growth factor-β and matrix metalloproteases have also been controlled 
by inflammatory pathways, which can all cause structural remodeling of the atria. The progression 
of thromboembolism, a detrimental complication of AF, is also associated with inflammatory 
activity. Thus, understanding the complex pathophysiological processes and dynamic changes of 
AF-associated inflammation might help to improve specific anti-inflammatory strategies for the 
prevention of AF (Hu et al., 2015). 
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Figure 14: Sources of inflammation in AF patients. Activated inflammatory pathways 
significantly alter the remodeling of the atria. Where, Ang II: angiotensin II; HSP: heat shock 
protein; MPO: myeloperoxidase; PDGF: platelet-derived growth factor; ROS: reactive oxygen 
species; TGF-β: transforming growth factor β (Hu et al., 2015). 
 
 
 
 
Figure 15: Association of inflammatory pathways in cardiac fibrosis. Where, IL: interleukin; 
MPO: myeloperoxidase; NF-κB: nuclear factor kappa B; PDGF: platelet-derived growth factor, 
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RAAS: renin-angiotensin-aldosterone system; TGF-β1: transforming growth factor β1; TNF: 
tumor necrosis factor (Dzeshka et al., 2015). 
 
2.8 Atrial fibrillation and oxidative stress 
Several studies conducted show a positive correlation between oxidative stress and AF induction 
and maintenance (Corradi et al., 2008; Li et al., 2010; Youn et al., 2013b). Increased levels of 
reactive oxygen species (ROS) such as superoxide anions and H2O2 have been found to be 
associated with AF in the myocardium (Kim et al., 2005; Kim et al., 2008b; Youn et al., 2013a; 
Zhang et al., 2012). The oxidized GSSG/reduced glutathione and oxidized cysteine/reduced 
cysteine ratios are increased in the blood of patients with AF (Neuman et al., 2007). Amplified 
ROS levels result in damage to proteins, lipids, and DNA, and aggravate inflammation. In addition, 
ROS have also been implicated in cardiac structural and electrical remodeling. In fact, it is shown 
that hydroxyl radical (OH−) and peroxynitrate (ONOO−) facilitate oxidative damage of myofibrils 
in AF (Babusikova et al., 2004; Mihm et al., 2001). With regard to atrial electrical remodeling, 
this has been found to be linked with intracellular calcium overload. Carnes et al., in a dog model, 
showed that AF induced by rapid pacing decreased myocardial tissue ascorbate levels and 
upregulated protein nitration (Carnes et al., 2001). Coronary artery bypass surgery, which is often 
intricated by post-operative AF, is accompanied with an increase in oxidized glutathione and lipid 
peroxidation (Basu et al., 2000; Wolin and Gupte, 2005). In patients with persistent AF and mitral 
valve disease, higher myocardial tissue levels of the inducible oxidative stress marker heme 
oxygenase 1 (HO-1) were documented compared to controls. Interestingly, HO-1 was more 
articulated where the structural remodeling peaked (left atrial posterior wall vs left atrial 
appendage). In comparison with controls, both HO-1 overexpression and greater 3-nitrotyrosine 
levels were noted in the left and right atrial free walls of individuals with idiopathic persistent AF 
(Corradi, 2014b). 
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Figure 16: Oxidative stress in cardiac fibrosis. Where, ERK: extracellular signal-regulated kinase; 
JNK: c-Jun N-terminal kinase; MAPK: mitogen-activated protein kinase; NADPH: reduced 
nicotinamide-adenine dinucleotide phosphate; NOS: nitric oxide synthase; p38: p38 mitogen 
activated protein kinase; ROS: reactive oxygen species (Dzeshka et al., 2015). 
 
2.9 Atrial fibrillation, stroke and microparticles 
AF has been found in about 25% of patients admitted with ischemic stroke as it increases the risk 
of stroke by 3–6 fold. The most devastating complication of AF is stroke which causes death, 
neurological deficits, longer hospitalization and disability. Many studies have documented the 
relationship between AF and stroke. The Stroke Prevention in Atrial Fibrillation Study (SPAF III) 
data revealed that up to 45% of the patients enrolled had ECG documentation of AF. Stroke can 
occur as the first manifestation of AF. Based on the STROKESTOP trial it is suggested that 
patients with silent AF should be screened for the risk of stroke (Friberg et al., 2013). Several 
stroke risk prediction scores have been documented. The most widely accepted predictor is 
CHADS2 (Congestive Heart Failure (CHF), hypertension, age, diabetes, stroke/transient ischemic 
attack) however, recently CHADS2-VASC score has been suggested which additionally involves 
age >65 years, vascular disease and female sex. CHADS2 has been validated by several studies 
and CHADS2-VASC is more popular in Europe. There is a stepwise approach increase in risk of 
stroke as the CHADS2 or CHADS2-VASC score increases (Mason et al., 2012) . 
Being, small membrane vesicles, microparticles (MPs) that are found to shed from virtually all 
cells in response to stress have been extensively described in various atherothrombotic diseases. 
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Also, many recent findings propose a predominant role of circulating MPs in the setting of 
hypercoagulable state which is associated with supraventricular tachyarrhythmia (Jesel et al., 
2013; Wang et al., 2018), thus suggesting a critical association with atrial fibrillaton. 
 
 
 
 
Table 2: Risk scheme for CHADS2 and CHADS2-VAS2 (Shenasa et al., 2014) 
 
2.10 Management of Atrial fibrillation 
Atrial fibrillation management constitutes symptoms management and prevention of complications 
requiring treatment of associated cardiac or endocrine disease, control of cardiac rhythm and 
ventricular rate, and antithrombotic therapy (Kirchhof, Benussi et al. 2016, Andrade, Verma et al. 
2018). 
 
2.10.1 Rate control therapy in atrial fibrillation 
 
Rate control being an integral part of the AF management, has been often sufficient to improve AF-
related symptoms. Pharmacological rate control has been usually attained by medications that 
decrease the number of impulses conducting into the ventricles thus increasing the degree of block at 
AV node level. Most commonly used agents are β-blockers (e.g., metoprolol, bisoprolol or 
nebivolol), non-dihyrdopyridine calcium channels blockers (e.g., diltiazem or verapamil) or digitalis 
compounds (Andrade, Verma et al. 2018). Sometimes, when pharmacological interventions are 
inefficient or not tolerated in AF subset patients then, the option is a non-specific and palliative last 
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resort strategy consisting of AV node ablation and pacemaker implantation (Dobrev and Nattel 2010, 
Ravens 2010). 
 
2.10.2 Rhythm control therapy in atrial fibrillation 
 
Rhythm control drugs target to restore a normal sinus rhythm, process called cardioversion. The 
classic antiarrhythmic Na+ current inhibitors, class I drugs decrease excitability whereas, K+ channel 
blocking, class III drugs suppress re-entry circuits by increasing action potential duration and 
repolarization. Amiodarone, being most frequently used antiarrhythmic drug to achieve and maintain 
normal sinus rhythm also possess heart rate lowering effect thus concomitantly can be used for rate 
control. However, in some cases the use of amiodarone is limited due to its severe adverse effects 
mainly pulmonary toxicity, skin discoloration, thyroid toxicity, corneal deposits, optic neuropathy, 
and sinus bradycardia (Schmidt, Kisselbach et al. 2011). Although many clinicians are of the view 
that preserving sinus rhythm results in improved outcomes in AF patients, however, all trials that 
compared rhythm control and rate control to rate control alone (alongwith appropriate 
anticoagulation) resulted in neutral outcomes (Kirchhof, Benussi et al. 2016). Thus, in clinical 
practice, the decision between rate or rhythm control relies on various patient-specific factors 
constituting duration and frequency of AF episodes, underlying structural or endocrine disease, and 
the consequences of previous treatment regimes (Andrade, Verma et al. 2018) 
 
2.10.3 New antiarrhythmic drugs 
 
Dronedarone was approved as new antiarrhythmic drug based on the results of a Placebo Controlled, 
Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the 
Prevention of Cardiovascular Hospitalization or Death from any Cause in Patients with Atrial 
Fibrillation/Atrial Flutter (ATHENA trial) (Hohnloser, Crijns et al. 2009) that shows both rhythm and 
rate control by dronedarone in AF patients, with less side effects compared with amiodarone. Thus, 
showing decreased frequency of hospitalization resulting from cardiovascular events or death in high-
risk AF patients. Another, antiarrhythmic drug vernakalant granted market approval after a Phase III 
Superiority Study of Vernakalant vs Amiodarone in Subjects with Recent Onset Atrial Fibrillation 
(AVRO) trial for the conversion of recent-onset AF to sinus rhythm (Dorian, Pinter et al. 2007, 
Dobrev, Hamad et al. 2010). The trial showed dominance of vernakalant over amiodarone for 
cardioversion within 90 minutes (Camm, Capucci et al. 2011). 
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2.10.4 Catheter ablation of atrial fibrillation  
 
Catheter ablation has been predominantly achieved by isolation of the pulmonary veins, sometimes 
necessitate whole isolation to achieve full effectiveness and supplementary ablation in the posterior 
left atrial wall. When it is performed in well-equipped centres by sufficiently trained teams appeared 
to be more effective than antiarrhythmic drug therapy in maintaining sinus rhythm (Camm, Kirchhof 
et al. 2010). 
 
2.10.5 Prevention of thromboembolic events in atrial fibrillation 
 
With Atrial fibrillation there is an increased risk of stroke, and it has been shown by various studies 
that oral anticoagulation consisting vitamin K antagonists (VKA) are more efficacious with respect to 
aspirin regarding stroke prevention (Hart, Benavente et al. 1999, Gage, Waterman et al. 2001, Gage, 
van Walraven et al. 2004, Fuster, Ryden et al. 2006). Antithrombotic therapy is advised on the basis 
of systemic embolism and patient-specific evaluation of risk factors for stroke (Lip, Nieuwlaat et al. 
2010, Fuster, Ryden et al. 2011) In patients with a CHADS2 score of 0–1 additional risk stratification 
using the CHADS2 -VASC scheme has been recommended. Direct thrombin inhibitors (e.g., 
dabigatran) and factor Xa inhibitors (e.g., rivaroxaban, apixaban) are new oral anticoagulant drugs 
that are effective, safe and convenient to use (Connolly, Ezekowitz et al. 2009, Lopes, Alexander et 
al. 2010). In addition, the results of the Stroke Prevention using the Oral Direct Factor Xa Inhibitor 
Rivaroxaban Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation (ROCKET AF) 
trial (2010) showed that the factor Xa inhibitor rivaroxaban was as effective as warfarin in preventing 
stroke in AF patients and did not increase their risk of bleeding.  
 
2.10.6 Interventional approaches to stroke prevention 
 
Almost 90% of thromboembolisms linked with AF have been due to thrombi originating from the left 
atrial appendage (LAA). Therefore, occlusion of the LAA deliver a non-pharmacological substitute 
for curtailing the risk of stroke in AF patients (Kanderian, Gillinov et al. 2008, Dawson, Asopa et al. 
2010). 
 
2.10.7 Upstream therapy  
 
Upstream therapy targeted against myocardial remodeling accompanied with hypertension and heart 
failure may hinder AF development (primary prevention) and can also decrease recurrence rates and 
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progression to permanent AF (secondary prevention) (Savelieva, Kakouros et al. 2011). Angiotensin-
converting enzyme inhibitors, angiotensin II receptor blockers, and statins has been considered for 
primary and secondary prevention in patients with concomitant structural heart disease and in cases of 
recurrent AF despite antiarrhythmic drug therapy respectively (Fuster, Ryden et al. 2006, Camm, 
Kirchhof et al. 2010). However, evidences from different trials conducted for upstream therapy for 
prevention of atrial remodeling still remains controversial (Savelieva and Camm 2007, Disertori, 
Barlera et al. 2012) 
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3 ENDOCARDIAL ENDOTHELIAL CELLS 
3.1 Introduction 
 
Cardiac endothelial cells comprise microvascular endothelial cells (MVECs) and endocardial 
endothelial cells (EECs), whereas vascular endothelial cells line the interior surface of blood 
vessels. Endocardial endothelium line the complex cavitary surface of the heart wall that continues 
over the surface of the valve and extends on to form the lining of large blood vessels. By creating 
a natural biological barrier (blood-heart barrier) between the circulating blood in heart cavities and 
cardiomyocytes, endocardial endothelium creates a complex but finely tuned balance of 
interactions between these units (Brutsaert, 2003). Endocardial endothelial cells constitute 
endocrine and sensory role, thus playing an important physiological role on cardiomyocytes, 
terminal network of Purkinje fibers and subendocardial nerve plexus (SNP) (Verma and Anderson, 
2002). 
The existence of an intact endocardial endothelium significantly modify the contractility of the 
heart, hence, the change in the contraction curve can be observed if there is selective damage or 
dysfunction of endocardial endothelium. Furchgott and Zawadski in 1980 first described the 
impact of vascular endothelium on the vascular smooth muscle contractility (Furchgott and 
Zawadzki, 1980) and later it was observed for the endocardial endothelium as well (Brutsaert et 
al., 1988; Shen et al., 2013; Smiljic et al., 2010). By increasing the sensitivity of myofilament to 
Ca2+ ions through the release of endothelial mediators the intact endocardial endothelium improves 
the contractility of the heart muscle (Shen et al., 2013). 
Endocardial and myocardial capillary endothelium release many autocrine and paracrine signaling 
substances such as nitric oxide (NO), endothelin (ET-1), prostaglandins (PGI2,  PGF2,  PGE2)  
and angiotensin II (Ang II) thus, having an affect on the contractility of cardiomyocytes. Also, in 
the regulation of cardiac inotropic state, the important role of other endothelial mediators, such 
as fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), neuregulin-1 
(NRG-1) and angiopoietin has also been documented (Brutsaert, 2003; Noireaud and 
Andriantsitohaina, 2014b). 
The development of endocardial endothelium and the endothelium of blood vessels ensues 
simultaneously during embryonic growth. Endocardial endothelium exhibit an important role for 
the proper formation of trabecular myocardium and in heart development. It is necessary for    
the trans-differentiation of myocytes into the heart conduction system cells and Purkinje's fibers. 
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In addition, they are also involved in endocardial-mesenchymal conversion and the development 
of endocardial cushions, which later on give rise to several imperative structures within the heart, 
including the valves, the membranous portion of the interventricular septum, and the atrial septum 
(Brutsaert, 2003). 
 
 
Figure 17: Paracrine relations between cardiac endothelial cells and cardiomyocytes. Endocardial 
endothelial cells (EECs) and intramyocardial capillary endothelial cells (IMCEs) react to physical 
and humoral stimuli by releasing various mediators such as nitric oxide (NO), endothelin 1, 
eicosanoid, and angiotensin II. These endothelial cells also release neuregulin-1 (NRG-1) which 
primarily acts on ErbB receptors found on myocardial cardiomyocytes. IMCEs also secrete 
parathyroid hormone-related peptide (PTHrP) which acts on PTH1 receptor (PTH1-R) present on 
cardiomyocytes. Gap junctions (GJ) facilitate cell-to-cell coupling for rapid intercellular inter- 
relationship of functional demands. Tight junctions (TJ, constituting zonula adherens) regulate the 
transendocardial endothelial-permeability via intercellular clefts. A large number of endothelial 
signaling molecules localize to caveolae (Cav). Sfl: subendocardial fibroelastic layer (or 
extracellular matrix including sympathetic nerve fascicles) (Noireaud and Andriantsitohaina, 
2014b). 
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3.2 Structural characteristics of endocardial endothelial cells 
 
The functional morphological characteristics of endocardial endothelium cells and myocardial 
capillary endothelium are not same as well as their embryonic origin. Thus, the impact of EECs 
and MVECs on myocardial contractility, rhythm and remodeling is different. Also, the distribution 
of receptors for these two endothelial types is not same. In addition, EECs and MVECs have 
diverse cytoskeletal features, such as the existence of contractile bundles of actin filaments (stress 
fibers) and vimentin and microtubule filaments. MVECs have more actin filaments as a 
consequence of greater shear stress exposure. Endocardial cells possess well established 
organelles, importantly Golgi apparatus, and in comparison to microvascular endothelium can 
synthesize more endothelial mediators such as prostacyclin, nitric oxide (NO). 
Moreover, it has been found that EECs are slightly larger compared to endothelial cells of all other 
components of the circulatory system (Mebazaa et al., 1995) and the specificity of EECs has been 
categorized by the existence of particular cellular connections and intracellular spaces when 
compared to vascular or microvascular endothelial cells (Dejana and Del Maschio, 1995; Mebazaa 
et al., 1995). Various complex structural gap-junctions regulate the transendothelial permeability 
and facilitate quick passage of charged ions (primarily Ca2+), secondary messenger molecules and 
small metabolites. 
The existence of plenty of gap junctions in endocardial endothelium, which are not so abundant in 
other endothelial structures, enable a functional connection and the behavior of endocardial 
endothelium as a single operating syncytium. The transcellular ion transport from blood to the 
cardiomyocytal interstitium occurs via passive diffusion through ion channels (inward rectifier 
K+  channels,   Ca2+-activated   K+  channels,   voltage-gated   K+  channels,   volume    activated  
Cl− channels, stretch-activated cation channels) and via active transport (Na+/K+-ATPase) 
(Kuruvilla and Kartha, 2003). The secondary messengers pass many gap junctions after the 
activation of individual EECs to the neighboring endocardial endothelial cells, thus amplifying 
their sensory capacity. 
 
3.3 Physiological role of endocardial endothelium 
 
Endothelial cells being metabolically active exert important paracrine, endocrine and autocrine 
functions including tissue growth and remodeling, immune responses, cell adhesion, angiogenesis, 
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hemostasis and vascular permeability. Endothelium-derived factors with vasodilatory and 
antiproliferative effects mainly include endothelium-derived hyperpolarization (EDH), nitric 
oxide (NO) and prosacylin (PGI2), while angiotensin II, reactive oxygen species (ROS) and 
endothelin-1 possess vasoconstrictive effects. Endothelial cells also secrete antithrombotic (NO 
and PGI2 both inhibit platelet aggregation) and prothrombotic molecules such as von Willebrand 
factor, which promotes platelet aggregation, and plasminogen activator inhibitor-1 (PAI-1), which 
inhibits fibrinolysis (Feletou, 2011; Sena et al., 2013). 
 
Figure 18: Various functions of endothelium (Sena et al., 2013). 
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Figure 19: Endothelial cells are responsible for various physiological functions, including: 1) 
modulation of vascular tone through release of vasodilators and vasoconstrictors; 2) regulation of 
blood fluidity and coagulation via release of factors that regulate platelet activity, the clotting 
cascade, and the fibrinolytic system; and 3) control of inflammatory processes through expression 
of cytokines and adhesion molecules. Where, Ach: acetylcholine; ATR: angiotensin II receptor; 
BK: bradykinin; EDHF: endothelium-derived hyperpolarisation factor; NO - nitric oxide; PAI-1: 
plasminogen activator inhibitor-1; PGH2: prostaglandin H2; PGI2: prostacyclin; O2 • – - superoxide 
anions; t-PA: tissue plasminogen activator; TM: thrombomodulin, TxA2: thromboxane A2; vWF: 
von Willebrand factor (Sena et al., 2013). 
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Figure 20: Relaxing/dilating and constrictive signals send by endothelial cells to the smooth 
muscle cells. Three central pathways have been showed: The constituent endothelial nitric oxide 
synthase (eNOS, NOS III) being regulated by endocrine and paracrine effects such as endothelin- 
1 (ETR, ET-1) and acetylcholine (ACh) as well as shear stress through pertussis toxin-sensitive 
Gq/i pathways, calcium, and calmodulin. Nitric oxide (NO) signals relaxation, but uncoupling can 
lead to increased oxidative stress (H2 O2). The endothelial cells also cause hyperpolarization of the 
cell membrane of smooth muscle cells (endothelium-dependent hyperpolarization factor (EDHF)). 
Cyclooxygenase 1 (COX) releases eicosanoids that constitute in the case of prostacyclin (PGI 2) 
relaxing results through cyclic AMP or  constrictive  effects  predominantly  for  thromboxane 
A2 (TXA2). Angiotensin II (Ang II) show direct (by angiotensin receptor 1 (AT1R)) or indirect 
constrictive effects through ET-1 (Barthelmes et al., 2017). 
3.3.1 Nitric oxide 
 
Cardiac endothelial cells produce and secrete many mediators which effect cardiac growth, 
metabolism, contractility and rhythm, mainly nitric oxide (NO), whose synthesis has been 
catalyzed by endothelial, neural and induced nitric oxide synthase (NOS) (Andries et al., 1998). 
Endothelium constitutive nitric oxide synthase (eNOS) has been found in the coronary 
endothelium, myocardial capillary endothelium, endocardial endothelium and in small amount  
in cardiomyocytes (Balligand et al., 1995) whereas, neuronal NOS (nNOS) has been found in 
cardiac myocytes; nerve fibers in the atrial tissue; in a subpopulation 
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of intracardiac ganglia and and in the perivascular nerve fibers of the ventricular myocardium 
(Zhang, 2016). On the other hand, inducible NOS (iNOS) is functional only under stress conditions 
and release of cytokines (Balligand et al., 2009). 
The cyclical changes in the heart during systole and diastole directly impacts the activity of eNOS 
and NO synthesis. The cyclical release of NO mainly in the subendocardial regions of the heart 
depicts endocardial endothelium as its major source (Balligand et al., 2009; Smiljic et al., 2014a). 
The endothelial-borne reactive oxygen species (ROS), such as superoxide anions, can abruptly 
quench NO synthesized by the endothelial cells, without altering the expression of eNOS (Paolocci 
et al., 2001). The myocardial tissue oxygen consumption is decreased by NO both in physiological 
and pathophysiological conditions (Trochu et al., 2000) which indicates its potential 
cardioprotective effect. Also NO can reversibly compete with oxygen for a common binding   
site on cytochrome-c oxidase which impedes electron transfer to oxygen. Nitric oxide produced 
by myocardial capillary endothelium and endocardial endothelium plays an important role in 
local myocardial   metabolism   (Jones   and    Bolli,    2006).    In    addition,    NO    also 
inhibits platelet aggregation and prevents binding of neutrophils to endothelium thus playing a 
fundamental role in cardiovascular disease protection. 
 
 
Figure 21: Atheroprotective characteristics of nitric oxide generated by endothelial nitric oxide 
synthase (M. Vanhoutte, 2018; Sena et al., 2013). 
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Figure 22: Depicts biosynthesis of nitric oxide and opposing roles of eNOS and nNOS in 
modulating heart contraction (Smiljic et al., 2014a). 
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Figure 23: Autocrine and paracrine nitric oxide modulation of cardiomyocyte (Smiljic et al., 
2014a). 
 
3.3.2 Vasostatin-1 and endothelin-1 
 
By regulating the contractility of the heart catecholamines and neurohormones play an important 
role in heart remodeling. Chronically elevated catecholamine (CA) levels are known to harm the 
heart (Chien et al., 1991; Goldspink et al., 2004; Samuels, 2007). Chromogranin A (CgA) being 
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an important soluble protein, is co-stored in and co-released with CAs from secretory vesicles 
found in adrenal medulla chromaffin cells (Mahapatra, 2008). CgA gives rise to several bioactive 
peptides via a posttranslational proteolytic processing mechanism. One of these peptides, 
vasostatin (VS), is a novel cardiac modulator and a stabilizer of adrenergic tone, which plays an 
important role in cardio-circulatory homeostasis and exhibit cardio-depressive and anti-adrenergic 
effects on isolated and perfused hearts in eel, frog and rat (Cerra et al., 2006; Corti et al., 2004; 
Gallo et al., 2007). Studies have shown that the anti-adrenergic effect prompted by VS-1 is due to 
the Ca2+-independent, PI3K-dependent endothelial release of NO and not due to direct interaction 
with cardiac cells. In addition, VS-1 also exhibits a protective effect in ischemic hearts via an 
adenosine/nitric oxide signaling mechanism (Cappello et al., 2007). This strongly suggests that 
these fragments demonstrate important role in the autocrine/ paracrine regulation of cardiac 
function. Thus, a molecular signaling pathway analysis indicated that the beneficial effects of VS- 
1 on cardiac remodeling may be mediated via the enhanced activation of the eNOS-cGMP-PKG 
pathway (Wang et al., 2016). This strategy was implied to inhibit hypertrophy, fibrosis, and 
ventricular remodeling whilst recouping the cardiac function in the experimental heart models of 
rats that were injected with isoprenaline (Krenek et al., 2009; Wang et al., 2016). 
EECs are a major source of endothelin-1 (ET-1) with cardiomyocytes its principal target. ET-1 
exhibit potent positive inotropic action exerted by amplified sensitivity of myofilaments to Ca2+ 
(Jacques et al., 2000). A positive inotropic outcome is the consequence of the activation of protein 
kinase C (PKC) and protein kinase A (PKA) (Chu et al., 2003). When there is no stimulation for 
ET-1 synthesis and secretion, it exerts an autocrine effect by binding itself to ETB receptors on 
endocardial endothelial cells. Small amounts of ET-1 play an important defensive role in adult 
heart by instigating the release of nitrogen oxides and PGI2 (Castrillo, 2016) 
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Figure 24: Depicts the possible role of endothelin-1 in the pathophysiology of myocardial 
infarction, heart failure and coronary artery disease (Castrillo, 2016). 
 
Figure 25: (A) show transverse section of healthy artery depicting the various layers of artery 
wall, release of endothelin 1 (ET-1) and nitric oxide (NO) by endothelial cells (B) showing 
alterations in the respective role for NO and ET-1 in the modulation of vascular tone after aging, 
various cardiovascular diseases and risk factors (Castrillo, 2016). 
 
A large number of nonendothelial cells in the heart, including cardiomyocytes, can also produce 
ET-1 in response to myocardial stretch, Ang II, and adrenaline (Morimoto et al., 2000). By 
increasing myocardial oxygen consumption it enhances the inotropic effect, while at the same time 
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through its powerful coronary vasoconstrictive effect it also decreases the oxygen supply (Smiljic 
et al., 2014b; Smiljic et al., 2018). 
 
3.3.3 Prostaglandins 
In response to various humoral, chemical, immunological, and mechanical stimuli. cardiac 
endothelial cells can synthesize and release prostaglandins. Cyclooxygenase that show a key 
regulatory role in prostaglandin synthesis (PGE2, PGF2α, PGI2) is expressed in all endothelial cells 
in the heart and is believed to have cytoprotective effects. PGI2 activates adenylate cyclase, causing 
increased production of cAMP resulting in vasodilation and it is also potent antiproliferative agent, 
reduces oxidative stress and prevents cellular adhesion to the vascular wall (Sena et al., 2013). 
PGH2 is found to be the precursor of the prostaglandin E2, F2 and thromboxane A2 (TxA2) thus 
playing an important role in platelet activation and aggregation (Vanhoutte and Tang, 2008). 
Moreover, in the endocardial zone the activity of COX-1 is twice as high compared with the 
myocardium. However, the positive inotropic effect of prostaglandin (PGE2 and PGF2α) could be 
completely abolished after the removal of EE in the atria of the heart. The positive inotropic effect 
is because of the release of prostaglandins from EECs upon the stimulation of muscarinic M3 
receptors (Tanaka et al., 2001). 
 
3.3.4 Angiotensin II 
The effect of Ang II on cardiac growth and contractile performance is the result of locally produced 
Ang II. Ang II is synthesized locally through ACE and an ACE-independent kinase pathway, both 
of which are expressed predominantly in coronary vascular and cardiac endothelial cells (Dostal 
and Baker, 1999). Ang II generally exerts a positive inotropic effect, which may not always be the 
case as different effects are obtained in different conditions. Through its G-protein-coupled Ang 
II type 1 receptor (AT1R), Ang II activates various intracellular protein kinases, such as receptor 
or non-receptor tyrosine kinases, which constitute epidermal-growth factor receptor (EGFR), 
platelet-derived growth factor receptor (PDGFR), c-Src, PYK2, FAK, JAK2. Also, Ang II 
activates serine/threonine kinases such as mitogen-activated protein kinase (MAPK) family, p70 
S6 kinase, Akt/protein kinase B and various protein kinase C isoforms. Ang II also induces the 
generation of intracellular ROS, which show perilous roles in activation and modulation of above 
signal transduction. Recent studies document that endothelial Ang II signaling negatively regulates 
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the NO signaling pathway and thereby induces endothelial dysfunction (Gomolak and Didion, 
2014; Nakashima et al., 2006; Watanabe et al., 2005). Many studies are conducted which describe 
the interactions of the cardiac synthesis, release and activity of Ang II with bradykinin-NO and 
PGI2 pathways, as well as with ET-1. Ang II and ET-1 (Meulemans et al., 1990), for example, 
elicit a synergistic effect on the heart while their receptors on cardiomyocytes are also coupled, 
through similar G proteins, so that their intracellular signaling pathways may be similar (Castrillo, 
2016). 
 
3.3.5 Reactive oxygen species (ROS) 
Reactive oxygen species (ROS) are reactive intermediates of molecular oxygen being 
physiologically formed in cells as byproducts of cellular metabolism, or as toxic molecules 
involved in bacterial killing and host defense. At physiological concentrations, ROS mainly act as 
important second messengers that transduce intracellular signals, which are involved in various 
biological processes (Mittal et al., 2014; Sena and Chandel, 2012; Thomas et al., 2008). However, 
when an aberrant production of ROS surpasses the buffering ability of the antioxidant defense 
systems or when antioxidant enzymes are flawed, oxidative stress occurs. In addition, several 
studies have documented that oxidative stress shows fundamental role in mediating the production 
and secretion of cytokines (Bulua et al., 2011; Zhou et al., 2011), thus relating ROS with 
inflammation and endothelial activation and dysfunction. ROS is generated by a variety of sources 
within the cell. The free radical superoxide anion (O2●-) is the first to be generated and is 
responsible for the formation of other reactive species of physiological relevance such as hydrogen 
peroxide (H2O2), hydroxyl radical (OH●-), and peroxynitrite (ONOO−). Superoxide anions 
produced through the partial reduction of molecular oxygen to O2●- by the mitochondrial electron 
transport chain (ETC), as well as by NADPH oxidase, uncoupled eNOS and xanthine oxidase. 
Reduction in NO bioavailability by increased NO degradation by superoxide anions, marks the 
onset of endothelial dysfunction. Specifically, superoxide anions react with NO and leads to the 
formation of peroxynitrite ONOO− (Landmesser et al., 2003; Wolin et al., 2010). In turn, 
peroxynitrite leads to protein nitration and results in dysfunction and death of endothelial cells. In 
addition, it is well known that cardiac myocytes have a high density of mitochondria. Therefore, 
the consumption of oxygen in cardiac myocytes is relatively higher and also any alterations in 
mitochondrial respiratory chain complexes provide an important contribution to the generation of 
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the oxidative stress-related chemical species (He and Zuo, 2015; Incalza et al., 2018). Moreover, 
Kuroda et al. (Kuroda et al., 2010) found that Nox4−/− mice displayed augmented cardiac 
hypertrophy whereas cardiac function was worsened by Nox4 overexpression. 
 
Figure 26: Dual actions of endothelial NOX4. The NOX enzymes release ROS as their only 
function. At normal physiological conditions, superoxide anion production and subsequently H2O2 
production enhance angiogenesis, migration, proliferation and survival of endothelial cells through 
ROS mediated p38 MAPK and Akt activation, however, under excessive oxidative stress, the 
NOX4-generated ROS result in an increase in the levels of pro-inflammatory cytokines and 
chemokines, as well as of adhesion molecules, thus resulting in an endothelial pro-thrombogenic 
phenotype. NOX4 is elevated in various diseases, such as pulmonary fibrosis, diabetes, diabetic 
nephropathy, atherosclerosis, and heart failure. On contrary, NOX4-generated ROS can result in 
intracellular signals that inhibit vascular injury and promote vasodilation, reduction in blood 
pressure and vascular remodeling (Incalza et al., 2018). 
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Figure 27: eNOS uncoupling. (a) In the presence of suitable concentration of substrate and co- 
factors, eNOS catalyzes the reduction and incorporation of O2 into the guanidine group of L- 
arginine to form NO and L-citrulline. Electrons being transferred from NADPH, bound to the C- 
terminal reductase domain, to the heme iron and cofactor tetrahydrobiopterin in the N-terminal 
oxygenase domain. (b) At conditions associated with limitation of L-arginine or 
tetrahydrobiopterin, oxidation of tetrahydrobiopterin to dihydrobiopterin, or in the presence of the 
competitive inhibitor ADMA, eNOS form superoxide anions instead of NO. Numerous stimuli 
that mimic the metabolic alterations underlying endothelial dysfunction have the ability to induce 
eNOS uncoupling. Where, BH4: tetrahydrobiopterin; BH2: dihydrobiopterin; ADMA: asymmetric 
dimethylarginine; oxLDL: oxidized LDL (Incalza et al., 2018). 
 
3.3.6 Peptide growth factors 
An increasing significance is given to peptide growth factors that play an important role in cell 
proliferation and angiogenesis and mainly include platelet-derived growth factor, basic fibroblast 
growth factor, insulin-like growth factor and vascular endothelial growth factor. VEGF has an 
important role in endorsing arteriogenesis and the conversion of endocardial endothelial cells into 
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coronary endothelial cells, predominantly after acute myocardial infarction. Thus, EECs are a 
source  of  endothelial  cells  in  the  development  of   arteriogenesis   in   pathological 
conditions (Miquerol et al., 2015a). 
Neuregulin-1 has been mainly synthesized in endocardial endothelial cells and myocardial 
capillary endothelium. ErbB3 receptors have been distributed in endothelial cells and 
ErbB2/ErbB4 receptor complex in cardiomyocytes. Soluble NRG-1 promotes a substantial 
upsurge in embryonic cardiac myocyte proliferation, as well as an improved survival and inhibition 
of apoptosis of cultured cardiomyocytes and can also persuade hypertrophic growth in both 
neonatal and adult ventricular cardiomyocytes (Smiljić et al., 2016). NRG-1 plays an important 
role in endothelial-myocardial signaling for normal cardiac function (Noireaud and 
Andriantsitohaina, 2014a; Parodi and Kuhn, 2014). Just like neuregulin-1, IGF-1, FGF-1, FGF- 
2, urocortin, VEGF, TGF-β1 and cardiotrophin-1 are all correlated with the inhibition of apoptosis 
in the heart. 
 
3.4 Endocardial endothelial dysfunction 
 
Intact endocardial endothelium is important for the embryonic development of the heart, the 
optimal rhythm and contractility as well as the remodeling of the heart. Impaired communication 
between the EE cells and cardiomyocytes and, endocardial endothelial dysfunction results in the 
development of heart and blood vessels diseases. The outcome of endothelial dysfunction is the 
declining    of    the    endothelial    barrier    regulation    and    the    electrolyte    imbalance     
of subendocardial interstitium. In addition, endothelial dysfunction has been associated with 
alteration of synthesis of endothelial mediators which primary influence cardiomyocyte 
performances and also the response of cardiomyocytes to circulating mediators or hormones. 
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Table 3: Differences between a healthy and a dysfunctional endothelium. 
Where, CECs: circulating endothelial cells; CRP: C-reactive protein; EMPs: endothelial 
microparticles; EPCs: endothelial progenitor cells; IL-6: interleukin-6; MPs: microparticules; NO, 
nitric oxide; PAI-1: plasminogen activator inhibitor 1; PGI2: prostacyclin; ROS: reactive oxygen 
species; sICAM: soluble intercellular adhesion molecule; sVCAM: soluble vascular cell adhesion 
molecule; TNF-: tumor necrosis factor alpha; vWF: von Willebrand factor (Sena et al., 2013). 
 
3.5 Endocardial endothelium dysfunction and heart diseases 
 
Numerous diseases of the cardiovascular system can not only be a consequence but also the cause 
of endocardial endothelial dysfunction. In the preservation of homeostasis of the heart and blood 
vessels,    the     endothelium     maintains     a     balance     between anti-thrombotic factors  
(NO, prostacyclin, plasminogen activator, protein kinase C, tissue factor inhibitor) and pro 
thrombotic       factors       (ET-1,        oxidant        radicals, plasminogen-activator        inhibitor 
1, thromboxane A2, fibrinogen,     tissue     factor).     Selective     damage     to     the  
endocardial endothelium and    subendocardium    occurs     in     arrhythmia,     atrial  
fibrillation, ischemia/reperfusion injury, cardiac hypertrophy and heart failure (Schoner et al., 
2015). Typical lesions of endocardial and microvascular endothelium are also been described 
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in sepsis, myocardial infarction, inflammation, thrombosis, and in hypertensive patients (Gray et 
al., 2010). 
In sepsis, endocardial endothelium shows a proinflammatory phenotype. Higher levels of the 
proinflammatory transcription factor NF-kB, endorse the adhesion of polymorphonuclear cells to 
EECs, and their migration into the subendocardial space and the interstitial space of the heart. 
Polymorphonuclear cells adhered to EECs leads to oxidative stress in EECs and cardiomyocytes, 
which have an effect on the contractility of the heart (Potz et al., 2016). 
Under physiological conditions, the endothelium hinders the formation of thrombus. In cardiac 
insufficiency, the ventricular endocardial endothelium displays prothrombotic characteristics. This 
causes frequent thromboembolic complications in patients with HF. However, endothelial 
dysfunction in HF due to increased release of the sympathetic mediators and vWF can be modified 
by the use of galanin as many studies suggested that neuropeptide galanin promotes an anti- 
thrombotic phenotype on endocardial endothelial cells (Tyrrell et al., 2017). The preserved 
function of EECs has been necessary in the revascularization of the areas damaged by a myocardial 
infarction. In the infarcted area, EECs have been identified as a source of endothelial cells used to 
encourage vascularization. The plasticity of endocardial endothelial cells plays an important role 
in the revascularization of ischemic heart tissue (Miquerol et al., 2015b). EE dysfunction or the 
dysregulation  of  the transforming  growth  factor in  EECs  can   lead   to   their   transition   
into mesenchymal cells. This occurs in endocardial fibroelastosis, a form of fibrosis where a de 
novo subendocardial layer is being formed that encapsulates the cardiomyocytes and stops heart 
growth (Xu et al., 2015). 
Fully removing or partially damaging EECs directly have an effect on contractile cardiac 
performance and results in lower contractility of cardiomyocytes. The inotropic effect of EE has 
been achieved through the synthesis and release of endothelial mediators, the sensory ability to 
detect changes in blood plasma and the quality of blood-heart barrier to control trans-endothelial 
transport. Thus, EECs plays an important role in Na+ transport. Increased Na+ plasma 
concentrations and high levels of aldosterone lead to an increased entry of Na+ into EECs and the 
transition to subendocardial space, endothelial glycocalcax and glycosaminoglycan network. 
Increased levels of Na+ in EECs modify their characteristics and lead to a decrease in NO synthesis 
(Bonilla et al., 2012). At the same time, higher Na+ levels in the subendocardial zones lead to an 
accumulation of fluids. 
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Endothelial dysfunction can be evaluated by determining the biomarkers of endothelial 
dysfunction (vWF, soluble thrombomodulin, CRP, cytokines, vascular cell adhesion molecule-1 
[VCAM-1], intracellular adhesion molecule-1 [ICAM-1], selectins P and E, asymmetric 
dimethyl arginine, circulating endothelial cells and microparticles). Along with markers of plaque 
destabilization and/or markers of ischemia or myocardial necrosis, they may offer additional 
prognostic information 
 
3.6 Endocardial endothelial dysfunction and atrial fibrillation 
 
Atrial   fibrillation   most   common   trigger   being    the    automatic    ectopic    activity    of 
left atrial cardiomyocytes with altered electrophysiological properties is due to the influence of 
congenital and/or acquired conditions and diseases (Go et al., 2001b). Series of morphological and 
functional changes constitute remodeling of the left atrium that occur as an adaptive response to 
factors that lead to atrial fibrillation. The endothelial cells promote fibroblast accumulation 
through an endothelial-mesenchymal transition in the atrium of patients with atrial fibrillation. 
Experiments   with   immunofluorescence   multi-labeling    identified    that heat    shock  
protein 47, prolyl-4-hydroxylase,  and  procollagen  type  1  co-localized   with   snail   and   
S100 calcium-binding proteinA4 (S100A4) within the endothelial cells of the left atrium, 
indicating the mesenchymal phenotype to produce collagen (Kato et al., 2017; Ter Maaten et al., 
2016) . 
Adaptive changes in left atrium normally depend on the duration of arrhythmias and the presence 
of other comorbidities such as heart failure, myocardial ischemia due to coronary insufficiency 
and proinflammatory conditions. Moreover, changes in the electrophysiological properties of 
cardiomyocytes favour situations enabling the reoccurrence and the formation of permanent forms 
of atrial fibrillation. With the changes in the structure and the function of the myocardium, there 
have been simultaneous alterations in the left atrial endocardium. Both dilation and 
hypocontractility may predispose to thrombosis (Nattel et al., 2008). Diseases and conditions that 
favour structural changes in myocardium and endocardium results in increased volume [dilatation] 
and reshaping of the left atrium and its auricle and reduced contractile ability of the myocardium, 
also, cause the loss of anticoagulant characteristics of the left atrial endocardium (Shirani and 
Alaeddini, 2000). 
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Structural changes in the atrial endocardial endothelium in AF have been manifested as endothelial 
cells edema and fibrinous transformation. At the same time, small areas of endothelial denudation 
can also be found with the formation of platelet aggregates, especially in the left atrium appendage, 
which can be observed as precursors for thrombosis. This results in rough and wrinkled appearance 
of endothelium (Masawa et al., 1993). Changes in the structure of atrial endocardial endothelium 
arose functional changes being characterized by synthesis and secretion of different mediators. 
Endothelial dysfunction in AF is characterized by a reduced synthesis of mediators with 
anticoagulant, antithrombotic,   anti-inflammatory   and anti-proliferative effects   such    as   
NO, prostacyclin and tissue     plasminogen     activator and      the      increased      production   
of procoagulant factors mainly von Willebrand factor, tissue factor, plasminogen activator 
inhibitor and microparticles. Also, there is an increased expression of adhesion molecules, the 
release of chemoattractants, growth factors and reactive oxygen species (Polovina et al., 2015) . 
The more intense expression of vWF by left atrial appendage (LAA) tissue being a significant 
predictor of postoperative AF. Other findings points towards a possible role of endothelial 
damage/dysfunction [as reflected by VWF changes] in the pathogenesis of postoperative AF 
(Kaireviciute et al., 2011). Impaired protein C activation on the left atrial endocardium attributable 
to low thrombomodulin expression may explicate its higher thrombogenicity and has a significant 
role in cardioembolic stroke (Cervero et al., 2011). Other study has described a reduced NOS 
activity in AF together with an increased release of von Willebrand factor enhanced infiltration 
of proinflammatory markers in endocardium and myocardium, accompanied by the presence of 
products of oxidative modification and markers of hypoxic damage within atrial tissue (Cai et al., 
2002) . EE cells of the left atrium synthesize and release NO that has an important role in the 
regulation of platelet activity, the inhibition of adhesion and procoagulant molecules on the surface 
of endothelial cells, and the modulation of inflammation and oxidative stress (Bonilla et al., 2012; 
Fleming and Busse, 2003). At physiological conditions, NO production in the left atrium is 
significantly higher than its production in any other part of the cardiovascular system. Systemic 
vascular endothelium produces NO under conditions of laminar blood flow. Turbulent blood flow 
reduces the activity of eNOS and the production of NO (Meulemans et al., 1990) . The entire 
cardiac output crosses through the left atrium, and the atrial endocardium represents an endocrine 
organ whose NO synthesis, through the formation of nitroso-thiol compounds, provides circulating 
NO donors in the systemic circulation (Cai et al., 2002; Matsushita et al., 2003). Thus, the atrial 
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endocardial dysfunction with a reduced NO synthesis may have an adverse effect on the function 
of systemic blood vessels. 
In patients with atrial fibrillation, there can be a systemic endothelial dysfunction that combines 
endocardial and vascular endothelial dysfunction resulting in increased hemodynamic load of the 
left atrium and increased synthesis and release of natriuretic peptides, Ang II, aldosterone and 
growth factors from the atrial myocardium (Ellinor et al., 2005; Nattel et al., 2008). These 
mediators can induce, along with paracrine effects, the adverse effects on distant tissues and 
organs, thus promoting the development of cardiovascular diseases. 
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4 ENDOTHELIAL SENESCENCE 
4.1 Cellular senescence 
Endothelial senescence drew great interest in the cardiovascular field after seeing its important 
role in the development of endothelial dysfunction (Erusalimsky, 2009; Herrera et al., 2010). 
Cellular senescence was mentioned more than 40 years ago by Leonard Hayflick as a phenomenon 
that restricted the proliferation of normal human cells in culture which after around 50 to 70 
population doublings being irreversibly arrested in G1 phase of the cell cycle show 
unresponsiveness to proliferative mitogenic stimuli (Hayflick, 1965; Sosinska et al., 2016). There 
are mounting evidences, which indicate that normal healthy endothelial cells gradually enter into 
a senescent replicative state in which they do not react to mitogenic stimuli although they remain 
metabolically active (Erusalimsky and Kurz, 2005, 2006). The long-term existence of senescent 
cells in tissues with age either due to the elevated rate of senescent cell formation or failure of 
aging immune system or decreased clearance (Burton and Krizhanovsky, 2014) has the potential 
to endorse age-related diseases and could contribute to explain the decline of organ function with 
aging (Salama et al., 2014).The ambivalence of senescence lies in the early benefit of tumor 
proliferation where it is being recognized as a potent tumor suppressor (Vijg et al., 2008) and the 
late deleterious impact associated to aging, this duality being known as antagonistic pleiotropy. 
Various stimuli constituting similar pathways can induce senescence (van Deursen, 2014) by 
telomere shortening (replicative senescence) or independent of telomere length that permanently 
induce cell senescence (pre-mature senescence like phenotype). Oncogene-induced senescence 
involves activation of oncogenes such as RAS (Burton and Krizhanovsky, 2014; Serrano et al., 
1997) and RAF involving DNA damage and has been associate with increased ROS (Bartkova et 
al., 2006) 
In addition, the activation of the ERK pathway could also initiate senescence by increasing the 
degradation of proteins required for cell cycle progression (Deschenes-Simard et al., 2013). Also, 
other pathways could stimulate endothelium senescence, independently of the DNA damage, 
probably through p38 and NFKB pathways activation. 
 
4.2 Biomarkers and features of senescence 
4.2.1 Morphological characteristics 
71  
Senescent cells possess various characteristic morphological and biochemical features as a 
consequence of their arrest in the G1 phase. Generally, senescent cells increase in size (Kurz et al., 
2000) and depending on the senescence trigger as well are usually large, flat, and multinucleated 
or rather refractile. Enhanced mTOR-dependent protein synthesis signaling has been suggested for 
better understanding of these changes (Fingar et al., 2002; Mamane et al., 2006). Cells which 
undergo H-RASv12 induced senescence, or stress-induced senescence or DNA damage-induced 
senescence showed common phenotypic characteristics such as the acquisition of a flat cell 
morphology (Astle et al., 2011) whilst, senescent cells resulting from BRAFE600 expression or 
the silencing of p400, attain a more spindle-shaped morphology (Kuilman et al., 2010b; Zhang et 
al., 2015). 
 
4.2.2 Cell cycle arrest 
The growth arrest is principally constant and cannot be reversed by acknowledged physiological 
stimuli (Campisi and d'Adda di Fagagna, 2007). However, multiple ways has been described to 
reverse the arrest, allowing cells to re-enter the cell cycle. The inactivation of p53 pathway allows 
senescence reversal while some of the interleukin revoke the arrest (Blagosklonny, 2011). This 
reversibility relies on p16 expression prior entering senescence. The tumor suppressor’s p16 and 
p21 are mediators of cell cycle arrest and senescence. Since, for the induction or maintenance of 
the senescence program neither p16 and p21 is strictly required, their predictive value is limited 
when used individually (d'Adda di Fagagna, 2008). 
 
4.2.3 Induction of senescence associated -beta-galactosidase activity (SA-β-gal) 
SA-β-gal is the most widely used senescence biomarker (Debacq-Chainiaux et al., 2009). The 
increase of β-gal activity in senescent cells is related to an expansion of the lysosomal 
compartment, leading to an increase in β-galactosidase activity which is detectable at pH 6.0 that 
is different from the acidic β-galactosidase activity found in normal cells at pH 4.0 (Dimri et al., 
1995; Lee et al., 2006; Yang and Hu, 2005). 
 
4.2.4 Senescence-associated heterochromatin foci (SAHF) 
At the nuclear level, senescent cells exhibit condensed heterochromatin (transcriptionally silent) 
foci known as senescence-associated heterochromatin foci (SAHF) (Narita et al., 2006) that are 
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detectable as clusters after DAPI labelling of the DNA and are distinct from the homogeneous 
staining in non-senescent cells. These DNA SAHF are found to be enriched in methylated lysine 
9 of histone H3 (a modification catalysed by the histone methyltransferase suv39h1) (Agger et al., 
2008) whereas histone H3-lysine 9 acetylation and lysine-4 methylation which are euchromatin 
(transcriptionally active) foci are excluded from SAHF. SAHF has been associated with the 
downregulation of genes regulated by the E2F transcription factor, such as cyclins, and to the 
occurrence of different pathways involving p16 or p53 proteins (Kuilman et al., 2010a). 
 
4.2.5 Secreted factors in senescence 
Large amount of proteins are secreted by senescent cells secrete constituting metalloproteinases, 
(MMPs), plasminogen activator inhibitor 1 (PAI-1) (Young and Narita, 2010), growth factors, 
proteases, cytokines, chemokines and many others which have strong autocrine and paracrine 
actions (Campisi, 2013). Cells undergoing either replicative or premature senescence show 
noticeable alterations in their secretome. This term encompasses the senescence-associated 
secretory phenotype (SASP), that has been controlled by microRNA, the cytokine receptor 
CXCR2, IL-1 receptor signaling, the transcription factors NF-қB and C/EBP-B, and the 
JAK/STAT signaling pathway (Jurk et al., 2014). The secretome consists of various 
proinflammatory proteins and growth factors, the composition of which subject to cell lineages or 
sources of triggers (Young and Narita, 2010). Activation of inflammatory transcriptome involves 
NF-κB and C/EBP-B transcription factors. 
Because senescent cells increasingly accumulate with progressive aging, it can be concluded that 
SASP display an important role in the time course of age-related diseases (Ovadya and 
Krizhanovsky, 2014). Also, it is possible that numerous inflammatory cytokines may have an 
indispensable part in the establishment and maintenance of the senescence arrest such as signaling 
through IL-8 (CXCR2) and IL-6 receptors was shown to be mandatory to induce cell senescence 
in response to oncogenic BRAF or replicative exhaustion. It had also been suggested that senescent 
cells may favour cancer by stimulating the proliferation of incipient tumour cells that exist in their 
microenvironment (Dumont et al., 2000; Kuilman et al., 2010b). 
 
4.3 Mechanism of senescence 
4.3.1 Replicative senescence 
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When the length of one or more telomeres attain a specific minimal threshold, usually 
characterized with the single-strand overhang erosion, the exposed telomeric DNA ends have been 
recognized as double-strand breaks (DSBs) by the DNA damage response (DDR) (Kuilman et al., 
2010b). The telomeres of vertebrate chromosome are distinct structures constituting of extended 
arrays of repetitive tandem hexameric units-TTAGGG (Nergadze et al., 2004). The presence of 
the telomeric repeats at the chromosome ends is important to guarantee proper functioning of 
telomeres and for endurance of chromosome integrity and stability (Blackburn, 2001). Telomere 
specific proteins shield chromosome from degradation or chromosomal end-to-end fusion during 
DNA-healing process (O’Sullivan and Karlseder, 2010). 
Telomeres have been subjected to abrasion due to the fact that DNA polymerase fails to completely 
replicate the lagging strands this so called “end replication problem” which leads to telomere 
shortening (de Magalhães and Passos, 2018; Storer et al., 2013). Together with the propagation of 
human cells in culture, telomeres are subjected to progressively shortened, ultimately causing cells 
to reach their “hayflick limit”. This phenomenon being termed as replicative (cellular) senescence. 
In addition, replicative senescence has also been linked to Rb tumor suppressor including p16, a 
cyclin-dependent kinase inhibitor. Indeed, both p53 and p16 activation seems to be mandatory for 
senescence induction in a multiplicity of human cell strains. It is possible that the relative 
contribution of these Rb proteins depend on the cell types; Depending of cell strains, onset of 
senescence could be deferred following p16 inactivation alone, following p53 inactivation or 
requiring both p53 and p16 inactivation (Kuilman et al., 2010b) 
 
4.3.2 Premature senescence 
It has also been known that senescence can also be induced in the absence of any noticeable 
telomere loss or dysfunction, by an assortment of conditions. Telomere extension by telomerase 
overexpression in human fibroblasts has been documented not to protect against senescence 
observed after exposure to UV, or H2O2, confirming the existence of a senescence mechanism 
independent of telomerase action (Gorbunova et al., 2002). This type of senescence has been 
described as premature senescence independent of telomere shortening (de Magalhães and Passos, 
2018). 
Premature senescence like phenotype can be induced in response to numerous conditions. Mainly 
recognized as stress-induced premature senescence, which constitute oxidative stress or DNA 
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damage, and oncogene-induced senescence (OIS) involving persistent mitogenic stimulation or 
exposure to radiation (Erusalimsky, 2009). 
 
4.3.3 Molecular machinery of cellular senescence 
In mammalian cells, the Rb and its family members have fundamental roles in the initiation of 
cellular senescence and the onset of cell cycle arrest (Ben-Porath and Weinberg, 2005; Johnson 
and Walker, 1999; Maddika et al., 2007). There are two different classes of CDKI, the KIP/CIP 
family CDKI (p21, p27, and p47) (Cerqueira et al., 2014) known to inhibit a wide range of CDK, 
and the INK4 family CDKI (p16, p15, p18 and p19), that binds and inactivates CDK4 and CDK6 
(Liggett and Sidransky, 1998). At physiological conditions, proliferating cells displayed a low 
expression of CDKI. In response to a variety of oncogenic stimuli responsible for DNA damage, 
the expression level of CDKI (p21 and p16) genes have been significantly up-regulated both in a 
p53-dependent and in p53-independent manner (Maddika et al., 2007; Rodier and Campisi, 2011). 
The activation of this pathway in turn inactivates all CDK, prevents Rb family protein 
phosphorylation and leads to cell cycle arrest (Kilbey et al., 2008; Sherr and Roberts, 1999). It had 
been also demonstrated that the activation of p16-RB pathway induces elevation of intracellular 
levels of ROS, thereby triggering activation of PKC. PKC is an important downstream mediator 
of the ROS signaling pathway that leads to cytokinetic block, which in turn promotes further ROS 
production and thereby maintain ROS-PKC activated in senescent cells (Bihani et al., 2007). p53 
is a tumor suppressor known as “guardian of the genome”. The importance of this tumor suppressor 
has been emphasized by the demonstration that p53 has been mutated or lost in a vast majority of 
the human cancers (Smith et al., 1995). Physiological p53 activity prevents from cancer and 
protects from aging, however unrestrained and excessive p53 activation still protects from cancer, 
but is known to be detrimental to healthy aging (Rufini et al., 2013). Several studies pointed that 
the excessive expression of p53 activity compromise healthy aging (Gottlieb and Vousden, 2010). 
Induction of p53 has been supposed to be essential for the induction of senescence mainly 
following its activation by DDR. One of the most important p53-target genes is its downstream 
effector CDKN1 A/p21, both overexpressed during replicative senescence (Thakur et al., 2010). 
In addition, p53 triggers expression of the AMP-activated protein kinase (AMPK), activating 
mTOR which acts to promote cell and tissue aging (Sengupta et al., 2010; Zoncu et al., 2011). 
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Figure 28: Characteristics of senescent cells. Senescent cells vary from other nondividing 
(quiescent, terminally differentiated) cells in many ways, although no single feature of the 
senescent phenotype has been exclusively specific. Features of senescent cells consists of 
essentially irreversible growth arrest; expression of SA-βGal and p16INK4a; profound release of 
various growth factors, cytokines, proteases, and other proteins (SASP); and nuclear foci 
containing DDR proteins (DNA-SCARS/TIF) or heterochromatin (SAHF). The pink circles in the 
nonsenescent cell (left) and senescent cell (right) represent the nucleus (Rodier and Campisi, 2011) 
76  
 
 
Figure 29: Various inducers have the ability alone or in combination to move the cells into the 
senescent cell fate via pathways involving p16INK4a/Rb, p53/p21, and likely other pathways. 
Stimuli normally consists of DNA damage (e.g., telomere shortening and single- and double-strand 
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breaks); oncogenic mutations (e.g., Ras, Myc, B-Raf); reactive metabolites (e.g., ROS, ceramides, 
fatty acids, high glucose); increase levels of mitogen and nutrient signals that enhance mTOR 
activity; and proteotoxic stress (e.g., protein aggregation and unfolded proteins). These lead to 
widespread alterations in gene expression and chromatin remodeling (heterochromatin formation) 
that consist of senescence-associated growth arrest, the SASP, and alterations in morphology. 
Accordingly, cellular senescence can be regarded as a cell fate reminiscent of differentiation, 
replication, or apoptosis (external and internal inducers, transcription factor cascades, gene 
expression changes and chromatin remodeling, leading to changes in function). Many intracellular 
autocrine loops emphasize development of irreversible replicative arrest, heterochromatin 
formation, and initiation of the SASP requiring days to weeks. Moreover, senescence also plays 
an important role in tissue dysfunction and chronic disease predisposition in addition to removing 
cells from the progenitor/stem cell pool, through the SASP and associated chronic sterile 
inflammation and degradation of the extracellular matrix (Tchkonia et al., 2013b). 
 
4.3.4 Reactive oxygen species 
Senescent cells activate downstream signaling pathways that trigger the production and release of 
ROS thereby creating a microenvironment characterized by increased oxidative stress 
(Unterluggauer et al., 2003). In human diploid fibroblasts, it has been shown that p16INK4a 
expression causes increased ROS generation via PKCδ activation (Takahashi et al., 2006). 
Telomere attrition has the ability to increase ROS production by induction of p21CIP1/WAF1 
expression in human lung and mouse embryonic fibroblasts and in intestinal crypts of Terc−/− G4 
mice (Passos et al., 2010). Passos and colleagues suggest a positive feedback loop between 
p21CIP1/WAF1 and reactive oxygen production, which is necessary for the induction and 
maintenance of senescence (Passos et al., 2010). The majority of ROS production during the 
induction of senescence is supposed to be originated from the mitochondria (Stowe and Camara 
2009). On the contrary, suppression of oxidative stress or hypoxia preserves telomere length and 
prolongs lifespan of cells (Bhayadia et al., 2016; Minamino and Komuro, 2007). 
Previous studies have also shown that NADPH oxidase subunits Nox1 and Nox4 have been 
involved in the excessive formation of ROS in senescent human endothelial cells (Schilder et al., 
2009). In addition, an upregulation of NADPH oxidase subunits p47phox, Nox2, and Nox4 was 
observed in JunD−/− mice displaying premature vascular senescence associated with an impairment 
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of the O2•-/NO balance (Paneni et al., 2013). Furthermore, Nox4 gene interference using small- 
hairpin RNA was able to delay replicative senescence in human umbilical vein endothelial cells 
(Lener et al., 2009). Previous studies have also shown that COX-2 contributed to the establishment 
and maintenance of senescence of human fibroblasts (Martien et al., 2013), and a low dose of 
aspirin delayed the onset of senescence in circulating endothelial progenitor cells (Hu et al., 2008). 
 
 
Figure 30: ROS can possess both endogenous and exogenous sources. The moderate levels of 
ROS are maintained by ROS production and release from specialized scavenging enzymes (Rufini 
et al., 2013). 
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Figure 31: Level of H2O2 present predict the physiological outcomes with large amounts of mROS 
are associated with damage to proteins, lipids, and nucleic acids and small amounts of mROS 
mainly act as signaling molecules to overcome the stress. Morever, even very small amounts of 
mROS are shown to be necessary for normal cell homeostasis. Thus, mROS have not been 
categorically harmful (Sena and Chandel, 2012). 
4.4 Senescence and endothelial dysfunction 
Endothelial function is impaired in aging and cellular senescence thus, endothelial cell senescence 
has been suggested to contribute to aging-related endothelial dysfunction, which plays a key role 
in the initiation and/or progression of various cardiovascular diseases (Herrera et al., 2010). It has 
been demonstrated that strong association exists between the presence of stress-induced cellular 
senescence and impaired endothelial function as depicted in mouse aortas showing an increased 
expression of senescence markers p16INK4a and p19ARF (Serrano et al., 1996; Wei et al., 2001). 
Also, the increased number of p21CIP1/WAF1-positive endothelial cells in aged aortas is 
consistent with the previous observations, which stated that p21CIP1WAF1 had been induced by 
oxidative stress in endothelial cells via ataxia telangiectasia mutated protein (Zhan et al., 2010). In 
addition, an increase in DNA damage foci containing activated H2AX (γH2AX) was found in 
endothelial cells, which has been regarded as a reliable indicator of senescence (Braun et al., 2012; 
Lawless et al., 2010). 
Moreover, one of the hallmarks of endothelial dysfunction is the inability of the endothelium to 
induce an appropriate vasodilatory response due to insufficient NO bioavailability (Deanfield et 
al., 2007). Thus, the studies conducted with cultured cells have demonstrated that endothelial cell 
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senescence is associated with the downregulation of endothelial nitric oxide synthase eNOS, the 
induction of a proinflammatory state, and DNA damages (Botden et al., 2012). In addition, several 
lines of evidence suggest that the blunted NO formation has been an early key event, which triggers 
the signal transduction cascade leading ultimately to endothelial senescence (Bhayadia et al., 2016; 
Kansui et al., 2002; Khemais-Benkhiat et al., 2016a). Indeed, treatment of young endothelial cells 
with the eNOS inhibitor, L-NAME, promoted a pronounced premature induction of endothelial 
senescence as assessed by SA-β-gal activity. Moreover, both the NO donor DETA-NO and 
transfection of eNOS into human umbilical vein endothelial cells has been shown to decrease the 
number of senescent endothelial cells (Hayashi et al., 2006). NO is being proposed to delay 
endothelial senescence by increasing telomerase activity thus preventing the alteration and the 
shortening of length of telomeres (Vasa et al., 2000). Also, NO may also retard the induction of 
senescence by preventing the downregulation of eNOS expression as the eNOS inhibitor L-NAME 
showed a pronounced decrease of the eNOS protein level in young cells. Moreover, NO may also 
contribute to postpone endothelial senescence by limiting the level of oxidative stress, a potent 
inducer of senescence, in endothelial cells 
Recent findings also suggest a predominant role of p53 in the mechanism underlying the 
downregulation of eNOS. Previous work has established that the overexpression of endothelial 
p53 induced endothelial dysfunction and decreased nitric oxide (NO) bioavailability in rat aortic 
sections and the downregulation of eNOS in cultured endothelial cells (Kumar et al., 2011), 
Indeed, p53 is shown to downregulate KLF2 expression, a positive transcriptional regulator of 
eNOS expression (Atkins and Jain, 2007), either directly by transcriptional repression (Kumar et 
al., 2011) or indirectly by upregulation of p66shc, a negative transcriptional regulator of KLF2 
(Kim et al., 2008a). 
 
4.5 Local angiotensin system and senescence 
The local angiotensin system has a determinant role in the induction of both replicative and 
premature endothelial senescent as indicated by the fact that both the ACE inhibitor and the AT1 
receptor blocker concentration-dependently reduced SA-β-gal activity. Activation of the local 
angiotensin system has been shown to contribute to the increased level of oxidative stress observed 
in pathological arteries such as in old arteries and in arteries from hypertensive animals and 
humans mostly by an AT1R-mediated activation of NADPH oxidase (Doughan et al., 2008; 
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Harrison et al., 2003; Khemais-Benkhiat et al., 2016a). It was found that Ang II–induced ROS- 
mediated DNA damage leads to accelerated biological aging of hVSMCs via acute SIPS, which is 
known to be telomere independent, and accelerated replicative senescence which has been 
associated with accelerated telomere attrition (Herbert et al., 2008; Imanishi et al., 2005). Also 
Ang II predominantly decreased the expression level of Bcl‐2, in part via the activation of 
extracellular signal‐regulated kinase (ERK). Moreover, findings also proposed that Ang II can 
induce senescence via the mitogen‐activated protein kinase (MAPK) signal pathway (Abbas et al., 
2017; Shan et al., 2008). 
 
4.6 Atrial fibrillation and senescence 
Mounting evidence proposed that extracellular matrix (ECM) and perivascular fibrosis had been 
increased progressively with age, resulting in cardiac remodeling and dysfunction in elderly 
individuals (Horn and Trafford, 2016). Moreover, telomere attrition affects mitochondrial 
function, thus promoting aging (Sahin et al., 2011), and short telomere length has been considered 
to be a hallmark of aging (Lopez-Otin et al., 2013). In addition, Carlquist et al recently found that 
AF subjects had shorter telomeres in comparison with SR subjects (Carlquist et al., 2016). These 
evidences propose that aging, also called replicative senescence play an important role in the 
development and maintenance of AF. In a previous study, increased expression of senescence 
markers, p21CIP1/WAF1 and p16INK4 and SA-β-gal was evidenced in AF patients   with valvular heart 
diseases. In this work, cardiac fibroblasts (CFs) were evidenced as predominant cells lineage that 
experience senescence. Altogether, this study establishes a link between premature senescence of 
CFs and the progression of AF. Moreover, Xie et al. also found that an increase in atrial fibrosis 
as assessed by sirius red staining has been associated with both paroxysmal AF (PaAF) and 
persistent AF (PeAF). In addition, atrial fibrosis is characterized by excessive deposition of ECM, 
comprising of Col I and Col III (Cao et al., 2013; Horn and Trafford, 2016; Wu et al., 2015; Xie 
et al., 2017). It was also showed that p16INK4a and SA-β-gal were positively correlated with atrial 
fibrosis in LAAs from patients with valvular diseases. Altogether the data suggested the possibility 
of the association of premature senescence with AF development with advanced atrial fibrosis (Xie 
et al., 2017). 
 
4.7 Senescence, coagulation cascade components and atrial fibrillation 
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Uncontrolled coagulation play an important role in the pathophysiology of several chronic 
inflammatory diseases. In these conditions, senescent cells have often been observed and have 
been involved in the generation of inflammation. The coincidence of hyper-coagulation, cell 
senescence, and inflammation proposes the existence of a common underlying mechanism (Sanada 
et al., 2016). Anti-coagulation therapy targeting cardiovascular diseases has made great advances 
in recent years (Maan et al., 2012). Treatment strategies directly targeting activated coagulation 
FXa have been established for AF and deep vein thrombosis (Konstantinides and Torbicki, 2014; 
Levy et al., 2014). Recent evidence suggests that activated coagulation factor Xa plays a role in 
the processes beyond blood coagulation (Esmon, 2014; Walenga et al., 2003). These non- 
hematologic functions have been mainly mediated by protease-activated receptors, PARs, 
(Sparkenbaugh et al., 2014) and increase tissue inflammation and remodeling (Esmon, 2014; Hara 
et al., 2015). Senescent cells have been frequently observed and appeared to be involved in the 
progression of chronic inflammation by releasing inflammatory cytokines, senescence-associated 
secretory phenotype (SASP) (Tchkonia et al., 2013a). When human umbilical vein endothelial 
cells were stimulated with FXa for 14 days it was found that continuous FXa stimulation decreased 
EC proliferation, up-regulated the senescence markers such as p53, p16INK4a, and senescence- 
associated β -galactosidase (SA-β gal)-positive cells, through up-regulation of insulin-like growth 
factor binding protein 5 (IGFBP-5) and early growth response 1 (EGR-1). Inhibition of FXa by a 
direct FXa inhibitor, rivaroxaban, or IGFBP-5 by siRNA decreased FXa-induced cell senescence, 
restoring cell proliferation (Sanada et al., 2016). Moreover, in an ischemic hind limb mouse model, 
FXa inhibited neovascularization by endothelial progenitor cell. However, rivaroxaban 
significantly restored FXa-induced impaired angiogenesis. These data indicated that FXa induced 
EC senescence which has been associated with inflammatory burden and overall remodeling, thus 
paving the way for atrial fibrillation perpetuation (Sanada et al., 2016). 
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AIMS OF THE STUDY 
Ageing is a main determinant of atrial remodeling that paves the way to atrial fibrillation (AF) and 
enhanced thrombogenicity. Preclinical studies on endothelial atrial cells are conspicuously 
lacking. As a result, the initial cellular triggers for clotting, inflammation and proteolysis in atrial 
fibrillation remain speculative. Endothelial cell senescence and dysfunction are the hallmark of 
cardiovascular diseases. Cellular senescence is a stress and damage response resulting in an 
irreversible cell cycle arrest and the appearance of distinct morphological and functional changes 
associated with impairment of cellular homeostasis. Senescent endothelial cells also secrete pro- 
inflammatory and pro-remodeling factors, which, in turn may alter tissue environment. In addition, 
previous studies have demonstrated a key role of Ang II in the pathogenesis of AF. Ang II type 1 
receptor (AT1R) activation is known to induce the activation of mitogen-activated protein kinases 
(MAPK) which in turn favors atrial remodeling through fibroblast proliferation, inflammation, 
oxidative stress cellular hypertrophy and apoptosis. 
It is known for many decades that AF has been associated with the activation of local and 
circulating coagulation factors (hypercoagulability). The AF-related hypercoagulability 
significantly enhances the risk of clot formation and stroke in patients with AF. However, little 
has been described about the potential role of AF-related hypercoagulability in atrial tissue 
remodeling and, in particular, the role of two major coagulation serine proteases, thrombin and 
factor Xa. Apart from its haemostatic effects, thrombin was also demonstrated to modulate cellular effects 
that are predominantly mediated by protease-activated receptors (PARs). 
Thus, this study aims 
• To develop an original model of primary cultures of atrial endothelial cells from pig 
hearts; 
• To characterize phenotypical changes associated with atrial endothelial cells (AECs) 
senescence (replicative and premature) and to depict the link between ageing and 
thrombogenicity; 
• To evaluate the impact of coagulation cascade-derived factors such as thrombin in the 
induction of premature AEC senescence possibly leading to the acquisition of a pro- 
inflammatory, pro-thrombotic and pro-fibrotic profile; 
• To study the role of reactive oxygen species (ROS) in the induction of AECs senescence; 
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• To study the effect of the local angiotensin system, a major inducer of senescence, on the 
induction of AECs senescence. 
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 Abstract 
 
Background: Ageing is a main determinant of atrial remodeling that paves the way to atrial 
fibrillation and enhanced thrombogenicity. However, the initial cellular events promoting 
proteolysis, inflammation and clotting in atrial fibrillation still remain speculative. The aim of this 
study was to establish a cell culture model of atrial endothelial cells (AECs), and to characterize 
the phenotypical changes associated with AECs ageing and, in particular, the role of the 
angiotensin II (Ang II) /AT1 receptor pathway, a major pro-senescence, pro-fibrotic and pro- 
thrombotic factor in the cardiovascular system. 
Methods and results: Porcine left AECs were isolated and cultured. Senescence, as 
assessed by senescence-associated β-galactosidase activity (SA-β-gal), was induced either 
by passaging cells from passage P1 to P4 (replicative senescence) or following exposure of 
cells at P1 to L-NAME (an eNOS inhibitor), H2O2 or Ang II (premature senescence). Both 
replicative and premature senescence were associated with an up-regulation of p53, p21 and 
p16, key regulators of the cell cycle. Senescent AECs phenotype was characterized by (i) cell 
thrombogenicity through tissue factor up-regulation, shedding of procoagulant microparticles, 
eNOS down-regulation and reduced NO-mediated inhibition of platelet aggregation, (ii) cell 
adhesion and inflammation through up-regulation of ICAM-1 and cyclooxygenase-2, (iii) 
proteolysis and fibrosis remodeling through MMP-2, 9 and TGF-ß1 expression, and (iv) up- 
regulation of the local Ang II system through enhanced angiotensin-converting enzyme (ACE) 
and AT1 receptors expression, and oxidative stress. Perindoprilat (an ACE inhibitor) and 
Losartan (an AT1 receptor antagonist) prevented AECs senescence. 
Conclusions: The present findings indicate that atrial endothelial senescence promotes 
thrombogenicity, inflammation, and matrix remodeling involving an up-regulation of the local 
Ang II system. They further suggest that the Ang II/AT1 receptor pathway may be a promising 
therapeutic target to delay atrial endothelial phenotypic changes associated with ageing. 
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Introduction 
 
Ageing is a main determinant of atrial remodeling that contributes to atrial fibrillation (AF) 
initiation and perpetuation and enhanced thrombogenicity. Because one of the main 
consequences of AF is thrombotic stroke, the hypothesis that AF per se is a pro-thrombotic 
disease has been raised 1. Evidences in favor of this paradigm include increased levels of 
plasma markers of a pro-thrombotic state such as von Willebrand factor, fibrinogen, D-dimer 
and pro-coagulant microparticles (MPs) in the plasma of AF patients 1, 2. Although the link 
between ageing and thrombogenicity has been extensively studied in epidemiological studies, 
little is known about phenotypical changes associated with AECs ageing that could contribute 
to clot formation. Moreover, preclinical studies on AECs are conspicuously lacking and have 
been hampered mostly by the inability to isolate and culture endothelial cells from the atrium. 
Therefore, the initial cellular triggers for clotting, inflammation and proteolysis induction in AF 
still remain mainly speculative. 
Endothelial cell senescence and dysfunction are hallmarks of cardiovascular diseases 3, 4. 
Cellular senescence is a stress and damage response resulting in an irreversible cell cycle 
arrest and the appearance of distinct morphological and functional changes associated with 
impairment of cell homeostasis. Indeed, senescent endothelial cells characterized by an 
increased senescence-associated ß-galactosidase (SA-ß-gal) activity, have been shown to 
secrete pro-inflammatory and pro-remodelling factors, which, in turn, may impact the tissue 
environment 3, 4. They are also characterized by an increased level of oxidative stress and a 
down-regulation of endothelial nitric oxide (NO) synthase expression resulting in a reduced 
bioavailability of the major vasoprotective factor NO 5. The senescence-inducing signals 
engage predominantly the p53/p21 and p16/retinoblastoma protein tumour suppressor 
pathways, as the final effectors of the senescence program. 
In the setting of AF, inflammation, oxidative stress, angiotensin II (Ang II), low or turbulent 
shear stress, increased mechanical stretch, hypoxia have all been involved in atrial 
remodeling. Moreover, rhythm disturbance-induced low and oscillatory shear stress resulted 
in blunted NO formation6 and induction of endothelial-derived MPs release 7 and endothelial 
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senescence via a p53-dependent pathway 8. Previous studies have also indicated a key role 
of Ang II in the pathogenesis of AF9. Indeed, the activation of the Ang II type 1 receptor (AT1R) 
leads to mitogen-activated protein kinases (MAPK) activation, which, in turn, promotes atrial 
remodeling by stimulating proliferation of fibroblasts, cellular hypertrophy and apoptosis. The 
importance of Ang II in atrial remodeling was further emphasized by studies demonstrating an 
enhanced Ang II production during tachypacing in canine hearts and arrhythmogenic atrial 
structural remodeling mediated by p38 MAPK phosphorylation10. Since ageing is a main 
determinant of AF, we have established a model of replicative and premature senescence in 
primary cultures of porcine left atrium endothelial cells (AECs), and characterized their 
phenotypic changes. Due to the fact that Ang II is a potent inducer of endothelial senescence, 
oxidative stress, MPs release and thrombogenicity 11, 12, we have examined the possibility that 
the local Ang II/AT1R pathway promotes premature atrial endothelial senescence. 
 
 
Materials and methods 
 
Chemicals 
 
Unless indicated, all chemicals and solvents were from Sigma-Aldrich (Sigma-Aldrich 
SARL, St Quentin Fallavier, France). Losartan was obtained from Merck Research 
Laboratories (NJ, U.S.A) and perindoprilat was obtained from Servier (Paris, France). 
 
 
Isolation and culture of atrial endothelial cells 
 
AECs were isolated from left atria after collection of porcine hearts from the local 
slaughterhouse (SOCOPA, Holtzheim, France). Heart-lung blocks were dissected to isolate 
the left atrium. At the level of mitral valve, the left ventricle was removed and ligation of 
pulmonary veins was done. Left atrium was cleaned and flushed with phosphate-buffered 
saline (PBS) without calcium to discard remaining blood. To prepare primary cultures, AECs 
were isolated by collagenase treatment (type 1, Worthington, 1 mg/ml for 40 min at 37 °C) and 
cultured in culture dishes containing MCDB131 medium (Invitrogen) supplemented with 
penicillin (100 UI/ml), streptomycin (100 UI/ml), fungizone (250 μg/ml), L-glutamine (2 mM, all 
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from Lonza, St Quentin en Yvelines, France) and 15% fetal calf serum and grown for 3-4 days 
(passage 0). The medium was changed every 48 h. To induce premature senescence, AECs 
were incubated at passage 1 either with H2O2 (100 µM) or L-NAME (1 mM) for 48 h. For Ang 
II induced premature senescence, cells were exposed to serum-free medium for 2 h before the 
addition of Ang II (100 nM) for 24 h in serum-free medium. In some experiments, cells were 
exposed to losartan or perindoprilat for 30 min before the addition of either H2O2 (100 µM) or 
L-NAME (1 mM). To induce replicative senescence, AECs were detached with trypsin- 
ethylenediaminetetraacetic acid (trypsin-EDTA, Life Technologies SAS) and further passaged 
at a ratio of 1:3 at regular intervals. For platelet aggregation experiments, AECs were cultured 
on Cytodex-3 beads, which were hydrated and sterilized according to the instructions supplied 
by the manufacturer (GE Healthcare Life Sciences). In some experiments, AECs at passage 
1 (P1) grown on Cytodex-3 beads were incubated in the absence or presence of L-NAME (1 
mM) for 30 min before their addition to platelet suspensions as reported previously 13. 
 
 
Determination of SA-β-gal activity by flow cytometry 
 
SA-β-galactosidase activity was determined by flow cytometry using the fluorogenic substrate 
C12FDG (5-dodecanoylaminofluorescein Di-β-D-galactopyranoside, Invitrogen, Life 
Technology, SAS) as described previously 14. AECs were pretreated with 300 µM chloroquine 
for 1 h to induce lysosomal alkalinization. C12FDG (33 µM) was then added to the incubation 
medium (without phenol red) for 1 h. At the end of the incubation period, AECs were washed 
with ice-cold PBS, resuspended following trypsinization and analyzed using a flow cytometer 
(FACScan, BD Bioscience, CA, USA). Data were acquired and analyzed using the Cellquest 
software (Becton Dickinson). Light scatter parameters were used to eliminate dead cells and 
subcellular debris. The C12-fluorescein signal was measured on the FL1 detector, and the 
proportion of ECs with SA-β-gal activity was estimated using the median fluorescence intensity 
of the population. Autofluorescence assessed in parallel in AECs not exposed to C12FDG was 
negligible. 
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Western blot analysis 
 
AECs were washed with PBS and then lysed in extraction buffer (composition in mM: NaCl 
150, Na3VO4 1, sodium pyrophosphate 10, NaF 20, okadaic acid 0.01 (Sigma), Tris/HCl 20 
(pH 7.5; QBiogene), a tablet of protease inhibitor (Roche) and 1% Triton X-100 (QBiogen). 
Equal amounts of proteins were separated on denaturing SDS (10-12%) polyacrylamide gel. 
Separated proteins were transferred electrophoretically onto nitrocellulose membrane (GE 
Healthcare Life Sciences). Blots were blocked at room temperature with 5% bovine serum 
albumin in PBS plus 0.1% Tween 20 (Sigma). For detection of proteins, membranes were 
incubated with the respective primary antibody: mouse monoclonal anti-eNOS (diluted 1:2500; 
BD Transduction Laboratories; cat. nº #610297), rabbit polyclonal anti-p53 (diluted 1:1.000; 
Santa Cruz; cat. nº SC-6243), mouse monoclonal anti-p21 (diluted 1:1000; Santa Cruz; cat. nº 
SC-817), rabbit polyclonal anti-p16 (diluted 1:1000; Delta Biolabs; cat. nº DB018), mouse 
monoclonal anti-tissue factor (TF, diluted 1:5000; Sekisui Diagnostics, LLC; cat. nº 4509), 
rabbit polyclonal anti-VCAM-1 (diluted 1:5000; Abcam; cat. nº ab134047), mouse monoclonal 
anti-ICAM-1 (diluted 1:1000; Abcam; cat. nº ab171123) mouse monoclonal anti-transforming 
growth factor-β1 (TGF-β1, diluted 1:2500; Abcam; cat. nº ab27969), rabbit polyclonal anti- 
cyclooxygenase-1 (COX-1, diluted 1:1.000; Abcam; cat. nº ab109025), rabbit polyclonal anti- 
COX-2 (diluted 1:1000; Abcam; cat. nº ab15191), rabbit polyclonal anti-angiotensin-converting 
enzyme (ACE, diluted 1:1000; Abbiotec; cat. nº 250450), rabbit polyclonal anti-angiotensin 
type 1 receptor (AT1R, diluted 1:1000; Abcam cat. nº ab124505), mouse monoclonal anti- 
MMP2 (diluted 1:1000; Abcam; cat. nº ab86607), rabbit polyclonal anti-MMP9 (diluted 1:1000; 
Abcam; cat. nº ab38898) or mouse monoclonal anti-β-tubulin (diluted 1:20000; Sigma-Aldrich; 
cat. nº T7816) overnight at 4 °C. After washing, membranes were incubated with the secondary 
antibody (peroxidase-labeled anti-rabbit or anti-mouse immunoglobulin G, dilution of 1:5000; 
Cell Signaling Technology; cat. nº #7074, #7076, respectively) at room temperature for 60 min. 
Prestained markers (Invitrogen) were used for molecular mass determinations. 
Immunocomplexes were detected by chemiluminescence reaction (ECL; Amersham, Les Ulis, 
France) followed by densitometric analysis using the software Image J. 
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Determination of oxidative stress 
 
P1 and P3 AECs were seeded in Millicell EZ SLIDE 8-well glass slides for 24 h, then exposed 
to serum-free MCDB 131 (Invitrogen) for 6 h. The redox-sensitive fluorescent dye 
dihydroethidium (DHE) was used to evaluate the formation of reactive oxygen species (ROS) 
15. AECs were incubated with DHE (5 μM) for 20 min at 37 °C in a light protected manner. To 
determine the cellular sources of ROS, cells were exposed either to N-acetyl cysteine (NAC, 
an antioxidant, 1 mM, 3 h), VAS-2870 (VAS, a NADPH oxidase inhibitor, 5 μM, 30 min), or 
indomethacin (INDO, a cyclooxygenase inhibitor, 30 μM, 30 min). AECs were then washed 
and mounted with fluorescent mounting medium (DAKO, S3023) and examined under confocal 
microscope (Leica SP2 UV DM Irbe). Images were analyzed using Image J software. 
 
 
Platelet aggregation 
 
Washed human platelet suspensions kindly provided by the Etablissement Français du Sang 
 
- Alsace (Strasbourg), were prepared as previously described 13. Suspensions of washed 
platelets (450 µl, 3.108 platelets/μl) were incubated for 2 min in a Chronolog 490 aggregometer 
(Stago BNL) with continuous stirring at 1000 rpm before addition of a submaximal 
concentration of U46619 (0.07 µM, a thromboxane A2 analog) and fibrinogen (1.6 mg/ml). A 
volume of 10 to 20 µl of beads covered with ECs was added to platelet suspensions 2 min 
before the addition of U46619. 
 
 
MPs isolation and measurement 
 
Microparticles (MPs) were collected from conditioned medium of senescent cells by sequential 
centrifugation under sterile conditions as described previously 16. Briefly, cells and cellular 
debris were discarded by a 2-steps 800 g centrifugation for 15 min at room temperature, and 
the supernatant was further centrifuged at 13 000 g and 4 °C for 60 min. The final suspension 
was kept in Hanks balanced solution (HBSS) less than 30 days at 4 °C. 
MPs measurement was performed by prothrombinase assay after capture onto Annexin-5 as 
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previously described using microplate spectrophotometric reader set in kinetic mode, at 405 
nm 17. This capture-based assay allows extensive washing of captured MPs, taking advantage 
of the high affinity of Annexin-5 for phosphatidylserine (Phtdser) exposed at MPs 
surface. MPs concentration was referred to as Phtdser equivalent, by reference to a standard 
curve made with synthetic vesicles of known amounts of PhtdSer 17. In some experiments, 
MPs-free supernatant was centrifuged during 4 h at 25 000 g to discard exosomes and 
assayed as a control of truly soluble content of the conditioned medium. 
 
 
Determination of MMPs activity by zymography 
 
MMP-2 and MMP-9 activities in conditioned medium of cultured AECs were analyzed by 
substrate-gel electrophoresis (zymography) with the use of SDS-PAGE (8%) containing 0.1% 
gelatin, as described previously 18. Then, gels were washed in denaturing buffer for 30 min 
and incubation was done in developing buffer for 24 h at 37 ̊ C. Thereafter, gels were stained 
in 30 % Coomassie blue for 30 min and then destained with destaining buffer. Gelatinolytic 
activity appeared as bands with blue background. Images were taken and the bands were 
analyzed using Image J software. 
 
 
Statistical Analyses 
 
Data are presented as mean ± SEM of n different experiments. Mean values were compared 
using Student’s paired t test or an analysis of variance followed by the post-hoc Bonferroni test 
to identify significant differences between treatments using GraphPad Prism (v5.0). The 
difference was considered to be significant when the P value was less than 0.05. 
 
 
Results 
 
Replicative passaging of atrial endothelial cells and eNOS inhibition promotes 
senescence 
Replicative passaging of AECs caused a progressive appearance of endothelial cells with 
increased levels of SA-β-gal activity (Figure 1A). Likewise, L-NAME, an eNOS inhibitor, and 
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H2O2, a strong inducer of premature endothelial senescence 11 promoted also AECs 
senescence (Figure 1B). The induction of senescence was also witnessed by a strong up- 
regulation of p53, a key regulator in cellular senescence, and of down-stream p21 and p16, 
key cyclin-dependent kinase inhibitors, in AECs at P4 (Figures 2A-C), and in L-NAME- and 
H2O2-treated AECs at P1 (Figures 2D-F). We have verified that the induction of replicative 
senescence did not heighten the level of apoptosis as reported previously in porcine aortic 
endothelial cells.19 
 
 
Atrial endothelial senescence, endothelial dysfunction, inflammation and 
thrombogenicity 
Because endothelial senescence is usually characterized by endothelial dysfunction and a 
reduced formation of NO 20, 21, the expression level of eNOS was assessed in AECs. A 
significant down-regulation of the expression level of eNOS was observed by Western Blot 
analysis in AECs at P4 compared to P1 (Figure 3A). Given the key role of NO to prevent very 
effectively platelet aggregation, we have investigated the potential of AECs to inhibit platelet 
aggregation. In contrast to AECs at P1, senescent AECs at P3, and L-NAME-treated AECs at 
P1 showed a reduced platelet anti-aggregatory effect suggesting a blunted formation of NO 
(Figure 3B). In addition, senescence shifted the endothelial phenotype to a pro-inflammatory 
and pro-coagulant status in AECs at P4 as evidenced by an increased expression level of 
intracellular adhesion molecule-1 (ICAM-1) and tissue factor (TF), and about a 3-fold 
enhancement of pro-coagulant MPs shedding (Figures 4A-C). In addition, H2O2 and L-NAME 
treatments of AECs at P1 also prompted an increased expression level of ICAM-1 and TF, and 
the shedding of MPs (Figures 4D-F). 
 
 
Atrial endothelial senescence is associated with characteristic pro-adhesive and tissue 
remodeling patterns 
To underscore the impact of atrial senescence on cell adhesion and remodeling, the 
expression level of TGF-ß1 and MMPs, pivotal mediators in the control of tissue remodeling 
11  
during cardiac fibrosis, were investigated in AECs at P1 and P4, and also in AECs at P1 
exposed to either L-NAME or H2O2. Both replicative senescence and premature senescence 
in response to H2O2 and L-NAME were associated with an increased expression level of TGF- 
ß1, MMP-2 and MMP-9 (Figures 5A-F). 
 
 
Redox-sensitive NADPH oxidase- and COX-mediated induction of replicative and 
premature AECs senescence 
Since NO is well-known to reduce oxidative stress, a potent inducer of endothelial 
senescence22 23, the role of oxidative stress in the induction of AECs senescence was 
determined. The level of oxidative stress as assessed using the redox-sensitive probe DHE, 
was increased in AECs at P3 compared to those at P1 (Figure 6A). Next, pharmacological 
tools were used to characterize the sources of ROS in senescent AECs. Exposure of AECs at 
P3 to either the antioxidant N-acetylcysteine, or an inhibitor of NADPH oxidase (VAS-2870) or 
COX (indomethacin) significantly reduced the level of oxidative stress and the SA-ß-gal 
activity, indicating that NADPH oxidase and cyclooxygenase pathways contribute to the redox- 
sensitive induction of replicative senescence (Figures 6A,B). Similarly, N-acetylcysteine, VAS- 
2870 and indomethacin also prevented the L-NAME-induced induction of senescence in AECs 
at P1 suggesting that eNOS-derived NO has a pivotal role to counteract the induction of AECs 
senescence (Figure 6C). 
 
 
The local redox-sensitive angiotensin system contributes to replicative and premature 
endothelial senescence 
Because oxidative stress has been shown to upregulate the expression of both ACE and ATR1 
in endothelial and vascular smooth muscle cells 24, 25 26, the role of the local angiotensin system 
in the induction of both replicative and premature AECs senescence was determined. 
Exposure of endothelial cells to either the ACE inhibitor perindoprilat or the AT1R blocker 
losartan decreased SA-β-gal activity in AECs at P3 (Figure 7A) and in L-NAME-treated AECs 
at P1 (Figure 7B). In addition, a significant upregulation of both ACE and AT1R protein levels 
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was observed in senescent AECs at P4 (Figures 7C,E) and in premature senescent L-NAME- 
and H2O2-treated AECs at P1 (Figures 7D,F). 
 
 
Ang II-induced AECs senescence promotes pro-inflammatory, pro-coagulant and pro- 
fibrotic responses, oxidative stress and the up-regulation of the local angiotensin 
system 
Since Ang II has been reported to be a strong inducer of senescence and MPs shedding 
through enhanced oxidative stress in cultured murine aortic ECs 11, we examined the possibility 
of a redox-sensitive induction of the local angiotensin system contributes to Ang II-induced 
senescence in AECs at P1 after a 24-h incubation period. As shown in Figure 8, exposure of 
AECs with 100 nM Ang II significantly increased SA-ß-gal activity (Figure 8A) and up-regulated 
the expression level of p53, p21 and p16 indicating a pro-senescent effect (Figures 8B-D). In 
addition, the premature senescence was associated with a decreased expression level of 
eNOS (Figure 8E) whereas those of VCAM-1 and TF were significantly increased (Figures 8F, 
G). Premature Ang II-induced senescence was also associated with the induction of a pro- 
fibrotic phenotype as indicated by an enhanced expression level of TGF-ß1, active MMP-2 and 
active MMP-9 (Figures 8H-J). Moreover, Ang II stimulated the formation of ROS in AECs at P1 
(Figure 8K) and triggered the up-regulation of ACE and AT1R protein expression levels 
(Figures 8L, M) 27. 
 
 
Discussion 
 
The present findings indicate that both replicative and premature atrial endothelial senescence 
promote thrombogenicity, inflammation, proteolysis, and fibrosis that are mediated by the local 
Ang II system. They further suggest that targeting the Ang II/AT1R pathway may be a 
promising therapeutic strategy to delay atrial endothelial phenotypical alterations associated 
with senescence. 
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Atrial endothelial senescence is associated with endothelial dysfunction and a pro- 
thrombotic pattern 
Although the potential role of senescence in endothelial dysfunction has lately attracted a lot 
of interest using cultured ECs and experimental models of atherosclerosis3, its impact during 
arrhythmogenic remodeling associated with AF remains unknown. Both premature endothelial 
senescence, as observed in response to Ang II or H2O2, and replicative endothelial senescence 
are characterized by oxidative stress and a pronounced down-regulation of eNOS expression 
and the endothelial formation of NO4, 5. The present findings further extent these previous 
reports by showing that replicative senescence promotes, besides blunted NO formation, a 
pronounced pro-thrombotic pattern in senescent AECs as indicated by their reduced ability to 
prevent platelet aggregation, the upregulation of the expression level of TF and the shedding 
of procoagulant MPs. We and others have recently demonstrated that senescent ECs-derived 
MPs act as effective mediators propagating a pro-senescent and pro-thrombotic message to 
neighboring healthy ECs and, hence, they will contribute to promote locally thrombus formation 
11. Besides representing a surrogate marker of vascular and endothelial dysfunction, circulating 
MPs, evidenced at elevated levels in AF 2, 28 or within hours following radiofrequency or 
cryoablation procedures 29, 30 might also contribute to endothelial dysfunction and thrombotic 
propensity of atrial cells. Because procoagulant MPs circulate at high levels during AF or during 
ablation procedures associated with thromboembolic complications, MPs might behave as 
potent effectors of stroke events during AF. Indeed, circulating levels of endothelial MPs were 
related to infarct size and clinical outcome in patients with acute ischaemic stroke 31. 
 
If the link between ageing and endothelial dysfunction appears robustly established, the 
relationship between ageing and the propensity to favor arterial thrombosis independently of 
other relevant risk factors remains controversial. In a recent investigation using organ chamber 
experiments, arterial thrombosis as induced by photochemical injury was not enhanced in old 
mice and was not associated with changes of the arterial expression of TF protein and activity, 
and of platelet activation 32. By contrast, another report showed that H2O2, a potent inducer of 
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senescence, promoted ageing-related platelet hyper-reactivity and thrombosis in mice 33. 
Moreover, alteration in atrial hemodynamics caused by AF rhythm disturbances promoted a 
prothrombotic endothelial pattern through enhanced TF expression 34. 
 
 
Atrial endothelial senescence is associated with a pro-adhesive pattern 
 
Besides the progressive establishment of a pro-thrombotic profile, pro-adhesive and pro- 
inflammatory proteins are another characteristic features of senescent cells (senescent- 
associated secretory phenotype) including an enhanced expression of ICAM-1 and secretion 
of various chemokines by senescent ECs 4. The relevance of the inflammatory response has 
recently been suggested by the colocalization of enhanced macrophages infiltration and 
thrombus formation within atrial tissues of AF patients 35 and by the enrichment of monocyte- 
platelet aggregates or CD11b expression in AF patients with proven thrombus formation 36. 
Other recent insights came from studies showing that (i) the extent of peri-atrial epicardial fat, 
a marker of AF burden and outcome after AF ablation, is associated with enhanced expression 
of ICAM-1 and vWF levels 37 and that (ii) inflammation of epicardial fat predicts the occurrence 
of paroxysmal AF38. In AF, several reports have underlined a possible nexus between the pro- 
thrombotic state and inflammation. For instance, recent data from a large cohort of patients 
with AF and receiving an anticoagulant treatment, have indicated that biomarkers of 
inflammation were significantly associated with an increased risk of mortality 39. 
The present findings indicate that the induction of AECs senescence is associated with the up- 
regulation of the adhesion molecule ICAM-1. Moreover, Toll-like receptor 4 activation, besides 
promoting the induction of senescence, has also been shown to stimulate the expression of 
VCAM-1 in ECs thereby promoting atrial thrombogenesis 40. Enhanced expression of ICAM-1 
on the endothelial cell surface will promote the binding of inflammatory cells that express 
CD11b/CD18 integrins (Mac1), and constitute a prerequisite for subsequent leukocyte 
extravasation 41. Moreover, Ang II has been shown to be a potent stimulus for polynuclear 
neutrophils activation and CD11b/CD18 expression 42 that could contribute to enhance 
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transmigration of inflammatory cells subsequent to an up-regulation of cytoadhesins at the 
surface of senescent ECs. In line with this view, endothelial senescence was demonstrated to 
alter tight junction integrity thereby promoting inflammatory cells transendothelial migration 43. 
The major role of leukocyte infiltration in atrial remodeling and AF vulnerability has been 
observed following the invalidation of the CD11 gene, which protected mice from AF 
vulnerability 42. These data are consistent with the recent demonstration of a strong relationship 
between the enlargement of the left atrium and the occurrence of inflammatory cells infiltration 
in AF patients44. Altogether, these data suggest that the pro-adhesive pattern associated with 
premature atrial endothelial senescence may favor leukocyte infiltration and atrial remodeling. 
 
 
Atrial endothelial senescence induces enhanced MMPs expression: relevance to 
fibrosis 
Several observational studies have pointed out the relationship between MMPs and TIMPs 
(tissue inhibitors of matrix metalloproteinases) expression as measured in atrial tissues or in 
the peripheral blood and the occurrence of AF 45. The human MMPs belong to a class of pro- 
inflammatory and pro-angiogenic factors that control tissue remodeling through the tuning of 
extracellular matrix degradation, and the release of TGF-β that triggers a pro-fibrotic pathway. 
Atrial fibrosis can lead to atrial remodeling that contributes to AF persistence. In aging mice, 
recent studies have depicted an enhanced metalloproteinase-9 (MMP-9) expression 
concomitant with the development of diastolic dysfunction, as a surrogate marker of cardiac 
fibrosis 46. Furthermore, the deletion of MMP-9 attenuated the age-related decline in diastolic 
function, in part, by reducing the TGF-ß pro-fibrotic signal 47. Recent findings have also 
underscored that TGF-β1 increased p16 expression and senescence through the production 
of mitochondrial ROS and most likely subsequent to a reduced level of various antioxidant 
mechanisms 48. Moreover, Xie J et al. observed that premature senescence is associated with 
atrial fibrosis in valvular AF as indicated by the analysis of left atrial appendages of patients 
before valve surgery.49 In the present study, the enhanced release of collagenases MMP-2 
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and 9 observed in senescent AECs is consistent with previous findings obtained in bovine 
aortic ECs 50. Altogether, these data emphasize the view that AECs senescence might 
contribute to cardiac tissue remodeling through MMPs-mediated extracellular matrix 
degradation and the TGF-ß pathway. 
 
 
The Ang II/ AT1 receptor pathway regulates atrial endothelial senescence 
 
Several reports have pointed out the paramount role of Ang II in atrial remodeling, fibrosis, and 
in the development of an arrhythmogenic substrate 51. In contrast, its impact on atrial 
endothelial cell function remains poorly studied. The fact that Ang II is a potent inducer of 
vascular endothelial senescence 12 prompted investigations whether the local angiotensin 
system contributes to AECs senescence. The present findings indicate that Ang II, at 
concentrations that could be reached in pathophysiological issues, is a strong inducer of AECs 
premature senescence to a similar level as that induced by H2O2, a well-known inducer of 
senescence, and L-NAME, an eNOS inhibitor. The importance of the Ang II/AT1R pathway in 
the induction of premature senescence is further emphasized by the demonstration that both 
losartan, an AT1R inhibitor and perindoprilat, an ACE inhibitor, abolished the induction of 
premature and replicative senescence. Altogether, these findings highlight a pivotal role of the 
local angiotensin system in the induction of endothelial senescence and its pro-adhesive, pro- 
thrombotic and pro-fibrotic phenotypes. 
 
 
Conclusion 
 
These findings provide compelling evidences indicating that atrial endothelial senescence 
promotes thrombogenicity through enhanced TF expression, blunted NO-mediated inhibition 
of platelet aggregation and procoagulant MPs shedding. Senescence also promoted the 
induction of an inflammatory response, proteolysis, fibrosis and the up-regulation of the local 
Ang II system. They further suggested that targeting the Ang II/AT1R pathway might be a 
17  
promising therapeutic strategy to delay atrial endothelial phenotypical alterations associated 
with ageing. 
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Figure legends 
 
Figure 1. Sequential passaging of AECs induces replicative senescence, and L-NAME and 
H2O2 induce premature senescence. (A) Senescence assessed by SA-β-gal activity in serially 
passaged AECs from P1 to P4. (B) AECs at P1 incubated with either H2O2 (100 μM) or L- 
NAME (1 mM) for 48 h before the determination of SA-β-gal activity. Results are shown as 
mean ± SEM of n= 3-4 different experiments. *P < 0.05 versus respective control, #P versus 
P2. 
 
 
Figure 2. Replicative and premature senescence are associated with an upregulation of major 
cell cycle regulatory proteins: p53, p21 and p16. Passaging of AECs from P1 to P4 and 
exposure of AECs at P1 to either L-NAME (1 mM) or H2O2 (100 μM) for 48 h increased the 
protein expression level of (A, D) p53, (B, E) p21 and (C, F) p16 as assessed by Western blot 
analysis. Results are presented as representative immunoblots (upper panels), and 
corresponding cumulative data (lower panels) and are shown as ± SEM of n = 3-4 different 
experiments. *P < 0.05 versus respective control. 
 
 
Figure 3. Replicative AECs senescence induces eNOS down-regulation and reduces the 
ability of AECs to inhibit platelet aggregation. (A) eNOS expression level in healthy P1 and 
senescent AECs at P4 as assessed by Western blots analysis. (B) AECs at P1 incubated with 
or without L-NAME (1 mM, 30 min), and ACEs at P3 were grown on microcarrier beads before 
their addition to platelet suspensions 2 min before a submaximal aggregation with U46619. 
Results are shown as mean ± SEM of n = 3-4 different experiments. *P < 0.05 versus 
respective control, #P < 0.05 L-NAME-treated AECs at P1 versus respective control. 
 
 
Figure 4. Replicative and premature senescence are associated with the induction of pro- 
inflammatory and pro-coagulant phenotypes in AECs. Passaging of AECs from P1 to P4 and 
exposure of AECs at P1 to either L-NAME (1 mM) or H2O2 (100 μM) for 48 h increased the 
protein expression level of (A, D) intracellular cell adhesion molecule ICAM-1, (B, E) tissue 
23  
factor (TF) as assessed by Western blot analysis, and (C, F) enhancement of pro-coagulant 
MPs shedding. Results are presented as representative immunoblots (upper panels) and 
corresponding cumulative data (lower panels) and are shown as mean ± SEM of n = 3-4 
different experiments. *P < 0.05 versus respective control. 
 
 
Figure 5. Replicative and premature senescence are associated with the induction of a pro- 
fibrotic phenotype in AECs. Passaging of AECs from P1 to P4 and exposure of AECs at P1 to 
either L-NAME (1 mM) or H2O2 (100 μM) for 48 h increased the protein expression level of (A, 
D) TGF-β1, (B, E) MMP-2 and (C, F) MMP-9 as assessed by Western blot analysis. Results 
are presented as representative immunoblots (upper panels) and corresponding cumulative 
data (lower panels) and are shown as mean ± SEM of n = 3-4 different experiments. *P < 0.05 
versus respective control. 
 
 
Figure 6. Role of oxidative stress in the induction of AECs senescence. (A) The level of 
oxidative stress in AECs at P3 was determined in the absence or presence of either N- 
acetylcysteine (NAC, an antioxidant, 1 mM, 3 h), VAS-2870 (VAS, a NADPH oxidase inhibitor, 
5 μM, 30 min), or indomethacin (INDO, a cyclooxygenase inhibitor, 30 μM, 30 min) before the 
addition of DHE (5 μΜ) for 20 min and the subsequent analysis of the fluorescent level by 
confocal microscopy. The level of oxidative stress in P1 AECs is also shown. Upper panel 
represents ethidium staining; lower panel corresponding cumulative data. (B, C) AECs at P3 
and P1 (treated or not with L-NAME 1 mM for 48 h) were either untreated or exposed to NAC, 
VAS or INDO before the subsequent determination of the SA-β-gal activity using flow 
cytometry. Results are shown as mean ± SEM of n = 3-4 different experiments. *P < 0.05 
versus respective control, #P < 0.05 versus AECs at P3 or L-NAME-treated AECs at P1. 
 
 
Figure 7 Role of the local angiotensin system in both replicative and premature senescence 
of AECs. (A, B) AECs at P3 and P1 (untreated or treated with L-NAME 1 mM) were either 
untreated or exposed to losartan (an AT1R antagonist, 10 µM) or perindoprilat (ACE inhibitor, 
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10 µM) for 48 h. (C-F) Passaging of AECs from P1 to P4 and exposure of AECs at P1 to either 
L-NAME (1 mM) or H2O2 (100 μM) for 48 h increased the protein expression level of ACE and 
AT1R as assessed by Western blot analysis. Results are presented as representative 
immunoblots (upper panels), and corresponding cumulative data (lower panels) and are shown 
as mean ± SEM of n = 3-4 different experiments. *P < 0.05 versus respective control, #P < 0.05 
versus L-NAME-treated AECs at P1. 
. 
 
Figure 8. Ang II-induced senescence promotes pro-inflammatory, pro-coagulant and pro- 
fibrotic, oxidative stress and up-regulation of local angiotensin system in AECs at P1. AECs 
were exposed to Ang II (100 nM) for 24 h before determination of senescence (A), protein 
expression level of target proteins (B-J, N, O), zymography (K, L), and oxidative stress (M). 
Results are shown as representative immunoblots or gelatinolytic activity (upper panels) and 
corresponding cumulative data (lower panels) and shown as mean ± SEM, n = 3-4, *P < 0.05 
versus respective control. 
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Abstract 
 
Background: Within the atria, besides its role in thrombus formation, recent findings have 
highlighted that thrombin conveys ‘non-hematological” functions through PAR-1 activation. 
This study examined the potential of thrombin to promote premature atrial endothelial cells 
(ECs) ageing and thrombogenicity and the shift towards pro-inflammatory, pro-fibrosis and 
pro-remodeling patterns. 
Methods: Primary porcine atria ECs were isolated from the left atrial tissue. The level of 
endothelial senescence was assessed as senescence-associated beta-galactosidase (SA-β-gal) 
activity using flow cytometry, oxidative stress using the redox-sensitive probe 
dihydroethidium, protein level by Western blot analysis, and matrix metalloproteinases 
(MMPs) activity using zymography. 
Results: Atrial endothelial senescence, as assessed by SA-β-gal activity, was induced by 
thrombin at clinically relevant concentrations. Likewise, thrombin induced the up-regulation 
of p53, a key regulator in cellular senescence, and of p21 and p16, key cyclin-dependent 
kinase inhibitors, in atrial ECs. NADPH oxidase, cyclooxygenases and the mitochondrial 
respiration complex contributed to thrombin-induced oxidative stress and senescence. 
Senescence-associated secretory phenotype of atrial ECs activated by thrombin was 
characterized by enhanced expression level of VCAM-1, tissue factor, TGF-ß and MMP-2 
and 9. In addition, the pro-senescence endothelial response to thrombin was associated with 
an overexpression of both ACE and AT1 receptors and was inhibited by perindoprilat and 
losartan. 
Conclusions: The present findings indicate that thrombin promotes premature ageing and 
senescence of atrial ECs and may pave the way to structural changes of the underlying atrial 
tissue by a local up-regulation of the angiotensin system and by promoting pro-inflammatory, 
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pro-fibrotic and pro-remodeling responses. They further suggest that targeting the angiotensin 
system may be of interest to delay thrombin-induced atrial endothelial senescence. 
 
 
 
Keywords: Ageing, thrombosis, atrial fibrillation endothelium, metalloproteinase, TGF 
 
 
Clinical Perspective 
 
1) What is known? Arial fibrillation (AF) activates the coagulation cascade with 
possible formation of intra-atrial thrombi and carry an intrinsic risk of cardioembolism 
and ischemic stroke. 
2) What is new? Thrombin induces atrial endothelial cells senescence and may pave the 
way to structural changes of the underlying atrial tissue by a local up-regulation of the 
angiotensin system and by promoting pro-thrombotic, pro-inflammatory, pro-fibrotic 
and pro-remodeling responses. 
3)  What are the clinical implications? These findings suggest that targeting thrombin 
and/or the angiotensin system may be of interest to delay thrombin-induced atrial 
endothelial senescence. 
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Introduction 
 
Atrial fibrillation (AF) is the most common sustained arrhythmia especially during ageing and 
portends an increased risk of thromboembolism, ischemic stroke and mortality 1. In atrial 
fibrillation, the classic paradigm involves thrombogenesis associated blood stasis in poorly 
contractile atria together with a hypercoagulable state, as witnessed by high circulating levels 
of fibrinolytic degradation products, plasminogen activator inhibitor (PAI)-1, thrombin- 
antithrombin complex and procoagulant microparticles levels (MPs; 1, 2. Detected at high 
concentrations in AF patients 3 and in patients with ischemic stroke 4, circulating MPs provide 
within the vasculature an additional phospholipidic surface enabling the assembly of tenase 
and prothrombinase complexes, ultimately leading to thrombin generation 5. Thrombin, a 
serine protease central to blood coagulation, converts soluble plasma fibrinogen into insoluble 
clot-forming fibrin polymers. Besides its role in thrombus formation, recent findings have 
highlighted that thrombin conveys ‘non-hematological” functions through PAR-1 activation 
and modulates key processes involved in AF initiation and maintenance such as atrial 
remodeling and tissue inflammation but also altered electrical and mechanical properties of 
atria 6-9. Because thrombin is short-lived in blood flow, most of its effects are exerted locally, 
near its site of generation within the atrium. As a consequence, neighboring endothelial cells 
(ECs) closed to a site of tissue injury and coagulation represent an important target of 
thrombin action 10. At the interface between blood flow and atria tissue, ECs play a 
determinant role in the tuning of hemostatic functions but the underlying mechanisms remain 
poorly investigated. Recent advances in the understanding of the purported mechanisms for 
thrombogenesis in cardiovascular diseases have suggested a key role for endothelial 
senescence in the modulation of important biological responses including thrombogenicity.  
In the setting of AF, two recent reports have highlighted the link between senescence, AF 
occurrence or extent of atrial fibrosis as a marker of tissue remodeling associated to AF 
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maintenance 11, 12. In addition to fibrotic remodeling of the atrial tissue, previous studies have 
emphasized that the senescence process is characterized by the acquisition of senescence- 
associated secretory phenotype (SASP) witnessed by cytokines release. In addition, besides 
this shift towards a pro-inflammatory pattern, we have recently demonstrated that endothelial 
senescence favors thrombogenicity through several mechanisms including tissue factor up- 
regulation, pro-coagulant MPs release, endothelial nitric oxide synthase down-regulation and 
reduced ECs-mediated nitric oxide-dependent inhibition of platelet aggregation 13. 
In the present study, taking advantage of an original model of culture of primary atrial ECs, 
we sought to examine whether thrombin, could promote atrial endothelial senescence. In 
addition, the possibility that atrial endothelial senescence shifts the cell phenotype towards 
pro-thrombotic, pro-fibrotic, pro-inflammatory and pro-remodeling patterns was examined. 
Moreover, since angiotensin II (Ang II) via NADPH oxidase-derived oxidative stress is a 
potent inducer of premature endothelial senescence and ECs express both angiotensin- 
converting enzyme (ACE) and angiotensin type 1 receptors (AT1R, 13, the potential role of 
the local Ang II/AT1R in the noxious impact of thrombin on premature endothelial 
senescence and dysfunction was determined. 
 
 
Materials and methods 
Chemicals 
Unless indicated, all chemicals and solvents were from Sigma-Aldrich (Sigma-Aldrich 
SARL, St Quentin Fallavier, France). Human thrombin was obtained from Etablissement 
Français du Sang-Alsace (EFS), Strasbourg, France. Losartan was obtained from Merck 
Research Laboratories (NJ, U.S.A) and perindoprilat from Servier, Paris, France. 
Isolation and culture of atrial endothelial cells 
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Atrial ECs were isolated from left atria after collection of porcine hearts from the local 
slaughterhouse (SOCOPA, Holtzheim, France). Heart-lung blocks were dissected to obtain 
complete left atrium. At the level of mitral valve, left ventricle was removed and ligation of 
pulmonary veins was done. The luminal surface of the left atrium was cleaned and flushed 
with phosphate-buffered saline (PBS) without calcium to discard remaining blood. To prepare 
primary cultures, ECs were isolated by collagenase treatment (type 1, Worthington, 1 mg/ml 
for 40 min at 37 °C) and cultured in culture dishes containing MCDB131 medium 
(Invitrogen) supplemented with penicillin (100 UI/ml), streptomycin (100 UI/ml), fungizone 
(250 μg/ml), L-glutamine (2 mM, all from Lonza, St Quentin en Yvelines, France) and 15% 
fetal calf serum and grown for 3-4 days (passage 0). The medium was changed every 48 h. 
Premature atrial ECs senescence was induced at passage 1 by incubating cells with either 
thrombin (1 or 3 U/ml) or Ang II (100 nM) for 24 h in serum-free medium 15 h after seeding. 
In some experiments, pharmacological modulators were added to atrial ECs, 30 min before 
adding thrombin (1 U/ml). 
 
 
Determination of SA-β-gal activity by flow cytometry 
 
SA-β-galactosidase activity was determined by flow cytometry using the fluorogenic substrate 
C12FDG (5-dodecanoylaminofluorescein Di-β-D-galactopyranoside, Invitrogen, Life 
Technology, SAS) as described previously 14. Atrial ECs were pretreated with 300 µM 
chloroquine for 1 h to induce lysosomal alkalinization. C12FDG (33 µM) was then added to 
the incubation medium (without phenol red) for 1 h. At the end of the incubation period, ECs 
were washed with ice-cold PBS, re-suspended following trypsinization and analyzed using a 
flow cytometer (FACScan, BD Bioscience, CA, USA). Data were acquired and analyzed 
using the Cellquest software (Becton Dickinson). Light scatter parameters were used to 
eliminate dead cells and subcellular debris. The C12-fluorescein signal was measured on the 
8 
 
FL1 detector, and the proportion of ECs with SA-β-gal activity was estimated using the 
median fluorescence intensity of the population. Autofluorescence assessed in parallel  in 
atrial ECs not exposed to C12FDG was negligible. 
Western blot analysis 
 
Atrial ECs were washed with PBS and then lysed in extraction buffer (composition in mM: 
NaCl 150, Na3VO4  1, sodium pyrophosphate 10, NaF 20, okadaic acid 0.01 (Sigma), Tris/HCl 
20 (pH 7.5; QBiogene), a tablet of protease inhibitor (Roche) and 1% Triton X-100 
(QBiogen)). Equal amounts of proteins were separated on denaturing SDS (10-12%) 
polyacrylamide gel. Separated proteins were transferred electrophoretically onto 
nitrocellulose membranes (GE Healthcare Life Sciences). Blots were blocked at room 
temperature with 5% bovine serum albumin in PBS plus 0.1% Tween 20 (Sigma). For 
detection of proteins, membranes were incubated with the respective primary antibody: mouse 
monoclonal anti-eNOS (diluted 1:2500; BD Transduction Laboratories; cat. nº #610297), 
rabbit polyclonal anti-p53 (diluted 1:1.000; Santa Cruz; cat. nº SC-6243), mouse monoclonal 
anti-p21 (diluted 1:1000; Santa Cruz; cat. nº SC-817), rabbit polyclonal anti-p16 (diluted 
1:1000; Delta Biolabs; cat. nº DB018), mouse monoclonal anti-tissue factor (TF, diluted 
1:5000; Sekisui Diagnostics, LLC; cat. nº 4509), rabbit polyclonal anti-VCAM-1 (diluted 
1:5000; Abcam; cat. nº ab134047), mouse monoclonal anti-tranforming growth factor β 
(TGF-β1, diluted 1:2500; Abcam; cat. nº ab27969), rabbit polyclonal anti-cyclooxygenase-1 
(COX-1, diluted 1:1.000; Abcam; cat. nº ab109025), rabbit polyclonal anti-COX-2 (diluted 
1:1000; Abcam; cat. nº ab15191), rabbit polyclonal anti-angiotensin-converting enzyme 
(ACE, diluted 1:1000; Abbiotec; cat. nº 250450), rabbit polyclonal anti-angiotensin type 1 
receptor (AT1R, diluted 1:1000; Abcam cat. nº ab124505), or mouse monoclonal anti-β- 
tubulin (diluted 1:20000; Sigma-Aldrich; cat. nº T7816) overnight at 4 °C. After washing, 
membranes were incubated with the secondary antibody (peroxidase-labeled anti-rabbit or 
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anti-mouse immunoglobulin G, dilution of 1:5000; Cell Signaling Technology; cat. nº #7074, 
#7076, respectively) at room temperature for 60 min. Prestained markers (Invitrogen) were 
used for molecular mass determinations. Immunocomplexes were detected by 
chemiluminescence reaction (ECL; Amersham, Les Ulis, France) followed by densitometric 
analysis using the software Image J. 
Determination of oxidative stress 
 
Atrial ECs were seeded in Millicell EZ SLIDE 8-well glass slide for 15 h, before exposure to 
serum-free MCDB 131 (Invitrogen) for 2 h. The redox-sensitive fluorescent dye 
dihydroethidium (DHE) was used to evaluate the formation of reactive oxygen species  (ROS; 
15. ECs were incubated with DHE (5 μM) for 20 min at 37 °C in a light protected manner. To 
 
determine the sources of ROS, cells were untreated or exposed to either N-acetyl cysteine 
(NAC, an antioxidant, 1 mM, 3 h), VAS-2870 (VAS, a NADPH oxidase inhibitor, 1 μM, 30 
min), indomethacin (INDO, a cyclooxygenase inhibitor, 10 μM, 30 min), SC-560 (a 
cyclooxygenase-1 inhibitor, 0.3 μM, 30 min), NS-398 (a cyclooxygenase-2 inhibitor, 3 μM, 
30 min), mitochondrial inhibitory complex (Rotenone, 1 μM, 30 min; KCN, 1 μM, 30 min; 
Myxothiazol, 0.5 μM, 30 min) before the addition of thrombin (1 U/ml) for 1 h in serum-free 
medium. In some experiments, ECs were incubated with either losartan (10 μM) or 
perindoprilat (10 μM) 30 min before the addition of thrombin (1 U/ml) for 24 h. ECs were 
then washed and mounted with fluorescent mounting medium (DAKO, S3023) and examined 
under confocal microscope (Leica SP2 UV DM Irbe). Images were analyzed using Image J 
software. 
Determination of MMP activity by zymography 
 
MMP-2 and MMP-9 activities in conditioned medium of cultured atrial ECs were analyzed by 
substrate-gel electrophoresis (zymography) with the use of SDS-PAGE (8%) containing 0.1% 
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gelatin, as described previously 16. Then, gels were washed in denaturing buffer for 30 min 
and incubated in developing buffer for 24 h at 37 ̊ C. Thereafter, gels were stained in 30 % 
Coomassie blue for 30 min and then destained with destaining buffer. Gelatinolytic activity 
appeared as bands with blue background. Images were taken and bands were analyzed using 
Image J software. 
Statistical analyses 
 
Data are presented as mean ± SEM of n different experiments. Mean values were compared 
using Student’s paired t test or an analysis of variance followed by the post-hoc Bonferroni 
test to identify significant differences between treatments using GraphPad Prism (v5.0). The 
difference was considered to be significant when the P value was less than 0.05. 
 
 
 
Results 
 
Thrombin induces atrial endothelial cells senescence 
 
Thrombin induced atrial ECs senescence as depicted by the increased level of SA-beta-gal 
activity, in a concentration-dependent manner (Figure 1A). Likewise, thrombin induced the 
up-regulation of the protein expression level of p53, a key regulator in cellular senescence, 
and of p21 and p16, key cyclin-dependent kinase inhibitors, in atrial ECs (Figures 1B-D). 
Similar responses were also observed in atrial ECs in response to Ang II, a strong inducer of 
premature endothelial senescence (Figure 1). 
 
 
Thrombin increases oxidative stress within atrial endothelial cells 
 
Since reactive oxygen species (ROS) are strong inducers of senescence 13, experiments were 
performed to determine whether oxidative stress is involved in thrombin-induced premature 
senescence using DHE. Indeed, thrombin (1 U/mL) increased the level of ethidium 
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fluorescence in ECs (Figure 2A). The source of ROS was characterized using inhibitors of 
major vascular sources of ROS including NADPH oxidase (VAS-2870), cyclooxygenases 
(COXs, indomethacin, INDO), COX-1 (SC-560), COX-2 (NS-398), and the mitochondrial 
respiration complex (MIT INH), and the antioxidant N-acetylcysteine (NAC). All 
pharmacological tools blunted the thrombin-induced formation of ROS (Figure 2A). 
Similarly, NAC, VAS-2870, INDO and MIT also prevented the thrombin-induced SA-ß-gal 
activity (Figure 2B). These findings suggest that NADPH oxidase, COXs and the 
mitochondrial respiration complex contribute to thrombin-induced oxidative stress and 
senescence in atrial ECs. In addition, Western blot analysis indicated that thrombin up- 
regulated COX-2, but not COX-1, in atrial ECs (Figure 3). 
 
 
Critical role of the local angiotensin system in thrombin-induced oxidative stress in 
atrial ECs 
Since many reports have underscored that endothelial senescence is critically dependent on 
the redox activation by the local angiotensin system 13, experiments were performed to 
examine the interplay between thrombin and the local activation of the angiotensin system. 
We first established that thrombin increased the expression level of ACE and AT1R in atrial 
ECs (Figures 4A, B). To determine whether Ang II mediates the thrombin-induced ECs 
oxidative stress, we examined the effect of losartan (AT1R antagonist) and perindoprilat 
(ACE inhibitor). The induction of oxidative stress-mediated senescence by thrombin was 
significantly blunted by pretreatment with the ACE inhibitor and also the AT1R antagonist 
(Figure 4C-D). 
 
 
Thrombin induces endothelial dysfunction, and pro-thrombotic and pro-inflammatory 
pattern 
12 
 
Because endothelial senescence is characterized by endothelial dysfunction and a reduced 
formation of NO 13, the effect of thrombin on eNOS protein expression was examined. A 
decreased in eNOS expression level was evidenced when ECs were exposed to thrombin (3 
U/mL) to the same extent that induced by Ang II (100 nM, Figure 5A). To underscore pro- 
thrombotic and pro-inflammatory pattern associated with ECs senescence, VCAM-1 and TF 
expression was examined. A concentration-dependent increased in VCAM-1 and TF 
expression level was observed in atrial ECs in response to thrombin and Ang II (Figures 
5B,C). 
 
 
Thrombin increases pro-fibrotic and pro-remodeling responses 
 
Since atrial remodeling is a key feature of AF 7, we investigated the link between thrombin- 
induced ECs senescence, TGF-ß, and the metalloproteinases MMP-2 and MMP-9. Previous 
studies have emphasized that TGF-ß is involved in the remodeling of extracellular matrix and 
is up-regulated in AF 17. As shown in Figure 6A, thrombin induced a concentration-dependent 
increase in the expression level of TGF-ß. In addition 18, experiments were performed to 
determine the impact of thrombin on the expression level of active MMP-2 and 9. As depicted 
in Figures 6B and C, thrombin-increased the active MMP-2 and 9 expression levels to a 
greater extent as Ang II in atrial ECs. Altogether, these findings indicate that thrombin- 
induced atrial endothelial senescence contributes to the acquisition of a pro-fibrotic and pro- 
remodeling pattern. 
 
 
Discussion 
 
The salient findings of the present study are as follows (i) thrombin induces oxidative stress 
and premature atrial endothelial senescence, (ii) phenotypical changes associated with 
thrombin-induced atrial endothelial senescence comprise the acquisition of pro-thrombotic, 
13  
pro-adhesive, pro-fibrotic and pro-remodeling patterns, (iii) pro-senescence endothelial 
response to thrombin is associated with an overexpression of both ACE and ATR1 and 
inhibited by perindoprilat and losartan, and (iv) the local angiotensin system acts as an 
important amplifying system to accelerate the acquisition of senescence-associated secretory 
phenotype. Altogether, these findings substantiate the view that thrombin, beyond its role in 
the coagulation process, shifts the atrial endothelium phenotype towards pro-thrombotic, pro- 
inflammatory, pro-fibrotic and pro-remodeling patterns and thereby, could contribute to 
further worsen the function of the atrial tissues paving the way to AF perpetuation. 
Recent data have challenged the classical causality of AF causing hypercoagulability by 
demonstrating that hypercoagulability per se induces pro-fibrotic and pro-inflammatory 
responses in adult atrial fibroblasts contributing to structural remodeling in the atria 6, 7, 9, 19. 
At the interface between blood flow and atrial tissue, the precise role of endothelium in 
response to thrombin activation remains conspicuously unexplored. Up to now, the 
understanding of endothelial dysfunction during AF was mainly based on studies performed 
on human umbilical vein ECs (HUVECs). To circumvent the possibility that endothelial 
function may vary according to the vascular bed, we have developed an original model of 
primary cultures of porcine atrial ECs, and the possibility that thrombin acts as a key effector 
of premature atrial senescence was examined. The present findings indicate that thrombin, at 
relevant concentrations achieved during vascular injury associated to thrombus formation 20, 
induced oxidative stress, premature ageing of atrial ECs and enhanced thrombogenicity. 
Using several pharmacological tools, the thrombin-induced oxidative stress in atrial ECs has 
been shown to involve several major sources of ROS including NADPH oxidase, 
cyclooxygenases, and the mitochondrial respiratory chain, and to promote ECs senescence. 
These pro-oxidant sources have also been involved in replicative senescence in coronary 
artery ECs 13, and both NADPH oxidase and the mitochondria are involved in endothelial 
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MPs-mediated oxidative stress in mouse aortic ECs 21. In other cell lineages (HUVECs), 
another group group has recently established that activated Factor Xa, another mediator of 
hypercoagulability, induces endothelial senescence through the up-regulation of insulin-like 
growth factor binding protein 5 and early growth response protein1 22. 
The impact of thrombin on the expression of eNOS remains highly controversial. Previous 
reports have suggested that thrombin activates PAR-1 and stimulates eNOS with subsequent 
NO formation and vascular relaxation 23, 24. By contrast, in the setting of paroxysmal AF, 
Akar et al., have demonstrated that the acute onset of AF in humans is associated within 
minutes with thrombin generation and concomitant platelet aggregation together with a swift 
decreased in NO formation as a marker of endothelial dysfunction 25. Likewise, in rabbits, 
short term paroxysmal AF was evidenced to induce oxidative stress, thrombin generation and 
endothelial dysfunction 26. Consistent with these findings, we could establish that thrombin 
induced in a concentration-dependent manner a significant decreased of eNOS expression in 
atrial ECs. Another characteristic feature of the acquisition of a pro-thrombotic pattern by the 
senescent atrial ECs is represented by an enhanced expression of tissue factor. Altogether, it is 
therefore likely that at the senescent atrial endothelial surface, both blunted NO-mediated 
inhibition of platelet aggregation and enhanced tissue factor expression contribute to the 
acquisition of a pro-thombotic pattern ultimately leading not solely to thrombin generation but 
also to amplification loops favoring further endothelial senescence. 
Besides its role in thrombus formation, recent data have highlighted that “non hemostatic 
effects” mediated by thrombin through PAR-1 activation could perpetuate AF by inducing 
inflammatory burden, atrial remodeling and modulation of the electrophysiological 
characteristics of pulmonary vein and/or left atrium tissue 7-9. The relevance of these findings 
was for instance emphasized by the demonstration that hypercoagulability promotes the 
development of a substrate for AF in transgenic mice and in goats with persistent AF 9. The 
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major importance of this pathway is demonstrated by the fact that pro-remodeling effects of 
thrombin could be blunted by pharmacological blockade of thrombin using dabigatran. In 
isolated rat atrial fibroblasts, recent findings by Spronk et al., has depicted that, thrombin 
enhanced the phosphorylation of the pro-fibrotic signaling AKT and ERK pathways, and 
increased the expression of TGF-ß and the pro-inflammatory factor monocyte chemo- 
attractant protein-1 27. The present findings extent these data by demonstrating that atrial ECs, 
when subjected to pro-senescent stimuli, constitute another importance source of bio-effectors 
involved in inflammatory cell infiltration, fibrosis and extracellular matrix proteolysis. 
Because central to the characterization of endothelial dysfunction is the expression of various 
cytoadhesins or selectins together with the production of proinflammatory chemokines, we 
investigated the impact of thrombin-induced endothelial senescence on VCAM-1 expression. 
Thrombin was evidenced as a potent inducer of VCAM-1 expression by senescent atrial ECs 
that may promote inflammatory cells infiltration within atrial tissues. Such an observation 
extends previous findings demonstrating that thrombin induces endothelial NF-B-dependent 
expression of ICAM-1 and VCAM-1 in SVEC4 mouse ECs 10. VCAM-1 is an 81 kDa 
sialoglycoprotein expressed by cytokine-activated vascular endothelium, that mediates cell 
adhesion and transendothelial diapedesis, and was recently evidenced as a potent marker of 
post operative AF 28. Other data have underlined that both inflammation and oxidative stress 
are responsible of electrical and structural changes that promoted increased automaticity and 
autonomic dysfunction leading to an increased risk of AF 29, 30. 
Another important determinant of structural changes occurring during AF is represented by 
TGF-ß. Recent data obtained by transgenic goat model overexpressing TGF-ß1 have 
emphasized the view that cardiac overexpression of TGF-ß leads to increased fibrosis within 
the atria tissue and favors not only P wave prolongation but also AF vulnerability 31. Other 
reports have previously established that mice that overexpress TGF-ß1 have pronounced atrial 
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fibrosis and increased susceptibility to AF induction via rapid atrial pacing 32. In human, 
senescence markers such as SA-ß-gal activity and p16 were positively correlated with the 
extent of atrial fibrosis 12. The impact of thrombin on endothelial TGF-ß expression remains 
controversial. The present demonstration of significant up-regulation of TGF-ß expression on 
thrombin-induced senescent atrial ECs challenges previous reports by Tang and coworkers 
describing a down-regulation of TGF-ß signaling on aortic or venous human ECs when 
submitted to thrombin stimulation 33. Recent data by Altieri et al., have underlined that 
sustained stimulation by thrombin induced the synthesis of TGF-ß by human atrial fibroblasts, 
which was counteracted by dabigatran, a direct thrombin inhibitor 6. Collectively,  these 
novels data reinforce the view that atrial tissues including atrial ECs constitute a potent source 
of pro-fibrotic mediator TGF-ß when submitted to thrombin stimulation. 
Another important regulator of structural changes during AF is represented by MMPs. For 
instance, it was recently established that fibrosis remodeling as assessed by total collagen in 
the left atrium is positively correlated to pro-fibrotic cytokines but also MMP-2 and 9 34. The 
striking increase of atrium content in MMP-2 and 9 described in AF patients contrasting with 
normal content of MMP-1 and 3 emphasizes the paradigm that MMP-2 and 9 are key 
effectors of matrix remodeling during AF 35. Our observation of a thrombin concentration- 
dependent up-regulation of active MMP-2 and 9 by senescent atrial ECs is in line with former 
studies performed on rat cardiac fibroblasts 36. By contrast, in human atrial fibroblasts, 
thrombin was found to mediate opposite effects by decreasing MMP-2 activity 6 (Although 
species dissimilarities in the nature of atrial tissue response to thrombin appear likely and 
hamper general extrapolation, our findings substantiate the view that the senescent atrial ECs 
may participate to extracellular remodeling when subjected to thrombin stimulation. Previous 
data have highlighted that enhanced fibrosis, as a consequence of TGF-ß signaling 
stimulation, paralleled the increase in collagen deposition and alterations in extracellular 
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matrix remodeling by MMPs. These structural alterations of the atrium tissue pave the way to 
perpetuation of arrhythmia because fibrosis is a determinant mechanism in the disruption of 
connectivity between myocytes and impair normal electrical conduction, thereby decreasing 
the wavelength of reentry 37. 
Another important determinant of structural changes associated to AF is represented by the 
angiotensin system 37. Epidemiological studies have extensively demonstrated the association 
between AF and hypertension or elevated Ang II 38.  The fact that Ang II is a potent inducer  
of endothelial senescence in several cell lineages including coronary artery ECs and also atrial 
ECs, and because ECs express high levels of ACE promoting Ang II formation, prompted us 
to test the hypothesis that the local angiotensin system may be involved in the pro-senescent 
effect of thrombin. We could establish that thrombin induced both ACE but also AT1R 
expression in atrial ECs. The importance of the local activation of the angiotensin system by 
thrombin was emphasized by the demonstration that losartan, an AT1R antagonist, and also 
perindoprilat, an ACE inhibitor, blunted thrombin-induced oxidative stress and induction of 
ECs senescence. Altogether, these findings highlight a pivotal role of the local angiotensin 
system in the thrombin-mediated induction of premature endothelial senescence via activation 
of AT1R. Collectively, our data substantiate a new paradigm linking thrombin and AF to each 
other, in a vicious amplification loop where AF favors thrombin generation and thrombin per 
se, by inducing premature ageing of the atrial ECs, shifts the phenotype of senescent 
endothelial cells towards pro-thrombotic pro-thrombotic, pro-inflammatory, pro-fibrotic and 
pro-remodeling patterns, promoting structural changes of the atrial tissue and AF 
maintenance. 
In conclusion, the present findings indicate that thrombin promotes premature ageing and 
senescence of atrial ECs and may pave the way to structural changes of the underlying atrial 
tissue by a up-regulation of the local angiotensin system and by promoting pro-inflammatory, 
18 
 
pro-fibrotic and pro-remodeling responses. They further suggest that targeting the angiotensin 
system may be of interest to delay thrombin-induced endothelial atrial senescence. 
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Figure legends 
 
Figure 1. Thrombin and Ang II induce senescence in atrial ECs at passage 1 and are 
associated with an up-regulation of major cell cycle regulatory proteins: p53, p21 and p16. 
Atrial ECs were either untreated or exposed to thrombin (1 or 3 U/ml) or Ang II (100 nM) for 
24 h before determination of senescence by SA-β gal activity (A), protein expression level of 
(B) p53, (C) p21 and (D) p16 as assessed by Western blot analysis. Results are presented as 
representative immunoblots (upper panels), and corresponding cumulative data (lower panels) 
and are shown as ± SEM of n = 3-4 different experiments. *P < 0.05 versus respective 
control. 
 
 
Figure 2. Thrombin induces oxidative stress promoting senescence in atrial ECs. (A) Atrial 
ECs were either untreated or exposed to N-acetylcysteine (NAC, an antioxidant, 1 mM, 3 h), 
VAS-2870 (VAS, NADPH oxidase inhibitor, 5 μM, 30 min), indomethacin (INDO, COX 
inhibitor, 30 μM, 30 min), SC-560 (COX-1 inhibitor, 0.3 μM, 30 min), NS-398 (COX-2 
inhibitor, 3 μM, 30 min) or a mitochondrial inhibitory complex (MIH; rotenone, 1 μM, 30 
min; KCN, 1 μM, 30 min; myxothiazole, 0.5 μM, 30 min) before the additon of thrombin (1 
U/ml, 1 h) and DHE (5 μΜ) during the last 20 min to determine the level of oxidative stress 
by confocal microscopy. Upper panels represent ethidium staining; lower panel corresponding 
cumulative data. (B) Atrial ECs were either untreated or exposed to NAC, VAS, INDO or 
MIH before the addition of thrombin (1 U/ml, 24 h) and subsequent determination of SA-β- 
gal activity using flow cytometry. Results are shown as mean ± SEM of n = 3-4 different 
experiments. *P < 0.05 versus respective control, #P < 0.05 versus thrombin-treated atrial 
ECs. 
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Figure 3. Thrombin and Ang II induce the expression of cyclooxygenase-2 in atrial ECs. 
Atrial ECs were either untreated or exposed to thrombin (1 or 3 U/ml) or Ang II (100 nM) 
before determination of the expression level of (A) COX-1 and (B) COX-2 as assessed by 
Western blot analysis. Results are shown as representative immunoblots (upper panels) and 
corresponding cumulative data (lower panels) and shown as mean ± SEM, n = 3-4, *P < 0. 05 
versus respective control. 
 
 
Figure 4. Thrombin-induced senescence promotes up-regulation of the local angiotensin 
system in atrial ECs. Atrial ECs were either untreated or exposed to losartan (an AT1R 
antagonist, 10 µM) or perindoprilat (ACE inhibitor, 10 µM) for 30 min before the addition of 
thrombin (1 U/ml) or Ang II (100 M) for 24 h, and the subsequent determination of the 
expression level of target proteins (A, B) as assessed by Western blot analysis, (C) oxidative 
stress by confocal microscopy, and (D) SA-β-gal activity using flow cytometry. Results are 
shown as representative immunoblots (upper panels) and corresponding cumulative data 
(lower panels) and shown as mean ± SEM, n = 3-4, *P < 0. 05 versus respective control, #P < 
0.05 versus thrombin-treated atrial ECs. 
 
 
Figure 5. Thrombin- and Ang II-induced senescence promotes pro-inflammatory and pro- 
coagulant phenotype in atrial ECs. Atrial ECs were untreated or exposed to either thrombin (1 
or 3 U/ml) or Ang II (100 nM) before determination of the expression level of target proteins 
as assessed by Western blot analysis. Results are shown as representative immunoblots (upper 
panels) and corresponding cumulative data (lower panels) and shown as mean ± SEM, n = 3- 
4, *P < 0. 05 versus respective control. 
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Figure 6. Thrombin- and Ang II-induced senescence promotes pro-fibrotic phenotype in atrial 
ECs. Atrial ECs were untreated or exposed to either thrombin (1 or 3 U/ml) or Ang II (100 
nM) before determination of the expression level of TGF-ß (A) as assessed by Western blot 
analysis, and MMP-2 and 9 activities by zymography (B, C). Results are shown as 
representative immunoblots or gelatinolytic activity (upper panels) and corresponding 
cumulative data (lower panels) and shown as mean ± SEM, n = 3-4, *P < 0. 05 versus 
respective control. 
  
 
 
 
 
 
Figure 1 A 
50 
 
40 
 
30 
 
20 
 
10 
 
0 
Control Ang II 
Thrombin (100 nM) 
B C (1 U/mL) (3 U/mL) D 
 
p53 
 
β-tubulin 
250 
 
200 
 
150 
 
100 
 
50 
 
0 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thrombin 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ang II 
(100 nM) 
p21 
β-tubulin 
200 
 
150 
 
100 
 
50 
 
0 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thrombin 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ang II 
(100 nM) 
p16 
β-tubulin 
400 
 
300 
 
200 
 
100 
 
0 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thrombin 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ang II 
(100 nM) 
(1 U/mL) (3 U/mL) (1 U/mL) (3 U/mL) (1 U/mL) (3 U/mL) 
* 
* 
* 
* 
* * 
* 
* 
* * * * 
p
5
3
/β
-t
u
b
u
li
n
 l
e
v
e
l 
(%
 C
o
n
tr
o
l)
 
S
A
-β
-g
a
l 
a
c
ti
v
it
y
 
(a
rb
it
ra
ry
 u
n
it
) 
p
2
1
/β
-t
u
b
u
li
n
 l
e
v
e
l 
(%
 C
o
n
tr
o
l)
 
p
1
6
/β
-t
u
b
u
li
n
 l
e
v
e
l 
(%
 C
o
n
tr
o
l)
 
 * 
# 
# # 
# # 
# 
 
 
 
 
 
 
 
Figure 2 
 
 
 
A 
        
3000 
 
 
 
 
 
2000 
 
 
 
 
 
1000 
 
 
 
 
 
 
Control  
Thrombin (1 U/mL, 1 h) 
NAC VAS-2870 INDO SC-560 NS-398 MIT INH 
E
th
id
iu
m
 f
lu
o
re
s
c
e
n
c
e
 
(a
rb
it
ra
ry
 u
n
it
) 
  
 
 
 
 
 
 
Figure 2 
 
 
 
B 
 
150 
 
 
100 
* 
# 
# # #
 
 
 
 
50 
 
 
 
 
0 
Control 
 
 
Thrombin (1 U/mL, 24 h) 
NAC VAS-2870 INDO MIT INH 
S
A
-β
-g
a
l 
a
c
ti
v
it
y
 
(a
rb
it
ra
ry
 u
n
it
) 
    
* 
* 
* 
 
 
 
 
 
 
 
Figure 3 
 
 
 
 
 
 
A B 
 
 
COX-1 
β-tubulin 
150 
 
 
100 
 
 
50 
 
 
0 
 
 
 
 
 
 
 
 
 
 
 
Control Ang II 
COX-2 
β-tubulin 
250 
 
200 
 
150 
 
100 
 
50 
 
0 
 
 
 
 
 
 
 
 
 
Control Ang II 
Thrombin (100 nM) Thrombin (100 nM) 
(1 U/mL) (3 U/mL) (1 U/mL) (3 U/mL) 
C
O
X
-1
/β
-t
u
b
u
li
n
 l
e
v
e
l 
(%
 C
o
n
tr
o
l)
 
C
O
X
-2
/β
-t
u
b
u
li
n
 l
e
v
e
l 
(%
 C
o
n
tr
o
l)
 
 * 
* 
* 
A
T
1
R
/β
-t
u
b
u
li
n
 l
e
v
e
l 
(%
 C
o
n
tr
o
l)
 
 
 
 
 
 
 
 
 
 
Figure 4 
 
 
 
 
A B 
 
ACE 
β-tubulin 
250 
 
200 
 
150 
AT1R 
β-tubulin 
250 
 
200 
 
150 
 
100 100 
 
50 50 
 
0 
Control 
 
Thrombin 
 
Ang II 
(100 nM) 
0 
Control 
 
Thrombin 
 
Ang II 
(100 nM) 
(1 U/mL) (3 U/mL) (1 U/mL) (3 U/mL) 
* 
* 
* 
A
C
E
/β
-t
u
b
u
li
n
 l
e
v
e
l 
(%
 C
o
n
tr
o
l)
 
  
 
 
 
 
 
 
 
 
Figure 4 
 
 
 
C D 
 
 
 
3000 
* 
2000 
# # 
 
1000 
200 
150 * 
# 
100  # 
 
50 
 
0 
Control 
Thrombin (1 U/mL, 24 h) 
Control 
Thrombin (1 U/mL, 24 h) 
Losartan 
(10 μM) 
Perindoprilat 
(10 μM) 
Losartan 
(10 μM) 
Perindoprilat 
(10 μM) 
E
th
id
iu
m
 f
lu
o
re
s
c
e
n
c
e
 
(a
rb
it
ra
ry
 u
n
it
) 
S
A
-β
-g
a
l 
a
c
ti
v
it
y
 
(a
rb
it
ra
ry
 u
n
it
) 
  
 
 
 
 
 
 
 
 
Figure 5 
 
 
 
A B C 
 
 
eNOS 
 
β-tubulin 
150 
 
 
100 
 
 
50 
 
 
0 
 
 
 
 
 
 
Control Ang II 
VCAM-1 
 
β-tubulin 
 
250 
 
200 
 
150 
 
100 
 
50 
 
0 
 
 
 
 
 
 
 
 
 
 
 
 
Control Ang II 
Tissue factor 
β-tubulin 
200 
 
150 
 
100 
 
50 
 
0 
 
 
 
 
Control Ang II 
Thrombin (100 nM) Thrombin (100 nM) Thrombin (100 nM) 
(1 U/mL) (3 U/mL) (1 U/mL) (3 U/mL) (1 U/mL) (3 U/mL) 
* 
* 
* 
* * 
* 
* 
* 
e
N
O
S
/β
-t
u
b
u
li
n
 l
e
v
e
l 
(%
 C
o
n
tr
o
l)
 
V
C
A
M
-1
/β
-t
u
b
u
li
n
 l
e
v
e
l 
(%
 C
o
n
tr
o
l)
 
T
F
/β
-t
u
b
u
li
n
 l
e
v
e
l 
(%
 C
o
n
tr
o
l)
 
  
 
 
 
 
 
 
 
 
Figure 6 
 
 
A B C 
 
TGF-β 
 
β-tubulin 
250 
 
200 
 
150 
 
100 
 
50 
 
0 
 
 
 
 
 
 
Control Ang II 
 
Latent MMP-2 
Active MMP-2 
250 
200 
150 
100 
50 
0 
 
 
 
 
 
 
 
 
 
 
Control Ang II 
 
Latent MMP-9 
Active MMP-9 
400 
 
300 
 
200 
 
100 
 
0 
 
 
 
 
Control Ang II 
Thrombin (100 nM) Thrombin (100 nM) Thrombin (100 nM) 
(1 U/mL) (3 U/mL) (1 U/mL) (3 U/mL) (1 U/mL) (3 U/mL) 
* # 
* 
* 
* 
* * *
# 
* 
* 
T
G
F
-β
/β
-t
u
b
u
li
n
 l
e
v
e
l 
(%
 C
o
n
tr
o
l)
 
A
c
ti
v
e
 M
M
P
-2
 
(%
 C
o
n
tr
o
l)
 
A
c
ti
v
e
 M
M
P
-9
 
(%
 C
o
n
tr
o
l)
 
156  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISSCUSSION AND 
PERSPECTIVES 
  
157  
DISCUSSION 
The present study provides a new paradigm in which atrial endothelial cells (AECs) senescence 
enhances thrombogenicity, inflammation, matrix remodeling and the up-regulation of the local 
angiotensin system. The findings further indicate that thrombin, in addition to its role in the 
coagulation process, play an important role in the induction of AECs premature senescence 
resulting in endothelial dysfunction associated with the down-regulation of the protective NO 
pathway and the induction of pro-infiltrative and pro-fibrotic responses. Altogether, these data 
provides novel mechanistic insights by which, thrombin as a result of hypercoagulability, may 
promote tissue remodeling and favour AF susceptibility. Our study also demonstrates a significant 
role of the local angiotensin system in the perpetuation of senescence-associated secretory 
phenotype. This can be documented by the fact that both perindoprilat (ACE) and losartan (AT1R) 
prevented AECs senescence. 
Atrial fibrillation AF has now become a serious epidemic across the world as its incidence is 
expected to double during the next 20 years besides the considerable progression in the diagnosis 
and treatment of AF (Andrade et al., 2014; Chugh et al., 2014). AF has a pronounced societal 
burden in terms of diminished quality of life, cost of care, risk for stroke, heart failure, dementia, 
and mortality. The prevalence of AF is strongly age dependent (Boriani, 2016) and a hallmark of 
aging is short telomere length. Several studies also suggest the possible role of short telomere 
length in AF (Carlquist et al., 2016; Denil et al., 2014). Replicative senescence which is associated 
with DNA damage and telomere erosion plays a fundamental role in aging and accompanied with 
cardiomyocyte hypertrophy, increased apoptosis and myocardial fibrosis (Cannata et al., 2016). 
On the other hand, premature senescence primarily with the focus to the elimation of damaged 
cells, is characterized by an irreversible form of cell cycle arrest (Campisi and d'Adda di Fagagna, 
2007; Cannata et al., 2016; Munoz-Espin and Serrano, 2014). In vivo, endothelial cell senescence 
has been documented in several types of pathological arteries including overlying atherosclerotic 
plaques of human coronary arteries and thoracic aortas of patients with ischemic heart diseases 
(Minamino et al., 2002). One study conducted on spontaneously hypertensive rats has shown high 
levels of vascular senescence in the aortic arch (Han et al., 2012) and in another study in the aorta 
of diabetic rats (Chen et al., 2002). Previous studies conducted with cultured cells have shown that 
endothelial cell senescence is associated with the down-regulation of endothelial eNOS, the 
induction of a proinflammatory state, and DNA damages (Botden et al., 2012). In another study it 
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was found that the overexpression of endothelial p53 induces endothelial dysfunction and decrease 
nitric oxide (NO) bioavailability in rat aortic sections, and the down-regulation of eNOS in 
cultured endothelial cells (Kumar et al., 2011). 
The identification of senescent cells, both in culture and in pathological arteries, relies 
predominantly on biomarkers and/or effectors of senescence including increased SA-β-gal activity 
(Abbas et al., 2017; Dimri et al., 1995) and the up-regulation of p53/p21 and/or p16-retinoblastoma 
signaling pathways (Khemais-Benkhiat et al., 2016b; Silva et al., 2017). Also, several lines of 
evidence suggest that the decreased NO bioavailability is a crucial early event triggering the signal 
transduction cascade leading ultimately to endothelial senescence. In good agreement with these 
previous observations, the present models of replicative endothelial senescence (induced by serial 
passaging of AECs) and premature endothelial senescence (induced by L-NAME, H2O2, Ang II 
and thrombin) showed an increased proportion of senescent AECs as assessed by SA-β-gal activity 
and the down-regulation of the expression of eNOS that was associated with the up-regulation of 
the cyclin-dependent kinase inhibitors p53, p21, p16, resulting in cell cycle arrest in the G0/G1 
phase (Burger et al., 2012; Sherr and McCormick, 2002). 
Although the major characteristic of senescent cells is irreversible cell‐cycle arrest, recent studies 
conducted revealed several important functions including secretion of various secretory proteins 
such as inflammatory cytokines, chemokines, growth factors, and MMPs, into the surrounding 
extracellular fluid, termed senescence‐associated secretory phenotypes (SASPs) (Watanabe et al., 
2017). In addition, there are convincing evidences indicating a strong relationship between left 
atrial (LA) inflammation and interstitial fibrosis to the pathogenesis of AF (Issac et al., 2007; Scott 
et al., 2018). Endothelial dysfunction is associated with increased endothelial expression of 
adhesion molecules, such as E-selectin, ICAM-1, and VCAM-1 thus exhibiting a proinflammatory, 
pro-oxidant and proadhesion features, which facilitate AF substrate formation (Casaclang-Verzosa 
et al., 2008; Pathak et al., 2013). Several studies have suggested that inflammation exerts its 
remodeling effects through ROS (Dandana et al., 2011; Kotur-Stevuljevic et al., 2007). ROS can 
result in increased expression of matrix metalloproteinases, resulting in an imbalance between 
accumulation and breakdown of extracellular matrix, enhancing LA fibrosis (Ait-Benali et al., 
2018; Rajagopalan et al., 1996). In fact, inflammatory cells have been demonstrated to infiltrate 
atrial tissue (Kume et al., 2017). Others authors have emphasized the view that cellular senescence 
is a direct signalling event which leads to endothelial dysfunction (Bhayadia et al., 2016). In line 
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with previous studies conducted on different cell cultures, the present findings underline that both 
replicative and premature AECs senescence is associated with pro-thrombotic, pro-inflammatory, 
pro-adhesive and pro-fibrotic cell phenotype. These phenoypical changes depicts fundamental 
structural alterations of the atrial tissue linked to senescence which ultimately ends up in overall 
structural remodeling thus impairing normal electrical conductivity and paving the way to atrial 
fibrillation (Johnston and Gillis, 2017; Kume et al., 2017; Nattel et al., 2008). 
Previous studies conducted on coronary artery endothelial cells showed that that oxidative stress 
is a major inducer of endothelial cell senescence and that it mediates both replicative and premature 
endothelial senescence (Khemais-Benkhiat et al., 2016b; Silva et al., 2017). These observations 
are in good agreement with the present study conducted on AECs. ROS can be generated by several 
sources such as mitochondrial respiratory complex I and III, xanthine oxidase, NADPH oxidase, 
COXs, and uncoupled eNOS. The pharmacological characterization of the enzymatic sources of 
ROS in the senescent AECs has indicated a significant contribution of NADPH oxidase, COXs, 
and the mitochondrial respiratory chain. This is in consistent with previous studies conducted 
showing involvement of NADPH oxidase subunits Nox1 and Nox4 in the excessive formation of 
ROS in senescent human endothelial cells (Schilder et al., 2009). In addition, one study also 
demonstrated an upregulation of NADPH oxidase subunits p47 phox, Nox2, and Nox4 in JunD−/− 
mice hence featuring premature vascular senescence linked with an impairment of the O2 •-/NO 
balance (Paneni et al., 2013). In another study, replicative senescence in human umbilical vein 
endothelial cells was shown to be delayed following in Nox4 gene interference using small-hairpin 
RNA (Lener et al., 2009). Previous studies also documented the important role of COX-2 in the 
establishment and maintenance of senescence of human fibroblasts (Martien et al., 2013). Indeed, 
a low dose of aspirin was found to delay the onset of senescence in circulating endothelial 
progenitor cells (Hu et al., 2008). Altogether, the previous studies and the present findings indicate 
that the expression of pro-oxidant enzymes promoting a sustained level of oxidative stress, which 
leads to the down-regulation of the eNOS-derived NO pathway and the subsequent induction of 
senescence. 
Many studies conducted previously depict a strong associated between the angiotensin system and 
structural remodeling link to AF perpetuation and maintenance. In line with this concept, activation 
of the local angiotensin system has been shown to contribute to the increased level of oxidative 
stress observed in pathological arteries such as in old arteries and in arteries from hypertensive 
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animals and humans mostly by an AT1R-mediated activation of NADPH oxidase (Doughan et al., 
2008; Harrison et al., 2003). Moreover, Ang II has been reported to be a potent inducer of 
premature senescence in endothelial cells (Abbas et al., 2017; Shan et al., 2014). In the present 
study, endothelial senescence was associated with an upregulation of the local angiotensin system 
as indicated by increased expression levels of ACE and AT1 receptors in both replicative and 
premature senescent AECs. The local angiotensin system has a determinant role in the induction 
of both replicative and premature endothelial senescent as indicated by the fact that both the ACE 
inhibitor and the AT1 receptor blocker reduced SA-β-gal activity. 
The present findings also point out an important role of the coagulation cascade components in the 
induction of senescence and in the acquisition of senescence-associated secretory phenotype. 
Thrombin has been shown to be a strong procoagulant and proinflammatory serine protease that 
contributes to the various cardiovascular pathologies by increasing the expression of cell adhesion 
molecules, stimulating the secretion of pro-inflammatory cytokines, activating inflammatory 
responses in atherosclerotic plaques, stimulating proliferation of smooth muscle cells, and 
exacerbating vascular lesions at sites of injury (Jaberi et al., 2018). The present study revealed the 
pro-inflammatory, pro-thrombotic and pro-fibrotic signaling functions of thrombin associated 
with the induction of senescence in AECs. This is consistent with a previous study with FXa 
(another component of the coagulation cascade) showing non-hematologic functions beyond blood 
coagulation including an inflammatory response and tissue remodeling and, hence, indicating that 
hyper-coagulation, cell senescence, and inflammation are linked. Altogether, our data substantiate 
the view that atrial endothelial senescence promotes thrombogenicity, inflammation, matrix 
remodeling and the up-regulation of the local Ang II system. The present findings further indicate 
that thrombin is a potent inducer of premature senescence in AECs leading to an endothelial 
dysfunction with the down-regulation of the protective NO pathway and the induction of pro- 
infiltrative and pro-fibrotic responses. They further suggest the involvement of the local 
angiotensin system and that targeting the Ang II/AT1R pathway may be a promising therapeutic 
strategy to delay atrial endothelial ageing. 
Numerous studies have emphasized the view that thrombin has pleiotropic cellular effects through 
the cleavage of protease-activated receptor (PAR)-1, including hemostasis, inflammation, cellular 
growth, and proliferation. The importance of this pathway was highlighted by the demonstration 
that direct thrombin inhibitors and PAR-1 antagonists prevent atrial remodeling and reduce AF 
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susceptibility (Jumeau et al., 2016b). In the light of these observations, the possible role of PAR-
1 antagonists in the prevention of senescence and senescence-associated-secretory phenotype 
remains to be explored in AECs. Moreover, the impact of other coagulation cascade components 
on the induction of AECs should be investigated. Another area of intense research relies on the 
role of microparticles (MPs), generated at high levels in AF, on the induction of AECs 
senescence.  Furthermore, all experiments were conducted on atrial endothelial cells taken from 
porcine which is considered not a pertinent pathological model regarding atrial fibrillation. Thus 
more experimental studies need to be performed using other models and also to mimic the 
original in vivo shear stress conditions. Studies can also be in pathological models of 
hypertension, diabetes in rabbits, dogs and goats to assess the score of atrial fibrillation. In 
addition ex vivo studies can be conducted on atrial appendages and localization of senescent 
cells can be done. 
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HASAN Hira 
Induction de la sénescence endothéliale auriculaire par 
l’angiotensine II et la thrombine : Rôle du stress oxydant et 
caractérisation du phénotype pro-thrombotique, pro-adhésif, 
protéolytique et pro-fibrotique 
RESUME 
De nombreuses études soulignent une relation directe entre la prévalence de la fibrillation 
auriculaire (FA) et le vieillissement. La senescence cellulaire et le phénotype sécrétoire associé 
semblent jouer un rôle central dans le développement de l'inflammation auriculaire. Cette 
inflammation est à l’origine d’un remodelage auriculaire délétère (stress oxydant, fibrose) 
favorable à la perpétuation et au maintien de la FA. Par ailleurs, il est connu que la FA favorise 
la coagulation locale et systémique. Cependant, l'impact des facteurs de la coagulation, 
notamment la thrombine, sur la FA est peu connu. L’objectif de cette étude était de déterminer le 
lien entre la sénescence des cellules endothéliales atriales et le phénotype pro-inflammatoire et 
pro-adhésif, la fibrose et le remodelage auriculaire tout en évaluant l’impact de la coagulation, et 
en particulier le rôle de la thrombine. 
RESUME EN ANGLAIS 
Many studies documented strong relationship between ageing and development of 
atrial fibrillation (AF). Moreover, it has been found that senescence and senescence-
associated- secretory-phenotype play an important role in development of overall atrial 
inflammation which can ultimately ends up in atrial structural remodeling paving the way to 
AF perpetuation and maintenance. Moreover, it has been known for decades that AF has 
been associated with the activation of local and circulating coagulation factors. However, little is 
known about the impact of coagulation-derived factors, in particular thrombin, on the onset of 
AF. The aim of the present study was to determine the link between atrial endothelial cells 
(AECs) senescence and the induction of pro-inflammatory, pro-adhesive, pro-fibrotic and 
pro-remodelling AECs patterns and also to evaluate the contribution of coagulation derived-
factors such as thrombin. 
